ABCG5 p.Gln604Glu
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 11138003
[PubMed]
Lee MH et al: "Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption."
No.
Sentence
Comment
62
letter 80 nature genetics • volume 27 • january 2001 A G G A A C T G A A T T Arg Asn stop Ile C G A Arg A G G A A C A T Tnormal proband 25 T G AG T C A G CC G G Arg Val stop Ser C G A Arg C G GG T C A G Cnormal proband 140 100 200 300 400 bp 500 M C2C2+ 146 C1+ 113 132 140 41 46 63 M 100 200 300 400 500 bp M 41 46 63 113 132 140 146 C1+ C2+ C2- M AlwNI CAGNNNCTG 1 272 normal 135 141 proband 25 bp bp Ava I CPyCGPuG normal 199 109 proband 140 166 33 109 100 200 300 400 bp 500 100 200 300 400 500 M 22 23 24 25 26 27 C1+ C2+ M bp C2- 500 22 23 M 155 157 158 159 160 C1+ C2+ C2- M 155 156 4000 C C C G T AG A CC A G Gln Asp Pro Val C G C Arg C A G G A C G T A Proband 157 Normal BstUI CGCG 112 196 probands 41, 132, 157 92 normal 112 104 probands 46, 113, 146 204 104 normal 112 10492 exon 6 R243* exon 9 R408* exon 9 R389H exon 9 R419P BstUI CGCG bp bp bp bp bp bp proband 146 C T TC T CC A TA C G Thr His Leu Leu Arg normal C T TC T CC G TA C G 1 GCTCCGGGAA AACCAC---- CTGGGGACCT T--------- -------CCT 50 wild-type 1 GCTCCGGGAA AACCACGCTG CTGGACGCCA TGTCCGGGAG GCTGGGGCGC 50 51 GGGGGGTCCT TCCTGGGGGA GGTGTATGTG AACGGCCGGG CGCTGCGCCG 100 51 GCGGGGACCT TCCTGGGGGA GGTGTATGTG AACGGCCGGG CGCTGCGCCG 100 proband wild-type proband wild-type proband 101 GGAGCAGTTC CAGGACTGCT TCTCCTACGT CCTGCAG... .......... 150101 GGAGCAGTTC CAGGACTGCT TCTCCTACGT CCTGCAG... .......... 150 M wt+mut 63 64 65 66 67 C1 C2 M 61 62 mut wt wt + mut 200bp 400bp 500bp 1 2 3 4 5 6 7 8 9 10 Table 1 • Frequency of nucleotide changes in unrelated Japanese and North Americans of European descent Nucleotide change Predicted consequences Carrier frequency Restriction endonuclease changes C167T P9P not screened gain of BstNI site ∆20 bp at 402 frameshift & truncated protein no carriers in 55 Japanese controls - C867T R243X not screened gain of AlwNI site G1306A R389H no carriers in 145 Japanese and 156 Caucasians Loss of BstUI site C1362T R408X not screened loss of AvaI site G1396A R419H no carriers in 145 Japanese and 156 Caucasians Loss of BstUI site G1396C R419P no carriers in 145 Japanese and 156 Caucasians Loss of BstUI site C1950G Q604E 36% carriers in Caucasians loss of SmlI site Mutations (R243X, R408X, and R419H/P) or polymorphism Q604E were screened in unrelated Japanese and North Americans of European descent, using the restriction assays described in Fig. 2.
X
ABCG5 p.Gln604Glu 11138003:62:2145
status: NEWX
ABCG5 p.Gln604Glu 11138003:62:2250
status: NEW91 The polymorphic variant, Q604E (open circle) is also within this loop.
X
ABCG5 p.Gln604Glu 11138003:91:25
status: NEW
No.
Sentence
Comment
131
Polymorphisms in ABCG5 and ABCG8 Gene Amino acid changes Nucleotide changes ABCG5 Pro 9 Pro CCC4CCT Gln 604 Glu CAA4GAA ABCG8 Glu 189 Glu GAA4GAG Gln 340 Glu CAG4GAG Lys 400 Thr AAG4ACG Ala 565 Ala GCC4GCT Ala 632 Val GCC4GTC Intron 9±19C4T Intron10 2bp deletion at +35C Intron10±50C4T In12 +22C4G Polymorphic changes detected in ABCG5 and ABCG8 are as documented.
X
ABCG5 p.Gln604Glu 11264985:131:100
status: VERIFIED
PMID: 11668628
[PubMed]
Hubacek JA et al: "Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia."
No.
Sentence
Comment
6
Nine nonsynonymous polymorphisms are also reported: I523V, C600Y, Q604E, and M622V in ABCG5; and D19H, Y54C, T400K, A632V, and Y641F in ABCG8.
X
ABCG5 p.Gln604Glu 11668628:6:66
status: VERIFIED36 Gene Exon NT change AA change Allele frequency RE ABCG5 ABCG8 ex. 11 ex. 13 ex. 13 ex. 13 ex. 1 ex. 2 ex. 8 ex. 13 ex. 13 c.1567 A>G c.1799 G>A c.1810 C>G c.1864 A>G c.52 G>C c.161 A>G c.1199 C>A c.1895 C>T c.1922 A>T I523V C600Y Q604E M622V D19H Y54C T400K A632V Y641F <1% <1% C=0.80/G=0.20 <1% G=0.94/C=0.06 A=0.61/G=0.39 C=0.80/A=0.20 C=0.83/T=0.17 A=0.99/T=0.01 XmnI TsrpI SexAI MseI NcoI MboII *The polymorphisms were found either in sitosterolemic probands or in genomic DNA from 24 individuals with high plasma cholesterol concentrations. Allele frequencies of the nonsynonymous sequence variants identified were determined in 50 unrelated Caucasians.
X
ABCG5 p.Gln604Glu 11668628:36:230
status: VERIFIED
PMID: 11893785
[PubMed]
Berge KE et al: "Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8."
No.
Sentence
Comment
125
Linkage disequilibrium between polymorphisms in ABCG5 and ABCG8 Locus 1 Locus 2 DЈ P ABCG5 Q604E ABCG8 D19H 0.47 0.001 ABCG8 Y54C 0.29 0.095 ABCG8 T400K 0.31 0.299 ABCG8 A632V 0.06 0.451 ABCG8 D19H ABCG8 Y54C 0.62 0.122 ABCG8 T400K 0.63 0.408 ABCG8 A632V 0.04 0.979 ABCG8 Y54C ABCG8 T400K 0.85 0 ABCG8 A632V 0.04 0.959 ABCG8 T400K ABCG8 A632V 0.69 0.016 Haplotypes were determined in 74 nuclear families.
X
ABCG5 p.Gln604Glu 11893785:125:97
status: VERIFIED126 Linkage disequilibrium between polymorphisms in ABCG5 and ABCG8 Locus 1 Locus 2 D9 P ABCG5 Q604E ABCG8 D19H 0.47 0.001 ABCG8 Y54C 0.29 0.095 ABCG8 T400K 0.31 0.299 ABCG8 A632V 0.06 0.451 ABCG8 D19H ABCG8 Y54C 0.62 0.122 ABCG8 T400K 0.63 0.408 ABCG8 A632V 0.04 0.979 ABCG8 Y54C ABCG8 T400K 0.85 0 ABCG8 A632V 0.04 0.959 ABCG8 T400K ABCG8 A632V 0.69 0.016 Haplotypes were determined in 74 nuclear families.
X
ABCG5 p.Gln604Glu 11893785:126:91
status: NEW128 Mean plasma sterol concentrations and sterol-cholesterol ratios in unrelated men and women with different ABCG5 and ABCG8 genotypes ABCG8 D19H ABCG8 Y54C ABCG8 T400K ABCG8 A632V ABCG5 Q604E DD n 5 128 DH/HH n 5 14 YY n 5 54 YC/CC n 5 85 TT n 5 95 TK/KK n 5 48 AA n 5 94 VA/VV n 5 49 QQ n 5 91 QE/EE n 5 51 Plasma sterol concentrations Cholesterol 202 6 41 194 6 33 199 6 39 203 6 40 197 6 38 207 6 42 195 6 38 b 213 6 40 198 6 40 204 6 40 Cholestanol 420 6 110 b 340 6 72 400 6 104 419 6 114 410 6 115 418 6 103 400 6 97 437 6 131 411 6 114 416 6 105 Desmosterol 200 6 70 196 6 79 195 6 66 202 6 74 1916 67 221 6 79 197 6 75 210 6 68 197 6 74 208 6 70 Lathosterol 308 6 135 365 6 252 308 6 120 320 6 168 296 6 136 354 6 171 309 6 165 329 6 116 314 6 154 322 6 145 Sitosterol 257 6 105 b 177 6 53 231 6 93 261 6 109 256 6 114 238 6 83 239 6 87 274 6 130 250 6 107 250 6 104 Campesterol 338 6 147 b 233 6 72 310 6 133 339 6 152 332 6 149 324 6 144 308 6 124 a 375 6 177 328 6 154 332 6 136 Plasma sterol-cholesterol ratios (mg/mg) Cholestanol 2.09 6 0.40 c 1.76 6 0.31 2.02 6 0.37 2.07 6 0.39 2.09 6 0.44 2.01 6 0.31 2.06 6 0.41 2.05 6 0.39 2.08 6 0.40 2.04 6 0.42 Desmosterol 0.99 6 0.26 1.00 6 0.32 0.97 6 0.25 0.99 6 0.28 0.96 6 0.25 a 1.06 6 0.30 1.00 6 0.29 0.98 6 0.23 0.98 6 0.27 1.02 6 0.27 Lathosterol 1.53 6 0.60 1.84 6 1.06 1.57 6 0.60 1.57 6 0.70 1.48 6 0.57 a 1.73 6 0.78 1.57 6 0.70 1.56 6 0.57 1.57 6 0.67 1.58 6 0.63 Sitosterol 1.28 6 0.45 c 0.94 6 0.32 1.18 6 0.45 1.29 6 0.45 1.30 6 0.48 a 1.15 6 0.35 1.24 6 0.42 1.29 6 0.51 1.27 6 0.44 1.23 6 0.48 Campesterol 1.67 6 0.62 c 1.21 6 0.36 1.56 6 0.59 1.66 6 0.63 1.68 6 0.62 1.54 6 0.60 1.58 6 0.59 1.74 6 0.65 1.64 6 0.63 1.61 6 0.59 Values are means 6 SD. Plasma cholesterol concentrations are in mg/dl.
X
ABCG5 p.Gln604Glu 11893785:128:184
status: NEW
PMID: 14703505
[PubMed]
Kajinami K et al: "ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin."
No.
Sentence
Comment
2
To test the hypothesis that genetic variation in ABCG5/8 might influence the plasma lipid response to statin therapy, we examined five nonsynonymous polymorphisms at the ABCG5/8 loci (Q604E, D19H, Y54C, T400K, and A632V) in 338 hypercholesterolemic patients treated with 10 mg atorvastatin.
X
ABCG5 p.Gln604Glu 14703505:2:184
status: VERIFIED37 In the present study, five prevalent DNA polymorphisms, one in ABCG5 (Q604E) and four in ABCG8 (D19H, Y54C, T400K, and A632V), were studied using a PCR-restriction length polymorphism method.
X
ABCG5 p.Gln604Glu 14703505:37:70
status: VERIFIED58 RESULTS Genotype, allele, haplotype frequencies, linkage disequilibrium Genotype distributions (wild-type allele homozygote, variant heterozygote, variant homozygote) in each polymorphism were as follows; Q604E (212, 112, 14), D19H (294, 43, 1), Y54C (138, 146, 54), T400K (196, 130, 12), and A632V (225, 96, 17).
X
ABCG5 p.Gln604Glu 14703505:58:205
status: VERIFIED60 Allele frequencies (wild-type, variant) were Q604E (0.79, 0.21), D19H (0.93, 0.07), Y54C (0.62, 0.38), T400K (0.77, 0.23), and A632V (0.81, 0.19).
X
ABCG5 p.Gln604Glu 14703505:60:45
status: VERIFIED63 Significant linkage disequilibrium was found in 5 out of 10 pairs of five polymorphisms: Q604E/D19H (D` ϭ 0.6503, P ?d; 0.0001), Q604E/Y54C (-0.3461, 0.0244), D19H/Y54C (-0.9986, 0.0003), Y54C/T400K (-0.4957, 0.0003), and T400K/A632V (-0.5484, 0.0456).
X
ABCG5 p.Gln604Glu 14703505:63:89
status: VERIFIEDX
ABCG5 p.Gln604Glu 14703505:63:127
status: NEWX
ABCG5 p.Gln604Glu 14703505:63:139
status: VERIFIED38 For the D19H polymorphism, a 131 bp fragment, including a G to C substitution site at codon 19 of the ABCG8 gene, was amplified using an oligonucleotide primer set (5Ј-GCTGGGTCTAAGAGAGCTGC-3Ј and 5Ј-CTTCCCATTGCT- CACTCACC-3Ј) with 35 cycles of amplification (95ЊC for 30 s, 60ЊC for 30 s, and 72ЊC for 30 s).
X
ABCG5 p.Gln604Glu 14703505:38:70
status: NEW
PMID: 15175352
[PubMed]
Gylling H et al: "Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity."
No.
Sentence
Comment
7
Low serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.-Gylling, H., M. Hallikainen, J. Pihlajamäki, J. Ågren, M. Laakso, R. A. Rajaratnam, R. Rauramaa, and T. A. Miettinen.
X
ABCG5 p.Gln604Glu 15175352:7:188
status: VERIFIED91 Because the D19H polymorphism of the ABCG8 gene and the Q604E polymorphism of the ABCG5 gene, the polymorphisms most strongly associated with cholesterol absorption and insulin action, were in linkage disequilibrium, we analyzed the effect of combined genotypes of these two polymorphisms on the levels of cholestanol (a marker of cholesterol absorption) and fasting insulin (a marker of insulin action).
X
ABCG5 p.Gln604Glu 15175352:91:56
status: VERIFIEDX
ABCG5 p.Gln604Glu 15175352:91:129
status: NEW92 Figure 2 demonstrates that the D19H polymorphism of the G8 gene was associated more strongly with cholesterol absorption and the Q604E polymorphism of the G5 gene was associated with fasting insulin.
X
ABCG5 p.Gln604Glu 15175352:92:129
status: VERIFIED97 The D19H polymorphism of the G8 gene was most strongly associated with cholesterol absorption, and the Q604E polymorphism of the G5 gene was associated with insulin action.
X
ABCG5 p.Gln604Glu 15175352:97:103
status: VERIFIED122 Effect of the combined genotypes of the D19H and Q604E polymorphisms of the G8 and G5 genes on serum cholestanol-to-cholesterol ratio (102 ϫ mmol/mol cholesterol) and serum insulin level (mU/l) in the study population (n ϭ 262).
X
ABCG5 p.Gln604Glu 15175352:122:49
status: VERIFIED6 Low serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.-Gylling, H., M. Hallikainen, J. Pihlajam&#e4;ki, J. &#c5;gren, M. Laakso, R. A. Rajaratnam, R. Rauramaa, and T. A. Miettinen.
X
ABCG5 p.Gln604Glu 15175352:6:188
status: NEW89 Because the D19H polymorphism of the ABCG8 gene and the Q604E polymorphism of the ABCG5 gene, the polymorphisms most strongly associated with cholesterol absorption and insulin action, were in linkage disequilibrium, we analyzed the effect of combined genotypes of these two polymorphisms on the levels of cholestanol (a marker of cholesterol absorption) and fasting insulin (a marker of insulin action).
X
ABCG5 p.Gln604Glu 15175352:89:56
status: NEW90 Figure 2 demonstrates that the D19H polymorphism of the G8 gene was associated more strongly with cholesterol absorption and the Q604E polymorphism of the G5 gene was associated with fasting insulin.
X
ABCG5 p.Gln604Glu 15175352:90:56
status: NEWX
ABCG5 p.Gln604Glu 15175352:90:129
status: NEW95 The D19H polymorphism of the G8 gene was most strongly associated with cholesterol absorption, and the Q604E polymorphism of the G5 gene was associated with insulin action.
X
ABCG5 p.Gln604Glu 15175352:95:103
status: NEW120 Effect of the combined genotypes of the D19H and Q604E polymorphisms of the G8 and G5 genes on serum cholestanol-to-cholesterol ratio (102 mmol/mol cholesterol) and serum insulin level (mU/l) in the study population (n 262).
X
ABCG5 p.Gln604Glu 15175352:120:49
status: NEW96 The D19H polymorphism of the G8 gene was most strongly associated with cholesterol absorption, and the Q604E polymorphism of the G5 gene was associated with insulin action.
X
ABCG5 p.Gln604Glu 15175352:96:103
status: NEW121 Effect of the combined genotypes of the D19H and Q604E polymorphisms of the G8 and G5 genes on serum cholestanol-to-cholesterol ratio (102 mmol/mol cholesterol) and serum insulin level (mU/l) in the study population (n 262).
X
ABCG5 p.Gln604Glu 15175352:121:49
status: NEW
PMID: 15209530
[PubMed]
Stefkova J et al: "ATP-binding cassette (ABC) transporters in human metabolism and diseases."
No.
Sentence
Comment
107
The other two polymorphisms (Q604E) in ABCG5 and (Y54C) in ABCG8 were not associated with plasma lipid levels.
X
ABCG5 p.Gln604Glu 15209530:107:29
status: VERIFIED
PMID: 15311998
[PubMed]
Hubacek JA et al: "Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels."
No.
Sentence
Comment
5
Missence polymorphisms (Gln604Glu in the ABCG5 and Asp19His, Tyr54Cys, Thr400Lys, and Ala632Val in the ABCG8) in these genes have been described.
X
ABCG5 p.Gln604Glu 15311998:5:24
status: VERIFIED7 Plasma lipid levels and changes in plasma lipid levels were independent of the Gln604Glu polymorphism in ABCG5 and Asp19His and the Ala632Val polymorphisms in ABCG8.
X
ABCG5 p.Gln604Glu 15311998:7:79
status: VERIFIED22 Another two polymorphisms, Ala632Val (Berge et al. 2002) and Gln604Glu (Weggemans et al. 2002), have been suggested to have an effect on plasma cholesterol levels.
X
ABCG5 p.Gln604Glu 15311998:22:61
status: VERIFIED23 To evaluate the role of the ABCG5 and ABCG8 variants in the genetic determination of plasma lipids, we analyzed non-synonymous polymorphisms in the ABCG5 (C1810G = Gln604Glu) and ABCG8 (G55C = Asp19His, A161G = Tyr54Cys, C1199A = Thr400Lys and C1895T = Ala632Val) genes, and searched for associations between the polymorphisms and plasma lipid levels, and between the polymorphisms and plasma lipid changes over a 8 years´ follow-up.
X
ABCG5 p.Gln604Glu 15311998:23:164
status: VERIFIED33 Polymorphism Primer sequence PCR product Enzyme Size Allele ABCG8 5`atggccgggaaggcggcagaggagag 83 bp BamH I 83 C (His) Asp19His 5`acttcccattgctcactcaccgagggat 56 + 27 G (Asp) ABCG8 5`agggcctccaggatagattgttctcctc 128 bp Bgl I 128 A (Tyr) Tyr54Cys 5`ccttgaacccaggcgtgcgcctacctg 102 + 26 G (Cys) ABCG8 5`agatgcctggggcggtgcagcagctt 108 bp Afl II 108 C (Thr) Thr400Lys 5`ggcttaatgtgatatacaaagacttggg 81 + 27 A (Lys) ABCG8 5`atgtctgtgtctccagatcctcaggg 105 bp Hae III 105 T (Val) Ala632Val 5`tacaggaccatgaagccaccgctgacgcc 79 + 26 C (Ala) ABCG5 5`aaccacacctgacactgtcaatcttttcct 117 bp Xho I 117 G (Glu) Gln604Glu 5`gggcaggttttctcaatgaattgaattcctc 86 + 31 C (Gln) DNA analysis Three ml of blood collected into EDTA tubes for DNA isolation were diluted with sterile water at a 1:1 ratio and stored at -20 °C. DNA was isolated by a standard method (Miller et al. 1988).
X
ABCG5 p.Gln604Glu 15311998:33:595
status: VERIFIED53 ABCG5 polymorphism and lipid parameters No association was found between the Gln604Glu polymorphism in the ABCG5 gene and lipid levels either in the general population or in males or females separately (both in 1988 and 1996).
X
ABCG5 p.Gln604Glu 15311998:53:77
status: VERIFIED58 Polymorphism 11 12 22 N (%) ABCG8 2 34 249 1- His 38 (6.7 %) Asp19His (0.7) (11.9) (87.4) 2- Asp 532 (93.3 %) ABCG8 97 130 58 1- Tyr 324 (56.8 %) Tyr54Cys (34.0) (45.6) (20.4) 2-Cys 246 (43.2 %) ABCG8 178 85 9 1- Thr 441 (81.1 %) Thr400Lys (65.4) (31.3) (3.3) 2- Lys 103 (18.9 %) ABCG8 24 96 165 1- Val 144 (25.3 %) Ala632Val (8.4) (33.7) (57.9) 2- Ala 426 (74.7 %) ABCG5 200 77 8 1- Glu 477 (83.7 %) Gln604Glu (70.0) (27.0) (2.8) 2- Gln 93 (16.3 %) Results are given as numbers (%).
X
ABCG5 p.Gln604Glu 15311998:58:401
status: VERIFIED52 ABCG5 polymorphism and lipid parameters No association was found between the Gln604Glu polymorphism in the ABCG5 gene and lipid levels either in the general population or in males or females separately (both in 1988 and 1996).
X
ABCG5 p.Gln604Glu 15311998:52:77
status: NEW57 Polymorphism 11 12 22 N (%) ABCG8 2 34 249 1- His 38 (6.7 %) Asp19His (0.7) (11.9) (87.4) 2- Asp 532 (93.3 %) ABCG8 97 130 58 1- Tyr 324 (56.8 %) Tyr54Cys (34.0) (45.6) (20.4) 2-Cys 246 (43.2 %) ABCG8 178 85 9 1- Thr 441 (81.1 %) Thr400Lys (65.4) (31.3) (3.3) 2- Lys 103 (18.9 %) ABCG8 24 96 165 1- Val 144 (25.3 %) Ala632Val (8.4) (33.7) (57.9) 2- Ala 426 (74.7 %) ABCG5 200 77 8 1- Glu 477 (83.7 %) Gln604Glu (70.0) (27.0) (2.8) 2- Gln 93 (16.3 %) Results are given as numbers (%).
X
ABCG5 p.Gln604Glu 15311998:57:401
status: NEW
PMID: 15520451
[PubMed]
Plat J et al: "Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers."
No.
Sentence
Comment
44
These criteria resulted in the selection of three SNPs: ABCG8 T400K, ABCG8 A632V, and ABCG5 Q604E.
X
ABCG5 p.Gln604Glu 15520451:44:92
status: VERIFIED54 Statistics Because of the limited number of subjects, and because plant sterol concentrations were not significantly different, heterozygous and homozygous carriers of the genetic variants [ABCG8 T400K (TKϩKK), ABCG8 A632V (VVϩVA), and ABCG5 Q604E (QEϩEE)] were combined before data analysis.
X
ABCG5 p.Gln604Glu 15520451:54:242
status: NEWX
ABCG5 p.Gln604Glu 15520451:54:254
status: VERIFIED61 Frequency distribution of the different genotypes in exons 8 (T400K) and 13 (A632V) of ABCG8 and in exon 13 (Q604E) of ABCG5 Subjects All Control Group Experimental Group All 112 42 70 ABCG8 T400K TT 77 (68.7) 30 (71.4) 47 (67.1) TK 31 (27.7) 11 (26.2) 20 (28.6) KK 4 (3.6) 1 (2.4) 3 (4.3) ABCG8 A632V AA 70 (62.5) 23 (54.8) 47 (67.1) VA 37 (33.0) 17 (40.5) 20 (28.6) VV 5 (4.5) 2 (4.8) 3 (4.3) ABCG5 Q604E QQ 81 (72.3) 33 (78.6) 48 (68.6) QE 29 (25.9) 9 (21.4) 20 (28.6) EE 2 (1.8) 0 (0) 2 (2.9) Values shown are absolute frequencies (with relative frequencies in parentheses).
X
ABCG5 p.Gln604Glu 15520451:61:109
status: VERIFIEDX
ABCG5 p.Gln604Glu 15520451:61:401
status: VERIFIED72 RESULTS Frequency distributions for the genotypes in exons 8 (T400K) and 13 (A632V) of ABCG8 and in exon 13 (Q604E) of ABCG5 are shown in Table 2.
X
ABCG5 p.Gln604Glu 15520451:72:109
status: VERIFIED80 Linkage disequilibrium between genotypes in exons 8 (T400K) and 13 (A632V) of ABCG8 and in exon 13 (Q604E) of ABCG5 Locus 1 Locus 2 DЈ 95% Confidence Interval ABCG8 T400K ABCG8 A632V 0.29 0.03-0.76 ABCG5 Q604E 0.81 0.06-0.97 ABCG8 A632V ABCG5 Q604E 0.0 -0.01-0.22 DЈ and the corresponding 95% confidence intervals were calculated by using all 112 subjects included in the study.
X
ABCG5 p.Gln604Glu 15520451:80:100
status: VERIFIEDX
ABCG5 p.Gln604Glu 15520451:80:204
status: NEWX
ABCG5 p.Gln604Glu 15520451:80:210
status: VERIFIEDX
ABCG5 p.Gln604Glu 15520451:80:243
status: NEWX
ABCG5 p.Gln604Glu 15520451:80:249
status: VERIFIEDX
ABCG5 p.Gln604Glu 15520451:80:643
status: NEWX
ABCG5 p.Gln604Glu 15520451:80:1292
status: NEW81 TABLE 4. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with absolute and cholesterol-standardized serum noncholesterol sterol concentrations Subjects Campesterol Sitosterol Lathosterol Campestanol Sitostanol Absolute concentrations (mol/l) All 15.8 Ϯ 5.3 6.0 Ϯ 2.4 5.2 Ϯ 2.1 0.5 Ϯ 0.3 0.4 Ϯ 0.2 ABCG8 T400K TT 16.9 Ϯ 5.5 6.6 Ϯ 2.6 5.0 Ϯ 2.1 0.5 Ϯ 0.4 0.4 Ϯ 0.2 TK/KK 13.5 Ϯ 3.8 4.8 Ϯ 1.4 5.7 Ϯ 2.1 0.5 Ϯ 0.3 0.4 Ϯ 0.2 P value Ͻ0.001 Ͻ0.001 0.070 0.887 0.675 ABCG8 A632V AA 16.3 Ϯ 5.6 6.2 Ϯ 2.6 5.1 Ϯ; 2.0 0.5 Ϯ 0.3 0.4 Ϯ 0.2 VV/VA 15.1 Ϯ 4.8 5.7 Ϯ 2.1 5.4 Ϯ 2.4 0.6 Ϯ 0.4 0.4 Ϯ 0.2 P value 0.280 0.266 0.516 0.349 0.759 ABCG5 Q604E QQ 16.3 Ϯ 5.4 6.3 Ϯ 2.5 5.1 Ϯ 2.1 0.5 Ϯ 0.3 0.4 Ϯ 0.2 QE/EE 14.6 Ϯ 5.0 5.4 Ϯ 2.2 5.4 Ϯ 2.3 0.6 Ϯ 0.4 0.4 Ϯ 0.2 P value 0.125 0.093 0.517 0.043 0.768 Cholesterol-standardized concentrations (102 ϫ mol/mmol cholesterol) All 303.4 Ϯ 98.0 115.0 Ϯ 44.5 97.3 Ϯ 33.5 9.8 Ϯ 6.6 7.6 Ϯ 4.3 ABCG8 T400K TT 324.2 Ϯ 98.5 125.2 Ϯ 45.8 93.2 Ϯ 35.0 9.6 Ϯ 6.8 7.5 ee; 4.4 TK/KK 257.7 Ϯ 80.8 92.4 Ϯ 31.9 106.4 Ϯ 28.4 10.2 Ϯ 6.1 7.7 Ϯ 3.9 P value Ͻ0.001 Ͻ0.001 0.053 0.636 0.862 ABCG8 A632V AA 305.8 Ϯ 95.3 117.3 Ϯ 47.3 95.2 Ϯ 32.2 9.3 Ϯ 6.1 7.6 Ϯ 4.2 VV/VA 299.3 Ϯ 103.3 111.0 Ϯ 39.8 101.0 Ϯ 35.8 10.6 Ϯ 7.2 7.6 Ϯ 4.4 P value 0.736 0.467 0.377 0.332 0.938 ABCG5 Q604E QQ 310.5 Ϯ 98.8 118.3 Ϯ 43.7 95.3 Ϯ 34.8 8.9 Ϯ 5.7 7.6 Ϯ 4.3 QE/EE 284.8 Ϯ 94.9 106.2 Ϯ 46.2 102.7 Ϯ 29.9 11.9 Ϯ 8.1 7.6 Ϯ 4.2 P value 0.216 0.198 0.298 0.029 0.987 Values shown are means Ϯ SD and were analyzed after a 4-week period of consumption of rapeseed oil-based margarine and shortening.
X
ABCG5 p.Gln604Glu 15520451:81:643
status: NEWX
ABCG5 p.Gln604Glu 15520451:81:812
status: VERIFIEDX
ABCG5 p.Gln604Glu 15520451:81:1292
status: NEWX
ABCG5 p.Gln604Glu 15520451:81:1696
status: VERIFIED87 Subjects with the QQ genotype (ABCG5 Q604E) showed significantly higher serum LDL cholesterol concentrations compared with QE/EE subjects (Table 5).
X
ABCG5 p.Gln604Glu 15520451:87:37
status: VERIFIED101 TABLE 5. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with serum lipid and lipoprotein concentrations Subjects LDL Cholesterol HDL Cholesterol Triacylglycerol mmol/l All 2.95 Ϯ 0.78 1.59 Ϯ 0.38 0.92 Ϯ 0.52 ABCG8 T400K TT 2.97 Ϯ 0.74 1.59 Ϯ 0.37 0.85 Ϯ 0.47 TK/KK 2.89 Ϯ 0.86 1.60 Ϯ 0.40 1.08 Ϯ 0.58 P value 0.622 0.976 0.025 ABCG8 A632V AA 3.03 Ϯ 0.78 1.58 Ϯ 0.39 0.91 Ϯ 0.48 VV/VA 2.81 Ϯ 0.77 1.61 Ϯ 0.36 0.93 Ϯ 0.58 P value 0.137 0.666 0.883 ABCG5 Q604E QQ 3.04 Ϯ 0.75 1.56 Ϯ 0.35 0.89 Ϯ 0.45 QE/EE 2.70 Ϯ 0.81 1.68 Ϯ 0.43 0.99 Ϯ 0.65 P value 0.039 0.145 0.342 Values shown are means Ϯ SD and were analyzed after a 4-week period of consumption of rapeseed oil-based margarine and shortening.
X
ABCG5 p.Gln604Glu 15520451:101:468
status: NEWX
ABCG5 p.Gln604Glu 15520451:101:558
status: VERIFIED114 However, if ABCG8 transports the same proportion of plant sterols out of the enterocytes and hepatocytes into the lumen and bile, respectively, as before plant stanol ester TABLE 6. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with changes in absolute and cholesterol-standardized serum noncholesterol sterol concentrations after consumption of plant stanol esters Subjects Campesterol Sitosterol Lathosterol Campestanol Sitostanol Absolute concentrations (mol/l) Experimental group Control -0.5 Ϯ 2.2 -0.5 Ϯ 1.2 0.0 Ϯ 1.1 -0.0 Ϯ 0.4 0.0 Ϯ 0.2 Stanol -6.3 Ϯ 3.9 -3.0 Ϯ 2.1 0.2 Ϯ 1.4 0.3 Ϯ 0.4 0.3 Ϯ 0.2 P value Ͻ0.001 Ͻ0.001 Ͻ0.001 Ͻ0.001 Ͻ0.001 Genotype group ABCG8 T400K TT -7.0 Ϯ 4.4 -3.4 Ϯ 2.3 0.2 Ϯ 1.2 0.2 Ϯ 0.4 0.3 Ϯ 0.2 TK/KK -4.9 Ϯ 2.4 -2.1 Ϯ 0.9 0.2 Ϯ 1.7 0.3 Ϯ 0.4 0.3 Ϯ 0.2 P value 0.042 0.017 0.989 0.526 0.967 ABCG8 A632V AA -6.5 Ϯ 4.5 -2.9 Ϯ 2.3 0.3 Ϯ 1.1 0.3 Ϯ 0.4 0.3 Ϯ 0.2 VV/VA -6.0 Ϯ 2.7 -3.0 Ϯ 1.6 0.2 Ϯ 1.3 0.2 Ϯ 0.4 0.3 Ϯ 0.2 P value 0.598 0.831 0.836 0.832 0.395 ABCG5 Q604E QQ -6.6 Ϯ 4.3 -3.1 Ϯ 2.3 0.1 Ϯ 1.5 0.2 Ϯ 0.4 0.3 Ϯ 0.2 QE/EE -5.8 Ϯ 3.1 -2.7 Ϯ 1.6 0.6 Ϯ 1.2 0.2 Ϯ 0.4 0.4 Ϯ 0.2 P value 0.448 0.413 0.185 0.956 0.097 Cholesterol-standardized concentrations (102 ϫ mol/mmol cholesterol) Experimental group Control -5.9 Ϯ 39.2 -7.8 Ϯ 22.4 0.5 Ϯ 19.5 -0.6 Ϯ 7.2 0.4 Ϯ 4.0 Stanol -103.1 Ϯ 70.6 -49.3 Ϯ 34.9 17.4 Ϯ 22.2 6.3 Ϯ 8.1 8.2 Ϯ 4.5 P value Ͻ0.001 Ͻ0.001 Ͻ0.001 Ͻ0.001 Ͻ;0.001 Genotype group ABCG8 T400K TT -116.7 Ϯ 76.5 -57.1 Ϯ 38.3 16.5 Ϯ 19.8 6.1 Ϯ 8.3 8.4 Ϯ 4.5 TK/KK -75.4 Ϯ 46.9 -33.5 Ϯ 19.0 19.2 Ϯ 26.7 6.8 Ϯ 7.6 7.7 Ϯ 4.6 P value 0.020 0.007 0.624 0.737 0.541 ABCG8 A632V AA -107.3 Ϯ 75.4 -49.3 Ϯ 38.8 16.0 Ϯ 23.9 6.1 Ϯ 8.3 8.3 Ϯ 4.4 VV/VA -94.6 Ϯ 60.3 -49.4 Ϯ 25.9 20.2 Ϯ 18.3 6.7 Ϯ 7.8 8.0 Ϯ 4.9 P value 0.483 0.998 0.465 0.756 0.780 ABCG5 Q604E QQ -106.3 Ϯ 75.6 -50.9 Ϯ 36.9 14.7 Ϯ 21.3 6.3 Ϯ 8.2 7.6 Ϯ 4.2 QE/EE -96.1 Ϯ 59.2 -46.0 Ϯ 30.6 23.2 Ϯ 23.5 6.3 Ϯ 7.9 9.5 Ϯ 4.9 P value 0.579 0.596 0.140 0.997 0.087 Values shown are means Ϯ SD. Changes in all parameters were calculated as the difference between values at the end of the run-in period (weeks 3 and 4) and the experimental period (weeks 11 and 12).
X
ABCG5 p.Gln604Glu 15520451:114:1012
status: NEWX
ABCG5 p.Gln604Glu 15520451:114:1229
status: VERIFIEDX
ABCG5 p.Gln604Glu 15520451:114:1804
status: NEWX
ABCG5 p.Gln604Glu 15520451:114:2304
status: VERIFIED132 Weggemans et al. (30) found that subjects with the ABCG5 Q604E EE genotype had higher serum cholesterol concentrations than carriers with the Q allele.
X
ABCG5 p.Gln604Glu 15520451:132:57
status: VERIFIED142 TABLE 7. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with changes in lipid and lipoprotein concentrations after consumption of plant stanol esters Subjects LDL Cholesterol HDL Cholesterol Triacylglycerol Control -0.06 Ϯ 0.36 0.01 Ϯ 0.16 0.02 Ϯ 0.23 Stanols -0.42 Ϯ 0.31 0.01 Ϯ 0.12 -0.04 Ϯ 0.30 P value Ͻ0.001 0.903 0.272 ABCG8 T400K TT -0.43 Ϯ 0.32 0.02 Ϯ 0.11 -0.01 Ϯ 0.22 TK/KK -0.38 Ϯ 0.30 -0.01 Ϯ 0.13 -0.09 Ϯ 0.42 P value 0.531 0.345 0.304 ABCG8 A632V AA -0.42 Ϯ 0.32 0.01 Ϯ 0.12 -0.00 Ϯ 0.25 VV/VA -0.41 Ϯ 0.29 -0.00 Ϯ 0.13 -0.10 Ϯ 0.38 P value 0.935 0.588 0.199 ABCG5 Q604E QQ -0.44 Ϯ 0.30 0.01 Ϯ 0.10 -0.01 Ϯ 0.34 QE/EE -0.36 Ϯ 0.34 -0.01 Ϯ 0.16 -0.09 Ϯ 0.18 P value 0.297 0.368 0.357 Values shown are means Ϯ SD. Changes in all parameters were calculated as the difference between values at the end of the run-in period (weeks 3 and 4) and the experimental period (weeks 11 and 12).
X
ABCG5 p.Gln604Glu 15520451:142:595
status: NEWX
ABCG5 p.Gln604Glu 15520451:142:709
status: VERIFIED43 These criteria resulted in the selection of three SNPs: ABCG8 T400K, ABCG8 A632V, and ABCG5 Q604E.
X
ABCG5 p.Gln604Glu 15520451:43:92
status: NEW53 Statistics Because of the limited number of subjects, and because plant sterol concentrations were not significantly different, heterozygous and homozygous carriers of the genetic variants [ABCG8 T400K (TKKK), ABCG8 A632V (VVVA), and ABCG5 Q604E (QEEE)] were combined before data analysis.
X
ABCG5 p.Gln604Glu 15520451:53:242
status: NEW60 Frequency distribution of the different genotypes in exons 8 (T400K) and 13 (A632V) of ABCG8 and in exon 13 (Q604E) of ABCG5 Subjects All Control Group Experimental Group All 112 42 70 ABCG8 T400K TT 77 (68.7) 30 (71.4) 47 (67.1) TK 31 (27.7) 11 (26.2) 20 (28.6) KK 4 (3.6) 1 (2.4) 3 (4.3) ABCG8 A632V AA 70 (62.5) 23 (54.8) 47 (67.1) VA 37 (33.0) 17 (40.5) 20 (28.6) VV 5 (4.5) 2 (4.8) 3 (4.3) ABCG5 Q604E QQ 81 (72.3) 33 (78.6) 48 (68.6) QE 29 (25.9) 9 (21.4) 20 (28.6) EE 2 (1.8) 0 (0) 2 (2.9) Values shown are absolute frequencies (with relative frequencies in parentheses).
X
ABCG5 p.Gln604Glu 15520451:60:109
status: NEWX
ABCG5 p.Gln604Glu 15520451:60:401
status: NEW71 RESULTS Frequency distributions for the genotypes in exons 8 (T400K) and 13 (A632V) of ABCG8 and in exon 13 (Q604E) of ABCG5 are shown in Table 2.
X
ABCG5 p.Gln604Glu 15520451:71:109
status: NEW79 Linkage disequilibrium between genotypes in exons 8 (T400K) and 13 (A632V) of ABCG8 and in exon 13 (Q604E) of ABCG5 Locus 1 Locus 2 D 95% Confidence Interval ABCG8 T400K ABCG8 A632V 0.29 0.03-0.76 ABCG5 Q604E 0.81 0.06-0.97 ABCG8 A632V ABCG5 Q604E 0.0 0.01-0.22 D and the corresponding 95% confidence intervals were calculated by using all 112 subjects included in the study.
X
ABCG5 p.Gln604Glu 15520451:79:100
status: NEWX
ABCG5 p.Gln604Glu 15520451:79:204
status: NEWX
ABCG5 p.Gln604Glu 15520451:79:243
status: NEW86 Subjects with the QQ genotype (ABCG5 Q604E) showed significantly higher serum LDL cholesterol concentrations compared with QE/EE subjects (Table 5).
X
ABCG5 p.Gln604Glu 15520451:86:37
status: NEW100 TABLE 5. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with serum lipid and lipoprotein concentrations Subjects LDL Cholesterol HDL Cholesterol Triacylglycerol mmol/l All 2.95 0.78 1.59 0.38 0.92 0.52 ABCG8 T400K TT 2.97 0.74 1.59 0.37 0.85 0.47 TK/KK 2.89 0.86 1.60 0.40 1.08 0.58 P value 0.622 0.976 0.025 ABCG8 A632V AA 3.03 0.78 1.58 0.39 0.91 0.48 VV/VA 2.81 0.77 1.61 0.36 0.93 0.58 P value 0.137 0.666 0.883 ABCG5 Q604E QQ 3.04 0.75 1.56 0.35 0.89 0.45 QE/EE 2.70 0.81 1.68 0.43 0.99 0.65 P value 0.039 0.145 0.342 Values shown are means SD and were analyzed after a 4-week period of consumption of rapeseed oil-based margarine and shortening.
X
ABCG5 p.Gln604Glu 15520451:100:468
status: NEW113 However, if ABCG8 transports the same proportion of plant sterols out of the enterocytes and hepatocytes into the lumen and bile, respectively, as before plant stanol ester TABLE 6. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with changes in absolute and cholesterol-standardized serum noncholesterol sterol concentrations after consumption of plant stanol esters Subjects Campesterol Sitosterol Lathosterol Campestanol Sitostanol Absolute concentrations (mol/l) Experimental group Control 0.5 2.2 0.5 1.2 0.0 1.1 0.0 0.4 0.0 0.2 Stanol 6.3 3.9 3.0 2.1 0.2 1.4 0.3 0.4 0.3 0.2 P value 0.001 0.001 0.001 0.001 0.001 Genotype group ABCG8 T400K TT 7.0 4.4 3.4 2.3 0.2 1.2 0.2 0.4 0.3 0.2 TK/KK 4.9 2.4 2.1 0.9 0.2 1.7 0.3 0.4 0.3 0.2 P value 0.042 0.017 0.989 0.526 0.967 ABCG8 A632V AA 6.5 4.5 2.9 2.3 0.3 1.1 0.3 0.4 0.3 0.2 VV/VA 6.0 2.7 3.0 1.6 0.2 1.3 0.2 0.4 0.3 0.2 P value 0.598 0.831 0.836 0.832 0.395 ABCG5 Q604E QQ 6.6 4.3 3.1 2.3 0.1 1.5 0.2 0.4 0.3 0.2 QE/EE 5.8 3.1 2.7 1.6 0.6 1.2 0.2 0.4 0.4 0.2 P value 0.448 0.413 0.185 0.956 0.097 Cholesterol-standardized concentrations (102 mol/mmol cholesterol) Experimental group Control 5.9 39.2 7.8 22.4 0.5 19.5 0.6 7.2 0.4 4.0 Stanol 103.1 70.6 49.3 34.9 17.4 22.2 6.3 8.1 8.2 4.5 P value 0.001 0.001 0.001 0.001 0.001 Genotype group ABCG8 T400K TT 116.7 76.5 57.1 38.3 16.5 19.8 6.1 8.3 8.4 4.5 TK/KK 75.4 46.9 33.5 19.0 19.2 26.7 6.8 7.6 7.7 4.6 P value 0.020 0.007 0.624 0.737 0.541 ABCG8 A632V AA 107.3 75.4 49.3 38.8 16.0 23.9 6.1 8.3 8.3 4.4 VV/VA 94.6 60.3 49.4 25.9 20.2 18.3 6.7 7.8 8.0 4.9 P value 0.483 0.998 0.465 0.756 0.780 ABCG5 Q604E QQ 106.3 75.6 50.9 36.9 14.7 21.3 6.3 8.2 7.6 4.2 QE/EE 96.1 59.2 46.0 30.6 23.2 23.5 6.3 7.9 9.5 4.9 P value 0.579 0.596 0.140 0.997 0.087 Values shown are means SD. Changes in all parameters were calculated as the difference between values at the end of the run-in period (weeks 3 and 4) and the experimental period (weeks 11 and 12).
X
ABCG5 p.Gln604Glu 15520451:113:1012
status: NEWX
ABCG5 p.Gln604Glu 15520451:113:1804
status: NEW131 Weggemans et al. (30) found that subjects with the ABCG5 Q604E EE genotype had higher serum cholesterol concentrations than carriers with the Q allele.
X
ABCG5 p.Gln604Glu 15520451:131:57
status: NEW141 TABLE 7. Relationships between genetic polymorphisms in ABCG8 and ABCG5 with changes in lipid and lipoprotein concentrations after consumption of plant stanol esters Subjects LDL Cholesterol HDL Cholesterol Triacylglycerol Control 0.06 0.36 0.01 0.16 0.02 0.23 Stanols 0.42 0.31 0.01 0.12 0.04 0.30 P value 0.001 0.903 0.272 ABCG8 T400K TT 0.43 0.32 0.02 0.11 0.01 0.22 TK/KK 0.38 0.30 0.01 0.13 0.09 0.42 P value 0.531 0.345 0.304 ABCG8 A632V AA 0.42 0.32 0.01 0.12 0.00 0.25 VV/VA 0.41 0.29 0.00 0.13 0.10 0.38 P value 0.935 0.588 0.199 ABCG5 Q604E QQ 0.44 0.30 0.01 0.10 0.01 0.34 QE/EE 0.36 0.34 0.01 0.16 0.09 0.18 P value 0.297 0.368 0.357 Values shown are means SD. Changes in all parameters were calculated as the difference between values at the end of the run-in period (weeks 3 and 4) and the experimental period (weeks 11 and 12).
X
ABCG5 p.Gln604Glu 15520451:141:595
status: NEW
PMID: 15816807
[PubMed]
Miwa K et al: "ATP-binding cassette transporter G8 M429V polymorphism as a novel genetic marker of higher cholesterol absorption in hypercholesterolaemic Japanese subjects."
No.
Sentence
Comment
3
We identified a novel mutation [859T/C (C287R)] and a novel polymorphism [1285A/G (M429V)] at the ABCG5/ABCG8 loci, as well as four polymorphisms reported previously [1810C/G (Q604E), 161G/A (C54Y), 1199C/A (T400K) and 1895C/T (A632V)].
X
ABCG5 p.Gln604Glu 15816807:3:176
status: VERIFIED14 Nucleotide Annealing Position Mutation change* Forward primer (5 → 3 ) Reverse primer (5 → 3 ) temperature (◦ C) Enzyme Size (bp) ABCG5 Exon 7 C287R 859T → C TCACACACTAACTACCTTCTGTTGTC ATGATGGGGAATGTGAAAGAAA 54 BstUI 191 Exon 13 Q604E 1810C → G ATCTAGATTCACAATGAACTTTCTA GTCCCTGCAAGTTGTAAGAG 53 XhoI 193 ABCG8 Exon 2 C54Y 161G → A GGAGGTCAGAGACCTCAAgT GCCCACCCTTTTATTTCCAC 56 RsaI 107 Exon 8 T400K 1199C → A ACACCTGTGTGGAAAGGTAAGGT GCGGGTTCAGTAATAAAATGACAG 57 MseI 216 Exon 9 M429V 1285A → G ATGCTGTTGCCTCAGCATCT AAGCTGTGTTCCTCTGAGCT 56 Tsp45I 306 Exon 13 A632V 1895C → T ATGTCTGTGTCTCCAGATCCTCAGgG TACAGGACCATGAAGCCACCGCTGAcGCC 63 HaeIII 105 sterols to cholesterol are known to be positively related to cholesterol absorption and negatively to cholesterol synthesis [1-4].
X
ABCG5 p.Gln604Glu 15816807:14:257
status: VERIFIED21 Indeed, it was previously proposed that common sequence variants in ABCG5 (Q604E) and ABCG8 (D19H and T400K) are associated with plasma plant sterol and lipid levels in normocholesterolaemic or mildly hypercholesterolaemic European-American populations [10-12].
X
ABCG5 p.Gln604Glu 15816807:21:75
status: VERIFIED48 Frequency distributions for the genotypes in exon 7 (C287R) and exon 13 (Q604E) of ABCG5, and in exon 2 (C54Y), exon 8 (T400K), exon 9 (M429V) and exon 13 (A632V) of ABCG8 are shown in Table 3.
X
ABCG5 p.Gln604Glu 15816807:48:73
status: VERIFIED51 Parameters Value Age (years) 62.4 +- 12.1 Gender (men/women) 48/52 BMI (kg/m2 ) 23.0 +- 3.5 Total cholesterol (mg/dl) 261 +- 48 Triacylglycerol (mg/dl) 135 +- 69 HDL-C (mg/dl) 56 +- 16 LDL-C (mg/dl) 179 +- 48 Sitosterol (µg/ml) 2.63 +- 1.0 Lathosterol (µg/ml) 3.00 +- 1.3 Table 3 Genotype distribution and allele frequencies of the polymorphisms in the ABCG5/ABCG8 gene Gene Mutation Nucleotide change Polymorphism Allele frequency ABCG5 Exon 7 C287R 859T → C T 0.99 C 0.01 Exon 13 Q604E 1810C → G C 0.89 G 0.11 ABCG8 Exon 2 C54Y 161G → A G 0.82 A 0.18 Exon 8 T400K 1199C → A C 0.88 A 0.12 Exon 9 M429V 1285A → G A 0.96 G 0.04 Exon 13 A632V 1895C → T C 0.995 T 0.005 found and the A632V variant was rare in our Japanese subjects.
X
ABCG5 p.Gln604Glu 15816807:51:499
status: VERIFIED57 Sitosterol Lathosterol Sitosterol/chol Polymorphism Genotype n (µg/ml) P value (µg/ml) P value (µg/mg) P value Lathosterol/chol (µg/mg) P value ABCG5 Exon 13 Q604E (1810C → G) QQ 78 2.63 +- 1.06 0.81 2.97 +- 1.36 0.73 1.03 +- 0.3 0.97 1.19 +- 0.55 0.84 QE 21 2.69 +- 0.72 3.09 +- 1.12 1.03 +- 0.40 1.16 +- 0.38 EE 1 1.2 3.2 0.6 1.57 ABCG8 Exon 2 C54Y (161G → A) CC 67 2.69 +- 0.98 0.19 2.82 +- 1.11 0.06 1.05 +- 0.36 0.06 1.12 +- 0.45 0.2 CY 30 2.57 +- 1.06 3.20 +- 1.33 1.02 +- 0.43 1.27 +- 0.57 YY 3 1.93 +- 0.31 4.23 +- 3.17 0.65 +- 0.12 1.38 +- 0.98 ABCG8 Exon 8 T400K (1199C → A) TT 76 2.64 +- 0.98 0.85 2.87 +- 1.10 0.14 1.03 +- 0.37 0.96 1.14 +- 0.45 0.17 TK 24 2.60 +- 1.07 3.34 +- 1.70 1.03 +- 0.44 1.31 +- 0.66 KK 0 ABCG8 Exon 9 M429V (1285A → G) MM 92 2.56 +- 0.94 0.003 3.03 +- 1.30 0.08 1.00 +- 0.36 0.002 1.19 +- 0.51 0.16 MV 8 3.64 +- 1.26 1.95 +- 0.53 1.45 +- 0.56 0.84 +- 0.36 VV 0 Table 5 Effect of the four polymorphism haplotypes in the ABCG5/ABCG8 gene on serum non-cholesterol levels Values are means +- S.D. The haplotype effects on serum non-cholesterol levels were assigned in all individuals using PHASE in 94 individuals.
X
ABCG5 p.Gln604Glu 15816807:57:174
status: NEW67 Of the 16 possible four-polymorphism haplotypes [1810C/G (Q604E), 161G/A (C54Y), 1199C/A (T400K) and 1285A/G (M429V)], six haplotypes were estimated to be present.
X
ABCG5 p.Gln604Glu 15816807:67:58
status: VERIFIED75 This result does not appear to be consistent with previous reports that the sequence variants in ABCG5 (Q604E) and ABCG8 (D19H and T400K) are associated with lower serum plant sterol levels in Western countries [10-12].
X
ABCG5 p.Gln604Glu 15816807:75:104
status: VERIFIED76 The results of our present study suggest that the frequencies of D19H and A632V variants of ABCG8 are rarer in Japanese than in European-American populations, and that these Q604E and T400K variants may not be as important in the regulation of non-cholesterol sterol levels in Japanese populations.
X
ABCG5 p.Gln604Glu 15816807:76:174
status: VERIFIED
PMID: 16029460
[PubMed]
Rees DC et al: "Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia."
No.
Sentence
Comment
174
Family Sitosterol level (lmol/l) ABCG5 ABCG8 A E77X (229G>T) A-I-2 44 m/n A-II-1 1471 m/m A-II-2 17 n/n A-II-3 57 n/n A-II-4 970 m/m A-II-5 625 m/m A-II-9 508 m/m B IVS11+3insT R50C (148C>T) E146X (436G>T), M622V (1864A>G) B-I-1 77 n/n m/n B-I-2 42 m/n n/n B-II-1 2230 m/n m/n B-II-2 2350 m/n m/n B-II-3 137 n/n m/n C Q604E (1810C>G) Q271X (811C>T) IV9-3insT IV8-1G/A C54Y (161G>A) C-I-1 114 m/n n/n m/n m/n C-I-2 29 m/m m/n n/n m/m C-II-1 2100 m/n m/n m/n m/n C-II-2 2580 m/n m/n m/n m/n D W361X (1083G>A) D-I-1 22 m/n D-II-1 715 m/m E W361X (1083G>A) E-I-1 23 m/n E-II-1 1844 m/m E-II-2 21 n/n Mutations are shown in bold and large font.
X
ABCG5 p.Gln604Glu 16029460:174:318
status: VERIFIED175 Polymorphisms (R50C and Q604E in ABCG5, C54Y in ABCG8) are shown in italics.
X
ABCG5 p.Gln604Glu 16029460:175:24
status: VERIFIED
PMID: 16507104
[PubMed]
Pandit B et al: "A detailed Hapmap of the Sitosterolemia locus spanning 69 kb; differences between Caucasians and African-Americans."
No.
Sentence
Comment
64
Only two loci in ABCG5, R50C and Q604E showed variations in our study population, the remaining 4 SNPs were invariant in all subjects and are not depicted in the haplotype analyses.
X
ABCG5 p.Gln604Glu 16507104:64:33
status: VERIFIED106 and INT1-7, and to a lesser extent between INT1-7 and both 5'UTR-19 and Q604E (Table 4).
X
ABCG5 p.Gln604Glu 16507104:106:72
status: VERIFIED132 The only cSNP we could estimate by this methodology in ABCG5 was Q604E (~4,000 y old).
X
ABCG5 p.Gln604Glu 16507104:132:65
status: VERIFIED144 A number of studies have been implicated this locus in disease (or physiologi- Table 4: Results of pair-wise LD analyses Population M1 M2 ChiSq Pval ∆2 D' Caucasian INT1-21 INT1-7 20.01 1E-05 0.545 0.866 5'UTR-19 INT1-7 9.61 0.002 0.256 0.594 Q604E INT1-7 7.14 0.008 0.239 0.489 T400K A632V 6.13 0.013 0.125 1.000 5'UTR-19 T400K 5.84 0.016 0.153 1.000 Q604E D19H 5.02 0.025 0.174 1.000 INT1-7 T400K 4.94 0.026 0.111 1.000 R50C D19H 4.79 0.029 0.234 0.484 INT1-21 T400K 4.45 0.035 0.153 1.000 E238L INT10-50 4.42 0.036 0.238 1.000 INT1-7 C54Y 4.41 0.036 0.138 0.739 5'UTR-19 C54Y 4.24 0.040 0.134 0.619 T400K INT10-50 3.92 0.048 0.040 1.000 5'UTR-19 A565A 3.86 0.049 0.127 1.000 Q604E INT1-21 3.66 0.056 0.128 0.420 INT10-50 A632V 3.29 0.070 0.132 0.641 5'UTR-19 INT1-21 2.86 0.091 0.071 0.267 C54Y T400K 2.74 0.098 0.082 0.433 African-American 5'UTR-19 T400K 11.01 9E-04 0.080 1.000 INT1-7 A565A 8.09 0.004 0.085 0.587 R50C D19H 6.96 0.008 0.205 1.000 T400K A565A 6.56 0.010 0.088 0.557 Q604E INT1-21 5.82 0.016 0.119 0.505 5'UTR-19 A565A 5.10 0.024 0.059 0.460 C54Y A565A 3.93 0.047 0.053 0.270 5'UTR-19 C54Y 3.49 0.062 0.047 0.481 R50C INT1-7 3.05 0.081 0.044 1.000 INT1-7 A632V 3.05 0.081 0.044 1.000 Q604E D19H 3.01 0.083 0.038 1.000 M1 = 1st marker in pair of SNPs, M2 = 2nd marker in pair of SNPs, ChiSq = Value of chi-square test of association, Pval = Two-sided P-value corresponding to chi-square value in ChiSq column assuming 1 degree of freedom.
X
ABCG5 p.Gln604Glu 16507104:144:249
status: NEWX
ABCG5 p.Gln604Glu 16507104:144:250
status: VERIFIEDX
ABCG5 p.Gln604Glu 16507104:144:358
status: NEWX
ABCG5 p.Gln604Glu 16507104:144:359
status: VERIFIEDX
ABCG5 p.Gln604Glu 16507104:144:684
status: NEW166 SNPs in intron 1 of ABCG8 show some linkage to a common non-synonymous SNP, Q604E, in ABCG5, but present in exon 13 (almost 20 kb apart).
X
ABCG5 p.Gln604Glu 16507104:166:76
status: VERIFIED177 SNP Allele Number of Disease Chromosomes* Number of Healthy Chromosomes* Frequency (disease chromosome) Frequency (healthy chromosome) Recombination Fraction Age Estimate (generations) R50C C 12 12 1 1 NA Q604E G 2 1 0.167 0.083 0.058833 17.7 5'UTR-19 T 11 10 0.917 0.833 0.033059 9.1 D19H G 12 12 1 1 NA NA INT1-21 C 12 7 1 0.583 0.005 0 INT1-7 C 11 11 0.917 0.917 NA C54Y A 9 5 0.75 0.417 0.02749 8.8 E238L G 12 12 1 1 NA T400K A 10 3 0.833 0.25 0.0002 2387 INT10-50 T 12 12 1 1 NA A565A C 12 12 1 1 NA G575R G 12 12 1 1 NA A632V C 11 10 0.917 0.833 0.005692 52.9 *Out of a total of 12 disease and 12 normal chromosomes, see Methods and ABCG8 are proposed to function as obligate heterodimers [54], and complete mutations in either gene seems to result in an identical phenotype [8], these genetic findings posit an enigma.
X
ABCG5 p.Gln604Glu 16507104:177:205
status: VERIFIED
PMID: 16518588
[PubMed]
Lally S et al: "Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein."
No.
Sentence
Comment
182
It is interesting to see that polymorphisms in the Q604E allele of the ABCG5 gene in men were associated with insulin resistance [32].
X
ABCG5 p.Gln604Glu 16518588:182:51
status: VERIFIED181 It is interesting to see that polymorphisms in the Q604E allele of the ABCG5 gene in men were associated with insulin resistance [32].
X
ABCG5 p.Gln604Glu 16518588:181:51
status: NEW
PMID: 16980816
[PubMed]
Viturro E et al: "Cholesterol and saturated fat intake determine the effect of polymorphisms at ABCG5/ABCG8 genes on lipid levels in children."
No.
Sentence
Comment
2
Methods: The polymorphisms ABCG5 C1950G (Gln604Glu) and ABCG8 C1895T (Ala640Val) were determined by polymerase chain reaction and restriction analysis in 1227 healthy school children, aged 6 to 8 years.
X
ABCG5 p.Gln604Glu 16980816:2:41
status: VERIFIED11 Studies undertaken to determine the relationship between dietary cholesterol absorption and plasma lipoprotein levels showed large individual differences in dietary cholesterol absorption, suggesting a genetic variation among humans in the regulation of this process.8,9 When cholesterol absorption was studied, two members of the human adenosine triphosphate (ATP) Binding Cassette (ABC) transporter family,10 ABCG5 and ABCG8, seem to play a capital role.10,11 These two ATP-dependent half-transporters join to form a transport unit that regulates the absorption of cholesterol from the diet (intestine) and its excretion in the bile (liver).11 Their discovery came from the study of a rare genetic disease, sitosterolemia, characterized by abnormal sterol levels in the blood, caused by the genetic disruption of the ABCG5/G8 transport unit.12 Several mutations in the ABCG5 and ABCG8 genes were identified at this time in sitosterolemic patients.13-15 In addition, common polymorphic variants of these genes have been hypothesized to be related to plasma lipid level differences in the general population, although this association is not clear yet.16,17 Thus, in this study we examined the influence of two of those polymorphisms in the ABCG5 and ABCG8 genes (C1950G [Gln604Glu] and C1895T [Ala640Val], respectively), on determining plasma lipid levels in a sample-based population of 1227 healthy Spanish children, with special attention to the potential effect of dietetic parameters in this determination.
X
ABCG5 p.Gln604Glu 16980816:11:1272
status: VERIFIED
PMID: 17002235
[PubMed]
Chan YM et al: "Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease."
No.
Sentence
Comment
71
Aside from the rare mutation of a homozygous form resulting in sitosterolemia, several common sequence variations have been described.71 Different studies have shown independently that the cross-sectional plant sterol-to-cholesterol ratio is associated with different ABCG5 and ABCG8 polymorphisms.10,27,72 Out of the five polymorphisms analyzed in relation to concentrations of plant sterols, D19H, Y54C, T400K, A632V, and Q604E, the polymorphisms D19H in exon 1 and T400K in exon 8 of ABCG8 show the most pronounced association.
X
ABCG5 p.Gln604Glu 17002235:71:424
status: VERIFIED72 Carriers of the H allele of the D19H polymorphism in ABCG8 were found to have a lower plasma campesterol-to-cholesterol ratio10,27 and sitosterol-to-cholesterol ratio,10 suggesting a higher activity of this variant.
X
ABCG5 p.Gln604Glu 17002235:72:424
status: NEW
PMID: 17827468
[PubMed]
Santosa S et al: "Single nucleotide polymorphisms in ABCG5 and ABCG8 are associated with changes in cholesterol metabolism during weight loss."
No.
Sentence
Comment
4
Homozygous Q604E variants in ABCG5 had larger (P , 0.05) reductions in cholesterol absorption and greater increases (P , 0.05) in synthesis in contrast to heterozygous and homozygous wild-type carriers.
X
ABCG5 p.Gln604Glu 17827468:4:11
status: VERIFIED7 The direction of the results is consistent with cross-sectional studies on the effects of Q604E and C54Y polymorphisms on plasma cholesterol.
X
ABCG5 p.Gln604Glu 17827468:7:90
status: VERIFIED32 More specifically, these SNPs include Q604E (RS6720173), I18427 (RS4148189), I7892 (RS4131229), and M216 (RS3806471) in ABCG5 and C54Y (RS4148211), D19H (RS11887534), T400K (RS4148217), and I14222 (RS6709904) in ABCG8 (11, 13, 16, 17).
X
ABCG5 p.Gln604Glu 17827468:32:38
status: VERIFIED36 In a cross-sectional study, Weggemans et al. (19) reported that individuals homozygous for the wild type of the Q604E SNP of ABCG5 had TC concentrations that were lower than those of carriers of at least one mutant allele.
X
ABCG5 p.Gln604Glu 17827468:36:112
status: VERIFIED82 SNPs Q604E, I18429, I7892, and M216 in ABCG5 and C54Y, D19H, I14222, and T400K in ABCG8 were determined using PCR-based TaqMan allele discrimination assays (Applied Biosystems, Foster City, CA) (29).
X
ABCG5 p.Gln604Glu 17827468:82:5
status: VERIFIED113 Effects of genotype on cholesterol metabolism Changes in cholesterol absorption were related to the Q604E SNP in ABCG5 (Table 3).
X
ABCG5 p.Gln604Glu 17827468:113:100
status: VERIFIED115 Individuals who were homozygous for the Q604E SNP also had higher initial (P 5 0.026 and P 5 0.039) cholesterol absorption (86.5 6 13.3%) compared with heterozygous (57.2 6 11.8%) and homozygous wild-type (59.7 6 18.5%) subjects.
X
ABCG5 p.Gln604Glu 17827468:115:40
status: VERIFIED119 When individuals who were heterozygous were grouped with individuals who were homozygous for the Q604E SNP variant, no significant differences were identified in indicators of cholesterol metabolism.
X
ABCG5 p.Gln604Glu 17827468:119:97
status: VERIFIED126 The results indicate that homozygous variant carriers of the Q604E SNP in ABCG5 experienced larger decreases in cholesterol absorption and increased FSR after weight loss.
X
ABCG5 p.Gln604Glu 17827468:126:61
status: VERIFIED132 Individual subject genotypes for each SNP in ABCG5 and ABCG8 ABCG5 ABCG8 Q604E I18429 I7892 M216 C54Y D19H I14222 T400K 11 11 12 12 12 11 11 11 11 11 11 11 11 11 11 12 12 12 11 11 11 12 12 12 11 11 12 12 12 11 11 12 11 11 22 22 22 11 11 11 11 11 22 12 12 11 12 11 12 12 11 11 11 11 11 12 11 11 11 11 11 11 11 22 22 12 11 11 11 12 12 11 11 11 12 12 12 12 12 12 11 11 22 22 22 11 11 11 12 12 12 12 22 11 11 11 12 12 11 11 11 12 12 12 11 11 11 11 12 11 11 11 12 12 11 11 11 12 12 11 22 12 11 11 11 12 12 11 11 11 12 12 12 11 11 11 11 11 12 11 11 12 12 11 11 11 12 12 22 11 11 11 12 12 11 11 11 11 11 12 12 11 11 11 11 11 11 12 12 12 22 22 12 11 11 12 11 12 11 11 11 11 11 22 11 11 22 22 22 11 11 11 11 11 12 12 12 11 11 11 12 12 12 11 11 12 12 11 22 12 12 11 11 11 12 11 12 11 12 12 12 11 11 12 11 11 22 22 22 11 11 11 12 11 22 22 22 11 11 11 11 11 11 11 12 11 11 11 11 11 12 22 12 11 11 11 12 11 11 11 11 12 11 11 11 11 11 11 11 11 11 11 12 12 12 12 12 11 11 12 SNP, single nucleotide polymorphism.
X
ABCG5 p.Gln604Glu 17827468:132:73
status: VERIFIED138 The Q604E SNP is located on exon 13 of the ABCG5 gene and is encoded on a loop that faces the luminal or cell surface (16).
X
ABCG5 p.Gln604Glu 17827468:138:4
status: VERIFIED147 A novel finding of this trial is that changes in cholesterol absorption and synthesis after weight loss, measured by stable isotopes, were affected by the Q604E and C54Y SNPs.
X
ABCG5 p.Gln604Glu 17827468:147:155
status: VERIFIED150 Cholesterol metabolism and change according to exon SNPs in ABCG5 and ABCG8 Cholesterol Biosynthesis Cholesterol Absorption Cholesterol Turnover SNP Initial Final Change Initial Final Change Initial Final Change %/day %/day %/day % % % % % % Q604E QQ 8.48 6 6.76 6.16 6 5.66 22.32 6 8.86 59.7 6 18.5a 65.7 6 13.7 5.94 6 18.3c 39.1 6 5.99 36.5 6 8.14 22.45 6 9.76 QE 13.9 6 9.05 6.48 6 3.95 27.39 6 9.36a 57.2 6 11.8b 64.5 6 18.0 7.33 6 15.6d 37.5 6 9.27 39.5 6 6.31 1.93 6 8.59 EE 7.91 6 4.91 9.60 6 5.09 1.69 6 10.0a 86.5 6 13.3a,b 55.7 6 13.5 230.8 6 1.90c,d 40.8 6 3.72 45.3 6 8.63 4.47 6 12.1 QE 1 EE 12.8 6 8.63 7.07 6 4.18 25.69 6 9.84 62.6 6 16.6 62.8 6 17.2 0.18 6 20.7 38.2 6 8.44 40.6 6 6.86 2.43 6 8.94 C54Y CC 9.96 6 8.83 5.18 6 4.88a 24.78 6 9.62 64.9 6 15.4 67.5 6 16.4 2.67 6 22.0 37.0 6 8.43 38.1 6 7.68 1.13 6 10.6 CY 8.95 6 5.34 8.79 6 5.35 20.17 6 7.60a 54.2 6 13.5 65.4 6 12.2 11.2 6 12.9 38.3 6 5.00 40.1 6 8.42 1.77 6 8.67 YY 14.1 6 9.07 5.99 6 3.74 28.09 6 10.3a 64.1 6 25.6 55.3 6 15.6 28.80 6 17.9 43.3 6 6.57 36.2 6 7.00 27.03 6 6.42 CY 1 YY 10.8 6 7.16 7.76 6 4.90a 23.08 6 9.28 57.9 6 18.8 61.7 6 14.0 3.85 6 17.5 40.0 6 5.87 38.8 6 8.00 21.17 6 8.89 D19H DD 10.1 6 6.68 6.54 6 5.28 23.55 6 8.28 58.8 6 15.9 61.8 6 13.3 3.00 6 17.2 39.1 6 6.00 38.2 6 7.59 20.70 6 8.41 DH 11.4 6 11.0 6.68 6 4.35 24.76 6 12.4 67.5 6 21.2 71.7 6 18.8 4.19 6 25.9 37.5 6 10.2 39.1 6 8.57 1.45 6 12.3 T400K TT 10.4 6 8.91 6.91 6 5.51 23.53 6 10.9 64.4 6 19.4 63.6 6 17.2 20.76 6 20.2 40.4 6 5.15 38.9 6 7.39 21.61 6 9.46 TK 1 KK 10.4 6 5.99 6.01 6 4.12 24.42 6 6.29 55.4 6 12.2 65.6 6 11.6 10.2 6 16.5 35.8 6 9.10 37.7 6 8.52 2.24 6 9.64 a,b Significant difference between groups (P , 0.05).
X
ABCG5 p.Gln604Glu 17827468:150:242
status: VERIFIED153 Genotype distribution and frequency of SNPs in introns and exons of ABCG5 and ABCG8 in the studied population Homozygous Wild Type Heterozygous Homozygous Variant SNP n Age BMI n Age BMI n Age BMI % years kg/m2 % years kg/m2 % years kg/m2 ABCG5 Q604E 19 (54.3) 48.6 6 6.56 31.0 6 2.92 13 (37.1) 50.2 6 7.24 32.0 6 2.79 3 (8.6) 51.0 6 6.56 30.6 6 2.45 I18429 22 (62.9) 49.1 6 6.91 31.2 6 2.81 13 (37.1) 49.9 6 6.51 31.7 6 2.91 0 (0) I7892 15 (42.9) 50.1 6 7.09 30.6 6 2.55 13 (37.1) 46.9 6 6.59 32.1 6 3.02 7 (20.0) 52.3 6 4.96 31.5 6 2.98 M216 18 (51.4) 50.3 6 6.89 30.6 6 2.33a 10 (28.6) 45.0 6 5.19b 33.2 6 2.99a 7 (20.0) 53.1 6 5.21b 30.6 6 2.85 ABCG8 C54Y 16 (45.7) 50.4 6 7.10 30.8 6 2.42 12 (34.3) 46.9 6 6.33 31.5 6 2.28 7 (20.0) 51.3 6 5.88 32.5 6 4.26 D19H 26 (74.3) 48.9 6 7.06 31.7 6 3.00 9 (25.7) 50.8 6 5.89 30.3 6 2.01 0 (0) I14222 25 (71.4) 48.6 6 7.16 31.5 6 3.06 10 (28.6) 51.2 6 5.18 31.0 6 2.17 0 (0) T400K 22 (62.9) 50.6 6 5.67 31.2 6 3.03 11 (31.4) 46.6 6 8.43 31.9 6 2.40 2 (5.7) 50.5 6 3.54 31.0 6 3.82 BMI, body mass index.
X
ABCG5 p.Gln604Glu 17827468:153:245
status: VERIFIED146 A trial by Chan et al. (35) that included 47 overweight men, however, resulted in observations consistent with those of the present investigation, in that they found no differences in sterol indicators of cholesterol absorption with respect to the D19H SNP.
X
ABCG5 p.Gln604Glu 17827468:146:155
status: NEW112 Effects of genotype on cholesterol metabolism Changes in cholesterol absorption were related to the Q604E SNP in ABCG5 (Table 3).
X
ABCG5 p.Gln604Glu 17827468:112:100
status: NEW114 Individuals who were homozygous for the Q604E SNP also had higher initial (P 5 0.026 and P 5 0.039) cholesterol absorption (86.5 6 13.3%) compared with heterozygous (57.2 6 11.8%) and homozygous wild-type (59.7 6 18.5%) subjects.
X
ABCG5 p.Gln604Glu 17827468:114:40
status: NEW118 When individuals who were heterozygous were grouped with individuals who were homozygous for the Q604E SNP variant, no significant differences were identified in indicators of cholesterol metabolism.
X
ABCG5 p.Gln604Glu 17827468:118:97
status: NEW125 The results indicate that homozygous variant carriers of the Q604E SNP in ABCG5 experienced larger decreases in cholesterol absorption and increased FSR after weight loss.
X
ABCG5 p.Gln604Glu 17827468:125:61
status: NEW131 Individual subject genotypes for each SNP in ABCG5 and ABCG8 ABCG5 ABCG8 Q604E I18429 I7892 M216 C54Y D19H I14222 T400K 11 11 12 12 12 11 11 11 11 11 11 11 11 11 11 12 12 12 11 11 11 12 12 12 11 11 12 12 12 11 11 12 11 11 22 22 22 11 11 11 11 11 22 12 12 11 12 11 12 12 11 11 11 11 11 12 11 11 11 11 11 11 11 22 22 12 11 11 11 12 12 11 11 11 12 12 12 12 12 12 11 11 22 22 22 11 11 11 12 12 12 12 22 11 11 11 12 12 11 11 11 12 12 12 11 11 11 11 12 11 11 11 12 12 11 11 11 12 12 11 22 12 11 11 11 12 12 11 11 11 12 12 12 11 11 11 11 11 12 11 11 12 12 11 11 11 12 12 22 11 11 11 12 12 11 11 11 11 11 12 12 11 11 11 11 11 11 12 12 12 22 22 12 11 11 12 11 12 11 11 11 11 11 22 11 11 22 22 22 11 11 11 11 11 12 12 12 11 11 11 12 12 12 11 11 12 12 11 22 12 12 11 11 11 12 11 12 11 12 12 12 11 11 12 11 11 22 22 22 11 11 11 12 11 22 22 22 11 11 11 11 11 11 11 12 11 11 11 11 11 12 22 12 11 11 11 12 11 11 11 11 12 11 11 11 11 11 11 11 11 11 11 12 12 12 12 12 11 11 12 SNP, single nucleotide polymorphism.
X
ABCG5 p.Gln604Glu 17827468:131:73
status: NEW137 The Q604E SNP is located on exon 13 of the ABCG5 gene and is encoded on a loop that faces the luminal or cell surface (16).
X
ABCG5 p.Gln604Glu 17827468:137:4
status: NEW149 Cholesterol metabolism and change according to exon SNPs in ABCG5 and ABCG8 Cholesterol Biosynthesis Cholesterol Absorption Cholesterol Turnover SNP Initial Final Change Initial Final Change Initial Final Change %/day %/day %/day % % % % % % Q604E QQ 8.48 6 6.76 6.16 6 5.66 22.32 6 8.86 59.7 6 18.5a 65.7 6 13.7 5.94 6 18.3c 39.1 6 5.99 36.5 6 8.14 22.45 6 9.76 QE 13.9 6 9.05 6.48 6 3.95 27.39 6 9.36a 57.2 6 11.8b 64.5 6 18.0 7.33 6 15.6d 37.5 6 9.27 39.5 6 6.31 1.93 6 8.59 EE 7.91 6 4.91 9.60 6 5.09 1.69 6 10.0a 86.5 6 13.3a,b 55.7 6 13.5 230.8 6 1.90c,d 40.8 6 3.72 45.3 6 8.63 4.47 6 12.1 QE 1 EE 12.8 6 8.63 7.07 6 4.18 25.69 6 9.84 62.6 6 16.6 62.8 6 17.2 0.18 6 20.7 38.2 6 8.44 40.6 6 6.86 2.43 6 8.94 C54Y CC 9.96 6 8.83 5.18 6 4.88a 24.78 6 9.62 64.9 6 15.4 67.5 6 16.4 2.67 6 22.0 37.0 6 8.43 38.1 6 7.68 1.13 6 10.6 CY 8.95 6 5.34 8.79 6 5.35 20.17 6 7.60a 54.2 6 13.5 65.4 6 12.2 11.2 6 12.9 38.3 6 5.00 40.1 6 8.42 1.77 6 8.67 YY 14.1 6 9.07 5.99 6 3.74 28.09 6 10.3a 64.1 6 25.6 55.3 6 15.6 28.80 6 17.9 43.3 6 6.57 36.2 6 7.00 27.03 6 6.42 CY 1 YY 10.8 6 7.16 7.76 6 4.90a 23.08 6 9.28 57.9 6 18.8 61.7 6 14.0 3.85 6 17.5 40.0 6 5.87 38.8 6 8.00 21.17 6 8.89 D19H DD 10.1 6 6.68 6.54 6 5.28 23.55 6 8.28 58.8 6 15.9 61.8 6 13.3 3.00 6 17.2 39.1 6 6.00 38.2 6 7.59 20.70 6 8.41 DH 11.4 6 11.0 6.68 6 4.35 24.76 6 12.4 67.5 6 21.2 71.7 6 18.8 4.19 6 25.9 37.5 6 10.2 39.1 6 8.57 1.45 6 12.3 T400K TT 10.4 6 8.91 6.91 6 5.51 23.53 6 10.9 64.4 6 19.4 63.6 6 17.2 20.76 6 20.2 40.4 6 5.15 38.9 6 7.39 21.61 6 9.46 TK 1 KK 10.4 6 5.99 6.01 6 4.12 24.42 6 6.29 55.4 6 12.2 65.6 6 11.6 10.2 6 16.5 35.8 6 9.10 37.7 6 8.52 2.24 6 9.64 a,b Significant difference between groups (P , 0.05).
X
ABCG5 p.Gln604Glu 17827468:149:242
status: NEW152 Genotype distribution and frequency of SNPs in introns and exons of ABCG5 and ABCG8 in the studied population Homozygous Wild Type Heterozygous Homozygous Variant SNP n Age BMI n Age BMI n Age BMI % years kg/m2 % years kg/m2 % years kg/m2 ABCG5 Q604E 19 (54.3) 48.6 6 6.56 31.0 6 2.92 13 (37.1) 50.2 6 7.24 32.0 6 2.79 3 (8.6) 51.0 6 6.56 30.6 6 2.45 I18429 22 (62.9) 49.1 6 6.91 31.2 6 2.81 13 (37.1) 49.9 6 6.51 31.7 6 2.91 0 (0) I7892 15 (42.9) 50.1 6 7.09 30.6 6 2.55 13 (37.1) 46.9 6 6.59 32.1 6 3.02 7 (20.0) 52.3 6 4.96 31.5 6 2.98 M216 18 (51.4) 50.3 6 6.89 30.6 6 2.33a 10 (28.6) 45.0 6 5.19b 33.2 6 2.99a 7 (20.0) 53.1 6 5.21b 30.6 6 2.85 ABCG8 C54Y 16 (45.7) 50.4 6 7.10 30.8 6 2.42 12 (34.3) 46.9 6 6.33 31.5 6 2.28 7 (20.0) 51.3 6 5.88 32.5 6 4.26 D19H 26 (74.3) 48.9 6 7.06 31.7 6 3.00 9 (25.7) 50.8 6 5.89 30.3 6 2.01 0 (0) I14222 25 (71.4) 48.6 6 7.16 31.5 6 3.06 10 (28.6) 51.2 6 5.18 31.0 6 2.17 0 (0) T400K 22 (62.9) 50.6 6 5.67 31.2 6 3.03 11 (31.4) 46.6 6 8.43 31.9 6 2.40 2 (5.7) 50.5 6 3.54 31.0 6 3.82 BMI, body mass index.
X
ABCG5 p.Gln604Glu 17827468:152:245
status: NEW
PMID: 18457353
[PubMed]
Kuo KK et al: "Significant association of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone disease."
No.
Sentence
Comment
125
Acalovschi and co-workers17 found that polymorphisms at D19H and Q604E were significantly associated with a lithogenic plasma lipid profile in siblings with gallstone disease.
X
ABCG5 p.Gln604Glu 18457353:125:65
status: VERIFIED
PMID: 18522623
[PubMed]
Rudkowska I et al: "Polymorphisms in ABCG5/G8 transporters linked to hypercholesterolemia and gallstone disease."
No.
Sentence
Comment
3
Various polymorphisms (A632V, T400K, D19H, M429V, and C54Y) in the ABCG8 and ABCG5 (Q604E) gene have been found to be associated with several facets of cholesterol metabolism, including baseline cholesterol level, cholesterol kinetics, individual responsiveness of plasma cholesterol to dietary and pharmaceutical interventions for hypercholesterolemia, and increased risk of gallstones.
X
ABCG5 p.Gln604Glu 18522623:3:84
status: VERIFIED10 The heterogeneity of the effect of dietary changes on plasma lipid concentrations among individuals is well known.5 Plasma lipids in certain persons are relatively unresponsive to dietary interventions, whereas others have enhanced sensitivity.5 For example, Weggemans et al.6 demonstrated that carriers of the ABCG5 Q604E Affiliations: I Rudkowska is with the School of Dietetics and Human Nutrition, Faculty of Agricultural and Environmental Sciences, McGill University, Ste-Anne-de-Bellevue, Quebec, Canada.
X
ABCG5 p.Gln604Glu 18522623:10:317
status: VERIFIED16 However, the response to diets either low or high in cholesterol on plasma TC and plasma low-density lipoprotein cholesterol (LDL-C) concentrations were shown not to be related to this genotype.Contrary to these results, Herron et al.7 found that a shift from a low- to a high-dietary-cholesterol diet in individuals with the ABCG5 Q604E mutant allele was associated with a greater increase in plasma LDL-C compared to subjects who were heterozygous or who carried only the wild-type allele.
X
ABCG5 p.Gln604Glu 18522623:16:332
status: VERIFIED17 Other studies8-10 failed to observe associations between the ABCG5 Q604E polymorphism and plasma lipid concentrations following dietary or drug intervention.
X
ABCG5 p.Gln604Glu 18522623:17:67
status: VERIFIED18 In addition, no differences in plasma TC and LDL-C were found in yet another study, which investigated associations of blood lipids in genotypes of healthy children with the polymorphisms ABCG5 Q604E and ABCG8 A640V.11 Since 55% of the children studied had at least one mutation in ABCG5 Q604E or ABCG8 A640V, a subanalysis was performed separating subjects according to their dietary cholesterol and saturated fat intakes.
X
ABCG5 p.Gln604Glu 18522623:18:194
status: VERIFIEDX
ABCG5 p.Gln604Glu 18522623:18:288
status: VERIFIED19 In this subanalysis, the researchers found that the presence of the mutant alleles was associated with higher plasma TC, LDL-C, and apolipoprotein B, but only in children with low cholesterol intake for ABCG8 A640V and low saturated fat intake for ABCG5 Q604E.11 These findings led to speculation that a gene-nutrient interaction could explain the individual variations in plasma lipid in response to changes in cholesterol and fat intake.
X
ABCG5 p.Gln604Glu 18522623:19:254
status: VERIFIED21 Hubacek et al.12 reported that none of the polymorphisms examined, including ABCG5 Q604E, ABCG8 D19H and A632V, were related to plasma lipid levels or changes in plasma lipid levels in subjects after "evolutionary" dietary changes from a traditional high-fat Eastern European diet to a lower-fat diet based on nutritional advice.
X
ABCG5 p.Gln604Glu 18522623:21:83
status: VERIFIED27 In addition, these investigators also observed that carriers of the T400K and A632V polymorphisms in the ABCG8 gene exhibited higher cholesterol synthesis and higher plasma TC, respectively.8 Gylling et al.9 failed to show an association between cholesterol kinetics and T400K and A632V polymorphisms in the ABCG8 gene, but found that carriers of the mutant Q604E allele of the ABCG5 gene had high cholesterol absorption and thus had higher characteristics of the insulin resistance syndrome.
X
ABCG5 p.Gln604Glu 18522623:27:358
status: VERIFIED28 In accordance, Santosa et al.14 found that women with the Q604E mutation in the ABCG5 gene had greater reductions in cholesterol absorption, along with higher increases in cholesterol synthesis, in contrast to wild-type allele carriers after a weight loss intervention.Additionally,among female subjects, heterozygous ABCG8 C54Y carriers had smaller decreases in cholesterol synthesis compared to homozygous allele carriers.14 These data correspond with evidence from the study mentioned above12 in which the Nutrition Reviews® Vol. 66():343-348344 Cys54 allele carriers possessed lower TC and LDL-C reductions.
X
ABCG5 p.Gln604Glu 18522623:28:58
status: VERIFIED29 ROLE OF RACE-RELATED DIFFERENCES IN ABC GENOTYPES Miwa et al.,15 studying a Japanese population, concluded that carriers of a novel ABCG8 M429V allele or a specific haplotype (wild-type allele of Q604E ABCG5, and wild-type allele of C54Y, wild-type allele of T400K, mutant allele of M429V in the ABCG8 gene), were associated with higher cholesterol absorption efficiency, as well as lower cholesterol synthesis rates.
X
ABCG5 p.Gln604Glu 18522623:29:196
status: VERIFIED30 These findings in the Japanese group are not without exception; no difference was observed in lipid profiles in relation to common polymorphisms studied previously [ABCG8 (A632V, T400K, D19H, and C54Y) and ABCG5 (Q604E)],6,7,11,12 which might be explained by the fact that carriers of ABCG8 D19H and A632A polymorphisms are rare in the Japanese population compared to Western populations.
X
ABCG5 p.Gln604Glu 18522623:30:213
status: VERIFIED31 Also, polymorphisms of Q604E and T400K alleles may not be as important in the regulation of non-cholesterol-sterol levels in the Japanese population.15 In a more recent trial, no detection of this SNP (ABCG8 M429V allele) was recorded in either the Caucasian or the African-American population studied, thereby potentially demonstrating a race-specific polymorphism.16 In general, these studies demonstrate the benefits of using an intermediate phenotype, such as cholesterol absorption and synthesis, to determine the link between SNPs and blood lipids in relation to a dietary treatment.
X
ABCG5 p.Gln604Glu 18522623:31:23
status: VERIFIED38 Other ABCG5 and G8 polymorphisms (Q604E, C54Y, T400K, and A632V) and CYP7A1 in hypercholesterolemic patients had no apparent association with responsiveness to statin treatment.
X
ABCG5 p.Gln604Glu 18522623:38:34
status: VERIFIED41 In addition, carriers of the mutant allele ABCG5 Q604E, compared to wild type, were found to have higher baseline plasma LDL-C.
X
ABCG5 p.Gln604Glu 18522623:41:49
status: VERIFIED47 Knowing this, it may be of interest to first determine if a relationship exists between cholesterol in the blood and cholesterol gallstones.Acalovschi et al.18 found that circulatory TC and triglyceride levels in gallstone patients were higher in carriers of the wild-type allele of the ABCG5 Q604E and ABCG8 D19H compared with mutant allele carriers.
X
ABCG5 p.Gln604Glu 18522623:47:293
status: VERIFIED51 On the other hand, Wang et al.24 investigated a possible association between three polymorphisms, including C54Y, T400K alleles of ABCG8, and Q604E of ABCG5 gene, and gallstone formation in a Chinese population.
X
ABCG5 p.Gln604Glu 18522623:51:142
status: VERIFIED61 Overall, these studies identify a variety of polymorphisms in ABCG8 (A632V, T400K, D19H, and C54Y) and in ABCG5 (Q604E) that have been linked with baseline cholesterol levels, cholesterol absorption, or responsiveness to dietary intervention.3-12,15-17 In addition, genetic variations in the ABCG8 gene (D19H and T400K) may increase the risk of gallstone disease in certain populations.22-24 Table 1 summarizes potential SNPs and the effects of the mutant allele on baseline blood lipid concentrations, cholesterol kinetics, responsiveness to interventions, and gallstone disease risk.
X
ABCG5 p.Gln604Glu 18522623:61:113
status: VERIFIED
PMID: 18581044
[PubMed]
Chen ZC et al: "Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance."
No.
Sentence
Comment
5
Five nonsynonymous polymorphisms of Q604E (ABCG5), D19H, C54Y, T400 K and A632 V (ABCG8) were analyzed by TaqMan genotyping assay.
X
ABCG5 p.Gln604Glu 18581044:5:36
status: VERIFIED42 Five nonsynonymous polymorphisms, including Q604E (rs6720173) of the ABCG5 gene and D19H (rs11887534), C54Y (rs4148211), T400K (rs4148217) and A632V (rs6544718) of the ABCG8 gene, were chosen for genotyping (http://www.ncbi.nlm.nih.gov/).
X
ABCG5 p.Gln604Glu 18581044:42:44
status: VERIFIED62 Five nonsynonymous polymorphisms (ABCG5: Q604E; ABCG8:D19H, C54Y, T400K, A632V) were genotyped in our population.
X
ABCG5 p.Gln604Glu 18581044:62:41
status: VERIFIED64 The minor allele frequencies (MAFs) of Q604E (C:G); D19H (G:C), C54Y (G:A) and T400K (C:A) were 10.5, 1.4, 9.7 and 8.0%, respectively.
X
ABCG5 p.Gln604Glu 18581044:64:39
status: VERIFIED69 Subjects with genotype Q604 (CC) had significantly higher serum total cholesterol levels than those of genotypes Q604E (CG) or 604E (GG).
X
ABCG5 p.Gln604Glu 18581044:69:113
status: VERIFIED72 This exhibited a significant trend with an increasing frequency of the C allele in Q604 (ABCG5) and D19H (ABCG8) genotypes from the Table 1 Serum cholesterol and LDL levels for the genotypes of ABCG5/ABCG8 Cholesterol (mg/dl) P LDL-C (mg/dl) P ABCG5: Q604E (C1810G) Genotype CC (n = 9) 225.9 ± 48.5 0.008 133.7 ± 40.0 0.733 CG (n = 203) 189.6 ± 37.6 130.1 ± 32.7 GG (n = 833) 187.2 ± 38.1 127.9 ± 35.9 ABCG8:D19H (G55C) Genotype GG (n = 1,016) 187.2 ± 37.9 0.005 127.8 ± 35.2 0.023 GC (n = 30) 207.1 ± 45.1 145.1 ± 40.6 CC (n = 0) - - ABCG8:C54Y (G161A) Genotype GG (n = 853) 187.3 ± 37.8 0.297 127.8 ± 35.4 0.671 GA (n = 189) 190.4 ± 40.0 130.0 ± 35.2 AA (n = 8) 171.6 ± 24.0 118.0 ± 23.8 ABCG8:T400 K (C1199A) Genotype CC (n = 885) 188.0 ± 38.2 0.869 128.3 ± 35.4 0.997 CA (n = 164) 186.9 ± 38.2 128.3 ± 34.3 AA (n = 2) 194.0 ± 22.6 131.0 ± 10.2 P values were obtained from a one-way ANOVA and the t test desirable to the moderately high and then to the high cholesterol category.
X
ABCG5 p.Gln604Glu 18581044:72:251
status: VERIFIED83 In addition, subjects with the D19H variant were associated with an almost threefold higher risk of developing high total cholesterol and LDL-C levels Table 2 Genotype frequency of ABCG5/ABCG8 versus categorized cholesterol level Serum cholesterol (mg/dl) Desirable (\200) Moderately high (200-239) High (C240) P ABCG5: Q604E (C1810G) Genotype CC 3 (0.43%) 2 (0.84%) 4 (3.5%) 0.004 CG+GG 692 (99.6%) 235 (99.2%) 109 (96.5%) ABCG8:D19H (G55C) Genotype GG 682 (98.0%) 227 (96.6%) 104 (92.9%) 0.009 GC 14 (2.0%) 8 (3.4%) 8 (7.1%) ABCG8:C54Y (G161A) Genotype GG 576 (82.1%) 190 (80.5%) 87 (77.7%) 0.517 GA+AA 126 (17.9%) 46 (19.5%) 25 (22.3%) ABCG8:T400 K (C1199A) Genotype CC 592 (84.3%) 197 (83.5%) 96 (85.0%) 0.927 CA+AA 110 (15.7%) 39 (16.5%) 17 (15.0%) P values were obtained from the chi-square test Table 3 Comparison of the biochemical characteristics of subjects with D19 (GG) and D19H (GC) genotypes GG GC P Number 1,016 30 Sex (M:F) 870:146 24:6 0.39 Age (years) 49.1 ± 9.2 49.8 ± 11.4 0.09 BMI (kg/m2 ) 24.4 ± 3.3 25.4 ± 4.2 0.09 SBP (mmHg) 125.4 ± 16.5 124.3 ± 13.8 0.76 DBP (mmHg) 77.6 ± 11.1 78.6 ± 7.0 0.64 CHOL (mg/dl) 187.2 ± 37.9 207.1 ± 45.1 0.005 TG (mg/dl) 139.8 ± 146.3 124.5 ± 46.8 0.57 LDL-C (mg/dl) 127.8 ± 35.2 145.1 ± 40.6 0.023 HDL-C (mg/dl) 52.2 ± 13.2 53.1 ± 10.1 0.77 F-glucose (mg/dl) 96.7 ± 28.7 98.4 ± 25.2 0.76 HOMA-IR 1.12 ± 2.00 3.21 ± 7.84 0.026 Data are shown as as mean ± SD Student`s t test was used for statistical analysis and the Mann-Whitney U test was used for HOMA-IR BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHOL, cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; F-glucose, fasting glucose; HOMA-IR, homeostatic model assessment insulin resistance Table 4 Risk stratification for the ABCG8 genotypes (D19H vs. D19) in terms of serum cholesterol and LDL-C levels D19 D19H P Moderately high versus desirable cholesterol Crude odds ratio 1 1.72 (0.71-4.14) 0.23 Adjusted odds ratio 1 1.54 (0.62-3.83) 0.35 High versus desirable cholesterol Crude odds ratio 1 3.75 (1.53-9.15) 0.004 Adjusted odds ratio 1 3.44 (1.32-8.97) 0.012 Moderately high versus desirable LDL-C Crude odds ratio 1 1.92 (0.67-5.54) 0.227 Adjusted odds ratio 1 1.65 (0.55-4.89) 0.37 High versus desirable LDL-C Crude odds ratio 1 3.51 (1.25-9.85) 0.017 Adjusted odds ratio 1 3.29 (1.10-9.82) 0.033 Desirable cholesterol indicates \200 mg/dl; moderately high cholesterol indicates 200-239 mg/dl; high cholesterol indicates C240 mg/dl Desirable LDL-C indicates \130 mg/dl; moderately high LDL-C indicates 130-159 mg/dl; high LDL-C indicates C160 mg/dl Logistic regression analysis was used to estimate the odds ratio, by adjusting for age and sex.
X
ABCG5 p.Gln604Glu 18581044:83:320
status: VERIFIED114 In a study of hypercholesterolemic subjects, Q604E polymorphism was linked to insulin resistance in men (Gylling et al. 2004).
X
ABCG5 p.Gln604Glu 18581044:114:45
status: VERIFIED70 The serum total cholesterol and the LDL-C level were significantly higher in subjects with the D19H (GC) genotype than those with D19 (GG).
X
ABCG5 p.Gln604Glu 18581044:70:113
status: NEW43 Five nonsynonymous polymorphisms, including Q604E (rs6720173) of the ABCG5 gene and D19H (rs11887534), C54Y (rs4148211), T400K (rs4148217) and A632V (rs6544718) of the ABCG8 gene, were chosen for genotyping (http://www.ncbi.nlm.nih.gov/).
X
ABCG5 p.Gln604Glu 18581044:43:44
status: NEW63 Five nonsynonymous polymorphisms (ABCG5: Q604E; ABCG8:D19H, C54Y, T400K, A632V) were genotyped in our population.
X
ABCG5 p.Gln604Glu 18581044:63:41
status: NEW65 The minor allele frequencies (MAFs) of Q604E (C:G); D19H (G:C), C54Y (G:A) and T400K (C:A) were 10.5, 1.4, 9.7 and 8.0%, respectively.
X
ABCG5 p.Gln604Glu 18581044:65:39
status: NEW73 This exhibited a significant trend with an increasing frequency of the C allele in Q604 (ABCG5) and D19H (ABCG8) genotypes from the Table 1 Serum cholesterol and LDL levels for the genotypes of ABCG5/ABCG8 Cholesterol (mg/dl) P LDL-C (mg/dl) P ABCG5: Q604E (C1810G) Genotype CC (n = 9) 225.9 &#b1; 48.5 0.008 133.7 &#b1; 40.0 0.733 CG (n = 203) 189.6 &#b1; 37.6 130.1 &#b1; 32.7 GG (n = 833) 187.2 &#b1; 38.1 127.9 &#b1; 35.9 ABCG8:D19H (G55C) Genotype GG (n = 1,016) 187.2 &#b1; 37.9 0.005 127.8 &#b1; 35.2 0.023 GC (n = 30) 207.1 &#b1; 45.1 145.1 &#b1; 40.6 CC (n = 0) - - ABCG8:C54Y (G161A) Genotype GG (n = 853) 187.3 &#b1; 37.8 0.297 127.8 &#b1; 35.4 0.671 GA (n = 189) 190.4 &#b1; 40.0 130.0 &#b1; 35.2 AA (n = 8) 171.6 &#b1; 24.0 118.0 &#b1; 23.8 ABCG8:T400 K (C1199A) Genotype CC (n = 885) 188.0 &#b1; 38.2 0.869 128.3 &#b1; 35.4 0.997 CA (n = 164) 186.9 &#b1; 38.2 128.3 &#b1; 34.3 AA (n = 2) 194.0 &#b1; 22.6 131.0 &#b1; 10.2 P values were obtained from a one-way ANOVA and the t test desirable to the moderately high and then to the high cholesterol category.
X
ABCG5 p.Gln604Glu 18581044:73:251
status: NEW84 In addition, subjects with the D19H variant were associated with an almost threefold higher risk of developing high total cholesterol and LDL-C levels Table 2 Genotype frequency of ABCG5/ABCG8 versus categorized cholesterol level Serum cholesterol (mg/dl) Desirable (\200) Moderately high (200-239) High (C240) P ABCG5: Q604E (C1810G) Genotype CC 3 (0.43%) 2 (0.84%) 4 (3.5%) 0.004 CG+GG 692 (99.6%) 235 (99.2%) 109 (96.5%) ABCG8:D19H (G55C) Genotype GG 682 (98.0%) 227 (96.6%) 104 (92.9%) 0.009 GC 14 (2.0%) 8 (3.4%) 8 (7.1%) ABCG8:C54Y (G161A) Genotype GG 576 (82.1%) 190 (80.5%) 87 (77.7%) 0.517 GA+AA 126 (17.9%) 46 (19.5%) 25 (22.3%) ABCG8:T400 K (C1199A) Genotype CC 592 (84.3%) 197 (83.5%) 96 (85.0%) 0.927 CA+AA 110 (15.7%) 39 (16.5%) 17 (15.0%) P values were obtained from the chi-square test Table 3 Comparison of the biochemical characteristics of subjects with D19 (GG) and D19H (GC) genotypes GG GC P Number 1,016 30 Sex (M:F) 870:146 24:6 0.39 Age (years) 49.1 &#b1; 9.2 49.8 &#b1; 11.4 0.09 BMI (kg/m2 ) 24.4 &#b1; 3.3 25.4 &#b1; 4.2 0.09 SBP (mmHg) 125.4 &#b1; 16.5 124.3 &#b1; 13.8 0.76 DBP (mmHg) 77.6 &#b1; 11.1 78.6 &#b1; 7.0 0.64 CHOL (mg/dl) 187.2 &#b1; 37.9 207.1 &#b1; 45.1 0.005 TG (mg/dl) 139.8 &#b1; 146.3 124.5 &#b1; 46.8 0.57 LDL-C (mg/dl) 127.8 &#b1; 35.2 145.1 &#b1; 40.6 0.023 HDL-C (mg/dl) 52.2 &#b1; 13.2 53.1 &#b1; 10.1 0.77 F-glucose (mg/dl) 96.7 &#b1; 28.7 98.4 &#b1; 25.2 0.76 HOMA-IR 1.12 &#b1; 2.00 3.21 &#b1; 7.84 0.026 Data are shown as as mean &#b1; SD Student`s t test was used for statistical analysis and the Mann-Whitney U test was used for HOMA-IR BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHOL, cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; F-glucose, fasting glucose; HOMA-IR, homeostatic model assessment insulin resistance Table 4 Risk stratification for the ABCG8 genotypes (D19H vs. D19) in terms of serum cholesterol and LDL-C levels D19 D19H P Moderately high versus desirable cholesterol Crude odds ratio 1 1.72 (0.71-4.14) 0.23 Adjusted odds ratio 1 1.54 (0.62-3.83) 0.35 High versus desirable cholesterol Crude odds ratio 1 3.75 (1.53-9.15) 0.004 Adjusted odds ratio 1 3.44 (1.32-8.97) 0.012 Moderately high versus desirable LDL-C Crude odds ratio 1 1.92 (0.67-5.54) 0.227 Adjusted odds ratio 1 1.65 (0.55-4.89) 0.37 High versus desirable LDL-C Crude odds ratio 1 3.51 (1.25-9.85) 0.017 Adjusted odds ratio 1 3.29 (1.10-9.82) 0.033 Desirable cholesterol indicates \200 mg/dl; moderately high cholesterol indicates 200-239 mg/dl; high cholesterol indicates C240 mg/dl Desirable LDL-C indicates \130 mg/dl; moderately high LDL-C indicates 130-159 mg/dl; high LDL-C indicates C160 mg/dl Logistic regression analysis was used to estimate the odds ratio, by adjusting for age and sex.
X
ABCG5 p.Gln604Glu 18581044:84:320
status: NEW115 In a study of hypercholesterolemic subjects, Q604E polymorphism was linked to insulin resistance in men (Gylling et al. 2004).
X
ABCG5 p.Gln604Glu 18581044:115:45
status: NEW
PMID: 18850127
[PubMed]
Zhao HL et al: "Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men."
No.
Sentence
Comment
47
Analyses of ABCG5/G8 and NPC1L1 Genotype SNPs The ABCG5/G8 polymorphisms, 1950 G [ C (Q604E), 145 G [ C (D19H), 1289 C [ A (T400 K) and 1572 (A632 V), as well as the NPC1L1 polymorphisms, 872 C [ G (L272L) and 3929 G [ A (Y1291Y), were screened from the published SNP data demonstrating an established functional significance for cholesterol modulation.
X
ABCG5 p.Gln604Glu 18850127:47:86
status: VERIFIED51 Analyses of ABCG5/G8 and NPC1L1 Genotype SNPs The ABCG5/G8 polymorphisms, 1950 G [ C (Q604E), 145 G [ C (D19H), 1289 C [ A (T400 K) and 1572 (A632 V), as well as the NPC1L1 polymorphisms, 872 C [ G (L272L) and 3929 G [ A (Y1291Y), were screened from the published SNP data demonstrating an established functional significance for cholesterol modulation.
X
ABCG5 p.Gln604Glu 18850127:51:86
status: NEW48 Analyses of ABCG5/G8 and NPC1L1 Genotype SNPs The ABCG5/G8 polymorphisms, 1950 G [ C (Q604E), 145 G [ C (D19H), 1289 C [ A (T400 K) and 1572 (A632 V), as well as the NPC1L1 polymorphisms, 872 C [ G (L272L) and 3929 G [ A (Y1291Y), were screened from the published SNP data demonstrating an established functional significance for cholesterol modulation.
X
ABCG5 p.Gln604Glu 18850127:48:86
status: NEW
PMID: 19005228
[PubMed]
Junyent M et al: "The effects of ABCG5/G8 polymorphisms on plasma HDL cholesterol concentrations depend on smoking habit in the Boston Puerto Rican Health Study."
No.
Sentence
Comment
28
Some of these studies reported significant associations between ABCG5/G8 SNPs (Gln604Glu, Thr400Lys, and Tyr54Cys) and total cholesterol and LDL-C, including 154 females undergoing weight loss (13), 112 subjects after consumption of plant stanol esters (14), and 263 mildly hypercholesterolemic patients (17).
X
ABCG5 p.Gln604Glu 19005228:28:79
status: VERIFIED30 Only two studies in patients with gallstone disease reported significant associations with HDL-C (16) and triglyceride (TG) concentrations (16, 18), but not with total cholesterol and LDL-C, for ABCG5 Gln604Glu and ABCG8 Thr400Lys SNPs, respectively.
X
ABCG5 p.Gln604Glu 19005228:30:201
status: VERIFIED27 Some of these studies reported significant associations between ABCG5/G8 SNPs (Gln604Glu, Thr400Lys, and Tyr54Cys) and total cholesterol and LDL-C, including 154 females undergoing weight loss (13), 112 subjects after consumption of plant stanol esters (14), and 263 mildly hypercholesterolemic patients (17).
X
ABCG5 p.Gln604Glu 19005228:27:79
status: NEW29 Only two studies in patients with gallstone disease reported significant associations with HDL-C (16) and triglyceride (TG) concentrations (16, 18), but not with total cholesterol and LDL-C, for ABCG5 Gln604Glu and ABCG8 Thr400Lys SNPs, respectively.
X
ABCG5 p.Gln604Glu 19005228:29:201
status: NEW
PMID: 20497293
[PubMed]
Katsika D et al: "Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype."
No.
Sentence
Comment
11
ABCG5 Q604E and ABCG8 D19H genotyping was performed in 24 unique MZ and eight dizygotic (DZ) twins from concordant pairs.
X
ABCG5 p.Gln604Glu 20497293:11:6
status: VERIFIED17 We also found a trend for a positive association between gallstone disease and the Q604E variant (OR, 1.47; 95% CI, 1.00-2.16; P = 0.052).
X
ABCG5 p.Gln604Glu 20497293:17:83
status: VERIFIED30 In Chinese populations, another nonsynonymous polymorphism, Q604E on the ABCG5 gene, was found to be associated with GD [16].
X
ABCG5 p.Gln604Glu 20497293:30:60
status: VERIFIED31 To further validate the contribution of the lithogenic ABCG5 Q604E and ABCG8 D19H variants to GD, we tested for these alleles in a twin-based association study after selected sampling from the Swedish Twin Registry(STR).
X
ABCG5 p.Gln604Glu 20497293:31:61
status: VERIFIED74 Results The ABCG5 Q604E and ABCG8 D19H variants were successfully genotyped in all samples.
X
ABCG5 p.Gln604Glu 20497293:74:18
status: VERIFIED76 Table 2 summarizes the allele and genotype distributions for the ABCG5 Q604E and ABCG8 D19H variants.
X
ABCG5 p.Gln604Glu 20497293:76:71
status: VERIFIED78 Seven and six MZ twin pairs were heterozygous Q604E and D19H carriers, respectively.
X
ABCG5 p.Gln604Glu 20497293:78:46
status: VERIFIED79 Concordance for GD was found in five twin pairs with Q604E or D19H variants, respectively.
X
ABCG5 p.Gln604Glu 20497293:79:53
status: VERIFIED81 Discordant MZ twins were disregarded from further calculations, as they cannot be Table 2 Alleles and genotypes (count / frequency) for ABCG8 D19H (A) and ABCG5 Q604E (B) in all unique monozygotic, dizygotic andcontrolgenomesforSwedishtwins MZ DZ NoGD GD NoGD GD n % n % n % n % (A)AllelefrequenciesofABCG8 D19HinSwedishtwins Allele / genotype Totalscreeningpopulation GG 99 90.8 36 81.8 114 90.5 48 77.4 GC 9 8.3 8 18.2 11 8.7 13 21.0 CC 1 0.9 0 0 1 0.8 1 1.6 StockholmCountyscreeningpopulation GG 7 87.5 19 79.2 0 4 50.0 GC 1 12.5 5 20.8 0 3 37.5 CC 0 0 0 0 0 1 12.5 Nationwidescreeningpopulation GG 99 90.9 17 85.0 114 90.5 44 81.5 GC 9 8.3 3 15.0 11 8.7 10 18.5 CC 1 0.9 0 0 1 0.8 0 0.0 (B)AllelefrequenciesofABCG5Q604EinSwedishtwins Allele / genotype Totalscreeningpopulation GG 74 67.9 32 72.7 85 67.5 26 41.9 GC 32 29.4 11 25.0 33 26.2 32 51.6 CC 3 2.7 1 2.3 8 6.3 4 6.5 StockholmCountyscreeningpopulation GG 6 75.0 18 75.0 0 0 1 12.5 GC 2 25.0 5 20.8 0 0 7 87.5 CC 0 0 1 4.2 0 0 0 0 Nationwidescreeningpopulation GG 74 67.9 14 70.0 85 67.5 25 46.3 GC 32 29.4 6 30.0 33 26.2 25 46.3 CC 3 2.7 0 0 8 6.3 4 7.4 MZ,uniquegenomesinconcordantMZpairswithGDandstone-freeuniqueMZgenomes;DZ,twinsinconcordantDZpairswith GDandnonrelated stone-freeDZtwins.
X
ABCG5 p.Gln604Glu 20497293:81:161
status: VERIFIED93 Of the 108 heterozygous Q604E carriers, 43 had GD and 65 did not. There were only 16 homozygous Q604E carriers, five of whom had GD.
X
ABCG5 p.Gln604Glu 20497293:93:24
status: VERIFIEDX
ABCG5 p.Gln604Glu 20497293:93:96
status: VERIFIED95 Amongst the MZ cases, 27.3% were Q604E carriers compared to 32.1% of MZ controls. Amongst the DZ cases, 58.1% were Q604E carriers comparedto32.5%ofDZcontrols.Overall,45.3%(48 of 106) of cases were positive for the Q604E allele, compared to 32.3% (76 of 235) of controls.
X
ABCG5 p.Gln604Glu 20497293:95:33
status: VERIFIEDX
ABCG5 p.Gln604Glu 20497293:95:115
status: VERIFIEDX
ABCG5 p.Gln604Glu 20497293:95:214
status: VERIFIED105 In the same study, the ABCG5 Q604E polymorphism was also found to be associated with GD, with an OR of 6.4 in (male) patients above 50 years of age [16].
X
ABCG5 p.Gln604Glu 20497293:105:29
status: VERIFIED122 Moreover, such misclassification would be expected to bias the estimates to the null, which means that the relationship between D19H (and Q604E) and GD would be, if anything, underestimated.
X
ABCG5 p.Gln604Glu 20497293:122:138
status: VERIFIED
PMID: 20543520
[PubMed]
Tsubakio-Yamamoto K et al: "Current therapy for patients with sitosterolemia--effect of ezetimibe on plant sterol metabolism."
No.
Sentence
Comment
108
Location of the gene mutation and hematological/ biochemical laboratory data in case 1 (at the time of PCI) and case 2 (at the first visit) Case 1 Case 2 ABCG5 mutation WBC (/ L) RBC ( 104 / L) Hemoglobin (g/dL) Platelet ( 104 / L) AST (IU/L) ALT (IU/L) CRP (mg/dL) Total Cholesterol (mg/dL) LDL Cholesterol (mg/dL) HDL Cholesterol (mg/dL) Triglyceride (mg/dL) Sitosterol ( g/mL) Campesterol ( g/mL) Stigmasterol ( g/mL) A1756C (R550S) G1362A (R419H) 7,610 382 9.8 18.5 14 16 0.3 172 87 67 121 87.8 48.8 4.0 G1306A (R389H) C1949 (Q604E) 6,370 385 10.9 12.5 29 26 1.0 289 229 85 172 88.5 84.5 7.2 Fig.3.
X
ABCG5 p.Gln604Glu 20543520:108:530
status: VERIFIEDX
ABCG5 p.Gln604Glu 20543520:108:568
status: NEW
PMID: 20581104
[PubMed]
Jakulj L et al: "ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis."
No.
Sentence
Comment
141
Associations between ABCG5/G8 polymorphisms and plasma lipids and non-cholesterol sterol ratios Lipids and Lipoproteins (mmol/l) Non-Cholesterol Sterol Ratios (g/mg) SNP N TC LDL-C HDL-C Triglycerides Campesterol/TC Sitosterol/TC Cholestanol/TC Lathosterol/TC Q604E QQ 171 6.16 ± 0.76 4.05 ± 0.61 1.54 ± 0.40 1.09 [0.29-3.56] 1.45 ± 0.64 1.12 ± 0.53 1.49 ± 0.33 1.24 ± 0.49 QE/EE 72 6.23 ± 0.73 4.11 ± 0.63 1.49 ± 0.36 1.19 [0.47-3.93] 1.47 ± 0.88 1.16 ± 0.63 1.46 ± 0.38 1.28 ± 0.57 D19H DD 219 6.19 ± 0.75 4.08 ± 0.61 1.52 ± 0.40 1.10 [0.29-3.93] 1.49 ± 0.69 1.16 ± 0.55 1.49 ± 0.34 1.24 ± 0.49 DH/HH 24 6.04 ± 0.81 3.90 ± 0.63 1.60 ± 0.38 1.15 [0.47-1.97] 1.24 ± 0.82 0.92 ± 0.53 1.38 ± 0.34 1.35 ± 0.64 Y54C YY 73 6.32 ± 0.73 4.14 ± 0.64 1.58 ± 0.37 1.09 [0.45-3.93] 1.59 ± 0.76 1.22 ± 0.60 1.53 ± 0.33 1.24 ± 0.53 YC/CC 171 6.12 ± 0.76 4.03 ± 0.61 1.51 ± 0.41 1.11 [0.29-3.56] 1.41 ± 0.68 1.09 ± 0.53 1.46 ± 0.34 1.26 ± 0.50 T400K TT 183 6.16 ± 0.75 4.03 ± 0.60 1.55 ± 0.40 1.10 [0.29-3.93] 1.48 ± 0.69 1.14 ± 0.55 1.49 ± 0.35 1.25 ± 0.48 TK/KK 61 6.24 ± 0.76 4.19 ± 0.66 1.47 ± 0.37 1.14 [0.47-2.61] 1.38 ± 0.76 1.09 ± 0.59 1.45 ± 0.31 1.27 ± 0.59 A632V AA 139 6.22 ± 0.72 4.12 ± 0.60 1.51 ± 0.37 1.12 [0.33-2.90] 1.49 ± 0.72 1.16 ± 0.58 1.51 ± 0.37 1.21 ± 0.49 AV/VV 105 6.14 ± 0.79 3.99 ± 0.63 1.57 ± 0.43 1.07 [0.29-3.93] 1.42 ± 0.70 1.09 ± 0.52 1.44 ± 0.30 1.31 ± 0.52 Values shown are means ± SD. Triglycerides are shown as median [range].
X
ABCG5 p.Gln604Glu 20581104:141:268
status: VERIFIED145 TABLE3.Characteristicsofstudiesincludedinthemeta-analysis Reference Number of SubjectsAge Male/ Female BodyMass IndexEthnicitySingleNucleotidePolymorphismsLipidsNon-CholesterolSterols nyearsnkg/m 2 Berge,2002(5)14855±1174/74NotreportedCaucasianD19H,T400K,Y54C,Q604E,A632VTCCAMP,SITO,CHOLST,LATHO Weggemans,2002(7)48626.3±11.6257/22921.7±3.0CaucasianQ604ETC- Gylling,2004(13)26253.1±8.1143/11926.4±6.5CaucasianD19H,T400K,Y54C,Q604E,A632VTC,LDL-C,HDL-C,TGCAMP,SITO,CHOLST,LATHO Plat,2005(11)a 11233±1641/7122.9±3.6CaucasianT400K,Q604E,A632VLDL-C,HDL-C,TGCAMP,SITO,LATHO Acalovschi,2006(27)72 e 56.3(36-80)30/4230.1±4.9CaucasianD19H,T400K,Y54C,Q604E,A632VTC,HDL-C,TG- Jakulj,etal. b 24558.4±7.5189/4825.8±3.0CaucasianD19H,T400K,Y54C,Q604E,A632VTC,LDL-C,HDL-C,TGCAMP,SITO,CHOLST,LATHO Miwa,2005(28)10062.4±12.148/5223.0±3.5AsianT400K,Y54C,Q604E-SITO,LATHO Wang,2007(29) a,c 13454.1±8.1134/023.2±2.3AsianT400K,Y54C,Q604ETC,LDL-C,HDL-C,TG- Chen,2008(8) a 104647.0±;9.3894/15224.9±2.4AsianD19H,T400K,Y54C,Q604E i TC,LDL-C,HDL-C,TG- Caamano,2008(30) d 10440±;1058/4625.5±3.3HispanicY54C,Q604ETC,LDL-C,HDL-C,TG- 11844±771/4727.6±4.9HispanicY54C,Q604ETC,LDL-C,HDL-C,TG- Santosa,2007(31) a 3549.4±6.70/3531.4±2.8Mixed f D19H,T400K,Y54C,Q604ETC,LDL-C,HDL-C,TG- Rudkowska,2008(32)2659.6±9.615/1126.4±2.7Mixed f D19H,T400K,Y54C,Q604ETC,LDL-C,HDL-C,TG- Chan,2004(33) a 4754.5±8.447/032±3.6Notreported g D19H,T400KTC,LDL-C,HDL-C,TGCAMP,SITO,LATHO Kajinami,2004(12) a 33858±11203/13527.0±3.0Notreported h D19H,T400K,Y54C,Q604E,A632VTC,LDL-C,HDL-C,TG- Herron,2006(9) a 9131.1±9.240/5124.8±4.7Notreported h Q604ETC,LDL-C,HDL-C- Total(WM)336446.7±10.52251/111323.9±3.5 Numberandcharacteristicsofstudiesincludedinthemeta-analysis.CAMP,campesterol/TCratio;CHOLST,cholestanol/TCratio;HDL-C,HDL-cholesterol;LATHO,lathosterol/TCratio;LDL-C, LDL-cholesterol;SITO,sitosterol/TCratio;TC,totalcholesterol;TG,triglyceride;WM,weightedmean.
X
ABCG5 p.Gln604Glu 20581104:145:265
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:289
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:404
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:450
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:505
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:562
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:637
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:681
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:775
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:780
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:891
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:895
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:1027
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:1077
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:1128
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:1242
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:1346
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:1426
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:1541
status: NEWX
ABCG5 p.Gln604Glu 20581104:145:1642
status: VERIFIEDX
ABCG5 p.Gln604Glu 20581104:145:1657
status: NEW12 We first investigated associations between five common ABCG5/G8 polymorphisms (p.Q604E, p.D19H, p.Y54C, p. T400K, and p.A632V) and plasma sterol levels in 245 hypercholesterolaemic individuals.
X
ABCG5 p.Gln604Glu 20581104:12:81
status: VERIFIED68 We genotyped five nonsynonymous polymorphisms in ABCG5/G8 [ABCG5: p.Q604E (rs6720173); ABCG8: p.D19H (rs11887534), p.Y54C (rs4148211), p.T400K (rs4148217), and p.A632V (rs6544718)] using allelic discrimination.
X
ABCG5 p.Gln604Glu 20581104:68:68
status: VERIFIED66 We genotyped five nonsynonymous polymorphisms in ABCG5/G8 [ABCG5: p.Q604E (rs6720173); ABCG8: p.D19H (rs11887534), p.Y54C (rs4148211), p.T400K (rs4148217), and p.A632V (rs6544718)] using allelic discrimination.
X
ABCG5 p.Gln604Glu 20581104:66:68
status: NEW139 Associations between ABCG5/G8 polymorphisms and plasma lipids and non-cholesterol sterol ratios Lipids and Lipoproteins (mmol/l) Non-Cholesterol Sterol Ratios (òe;g/mg) SNP N TC LDL-C HDL-C Triglycerides Campesterol/TC Sitosterol/TC Cholestanol/TC Lathosterol/TC Q604E QQ 171 6.16 &#b1; 0.76 4.05 &#b1; 0.61 1.54 &#b1; 0.40 1.09 [0.29-3.56] 1.45 &#b1; 0.64 1.12 &#b1; 0.53 1.49 &#b1; 0.33 1.24 &#b1; 0.49 QE/EE 72 6.23 &#b1; 0.73 4.11 &#b1; 0.63 1.49 &#b1; 0.36 1.19 [0.47-3.93] 1.47 &#b1; 0.88 1.16 &#b1; 0.63 1.46 &#b1; 0.38 1.28 &#b1; 0.57 D19H DD 219 6.19 &#b1; 0.75 4.08 &#b1; 0.61 1.52 &#b1; 0.40 1.10 [0.29-3.93] 1.49 &#b1; 0.69 1.16 &#b1; 0.55 1.49 &#b1; 0.34 1.24 &#b1; 0.49 DH/HH 24 6.04 &#b1; 0.81 3.90 &#b1; 0.63 1.60 &#b1; 0.38 1.15 [0.47-1.97] 1.24 &#b1; 0.82 0.92 &#b1; 0.53 1.38 &#b1; 0.34 1.35 &#b1; 0.64 Y54C YY 73 6.32 &#b1; 0.73 4.14 &#b1; 0.64 1.58 &#b1; 0.37 1.09 [0.45-3.93] 1.59 &#b1; 0.76 1.22 &#b1; 0.60 1.53 &#b1; 0.33 1.24 &#b1; 0.53 YC/CC 171 6.12 &#b1; 0.76 4.03 &#b1; 0.61 1.51 &#b1; 0.41 1.11 [0.29-3.56] 1.41 &#b1; 0.68 1.09 &#b1; 0.53 1.46 &#b1; 0.34 1.26 &#b1; 0.50 T400K TT 183 6.16 &#b1; 0.75 4.03 &#b1; 0.60 1.55 &#b1; 0.40 1.10 [0.29-3.93] 1.48 &#b1; 0.69 1.14 &#b1; 0.55 1.49 &#b1; 0.35 1.25 &#b1; 0.48 TK/KK 61 6.24 &#b1; 0.76 4.19 &#b1; 0.66 1.47 &#b1; 0.37 1.14 [0.47-2.61] 1.38 &#b1; 0.76 1.09 &#b1; 0.59 1.45 &#b1; 0.31 1.27 &#b1; 0.59 A632V AA 139 6.22 &#b1; 0.72 4.12 &#b1; 0.60 1.51 &#b1; 0.37 1.12 [0.33-2.90] 1.49 &#b1; 0.72 1.16 &#b1; 0.58 1.51 &#b1; 0.37 1.21 &#b1; 0.49 AV/VV 105 6.14 &#b1; 0.79 3.99 &#b1; 0.63 1.57 &#b1; 0.43 1.07 [0.29-3.93] 1.42 &#b1; 0.70 1.09 &#b1; 0.52 1.44 &#b1; 0.30 1.31 &#b1; 0.52 Values shown are means &#b1; SD. Triglycerides are shown as median [range].
X
ABCG5 p.Gln604Glu 20581104:139:267
status: NEW144 Characteristics of studies included in the meta-analysis Reference Number of Subjects Age Male/ Female Body Mass Index Ethnicity Single Nucleotide Polymorphisms Lipids Non-Cholesterol Sterols n years n kg/m 2 Berge, 2002 (5) 148 55 &#b1; 11 74/74 Not reported Caucasian D19H, T400K, Y54C, Q604E, A632V TC CAMP, SITO, CHOLST, LATHO Weggemans, 2002 (7) 486 26.3 &#b1; 11.6 257/229 21.7 &#b1; 3.0 Caucasian Q604E TC - Gylling, 2004 (13) 262 53.1 &#b1; 8.1 143/119 26.4 &#b1; 6.5 Caucasian D19H, T400K, Y54C, Q604E, A632V TC, LDL-C, HDL-C, TG CAMP, SITO, CHOLST, LATHO Plat, 2005 (11) a 112 33 &#b1; 16 41/71 22.9 &#b1; 3.6 Caucasian T400K, Q604E, A632V LDL-C, HDL-C, TG CAMP, SITO, LATHO Acalovschi, 2006 (27) 72 e 56.3 (36-80) 30/42 30.1 &#b1; 4.9 Caucasian D19H, T400K, Y54C, Q604E, A632V TC, HDL-C, TG - Jakulj, et al. b 245 58.4 &#b1; 7.5 189/48 25.8 &#b1; 3.0 Caucasian D19H, T400K, Y54C, Q604E, A632V TC, LDL-C, HDL-C, TG CAMP, SITO, CHOLST, LATHO Miwa, 2005 (28) 100 62.4 &#b1; 12.1 48/52 23.0 &#b1; 3.5 Asian T400K, Y54C, Q604E - SITO, LATHO Wang, 2007 (29) a , c 134 54.1 &#b1; 8.1 134/0 23.2 &#b1; 2.3 Asian T400K, Y54C, Q604E TC, LDL-C, HDL-C, TG - Chen, 2008 (8) a 1046 47.0 &#b1; 9.3 894/152 24.9 &#b1; 2.4 Asian D19H, T400K, Y54C, Q604E i TC, LDL-C, HDL-C, TG - Caamano, 2008 (30) d 104 40 &#b1; 10 58/46 25.5 &#b1; 3.3 Hispanic Y54C, Q604E TC, LDL-C, HDL-C, TG - 118 44 &#b1; 7 71/47 27.6 &#b1; 4.9 Hispanic Y54C, Q604E TC, LDL-C, HDL-C, TG - Santosa, 2007 (31) a 35 49.4 &#b1; 6.7 0/35 31.4 &#b1; 2.8 Mixed f D19H, T400K, Y54C, Q604E TC, LDL-C, HDL-C, TG - Rudkowska, 2008 (32) 26 59.6 &#b1; 9.6 15/11 26.4 &#b1; 2.7 Mixed f D19H, T400K, Y54C, Q604E TC, LDL-C, HDL-C, TG - Chan, 2004 (33) a 47 54.5 &#b1; 8.4 47/0 32 &#b1; 3.6 Not reported g D19H, T400K TC, LDL-C, HDL-C, TG CAMP, SITO, LATHO Kajinami, 2004 (12) a 338 58 &#b1; 11 203/135 27.0 &#b1; 3.0 Not reported h D19H, T400K, Y54C, Q604E, A632V TC, LDL-C, HDL-C, TG - Herron, 2006 (9) a 91 31.1 &#b1; 9.2 40/51 24.8 &#b1; 4.7 Not reported h Q604E TC, LDL-C, HDL-C - Total (WM) 3364 46.7 &#b1; 10.5 2251/ 1113 23.9 &#b1; 3.5 Number and characteristics of studies included in the meta-analysis.
X
ABCG5 p.Gln604Glu 20581104:144:289
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:404
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:505
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:637
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:775
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:891
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1027
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1128
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1242
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1346
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1426
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1541
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1657
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:1901
status: NEWX
ABCG5 p.Gln604Glu 20581104:144:2010
status: NEW67 We genotyped five nonsynonymous polymorphisms in ABCG5/G8 [ABCG5: p.Q604E (rs6720173); ABCG8: p.D19H (rs11887534), p.Y54C (rs4148211), p.T400K (rs4148217), and p.A632V (rs6544718)] using allelic discrimination.
X
ABCG5 p.Gln604Glu 20581104:67:68
status: NEW140 Associations between ABCG5/G8 polymorphisms and plasma lipids and non-cholesterol sterol ratios Lipids and Lipoproteins (mmol/l) Non-Cholesterol Sterol Ratios (òe;g/mg) SNP N TC LDL-C HDL-C Triglycerides Campesterol/TC Sitosterol/TC Cholestanol/TC Lathosterol/TC Q604E QQ 171 6.16 &#b1; 0.76 4.05 &#b1; 0.61 1.54 &#b1; 0.40 1.09 [0.29-3.56] 1.45 &#b1; 0.64 1.12 &#b1; 0.53 1.49 &#b1; 0.33 1.24 &#b1; 0.49 QE/EE 72 6.23 &#b1; 0.73 4.11 &#b1; 0.63 1.49 &#b1; 0.36 1.19 [0.47-3.93] 1.47 &#b1; 0.88 1.16 &#b1; 0.63 1.46 &#b1; 0.38 1.28 &#b1; 0.57 D19H DD 219 6.19 &#b1; 0.75 4.08 &#b1; 0.61 1.52 &#b1; 0.40 1.10 [0.29-3.93] 1.49 &#b1; 0.69 1.16 &#b1; 0.55 1.49 &#b1; 0.34 1.24 &#b1; 0.49 DH/HH 24 6.04 &#b1; 0.81 3.90 &#b1; 0.63 1.60 &#b1; 0.38 1.15 [0.47-1.97] 1.24 &#b1; 0.82 0.92 &#b1; 0.53 1.38 &#b1; 0.34 1.35 &#b1; 0.64 Y54C YY 73 6.32 &#b1; 0.73 4.14 &#b1; 0.64 1.58 &#b1; 0.37 1.09 [0.45-3.93] 1.59 &#b1; 0.76 1.22 &#b1; 0.60 1.53 &#b1; 0.33 1.24 &#b1; 0.53 YC/CC 171 6.12 &#b1; 0.76 4.03 &#b1; 0.61 1.51 &#b1; 0.41 1.11 [0.29-3.56] 1.41 &#b1; 0.68 1.09 &#b1; 0.53 1.46 &#b1; 0.34 1.26 &#b1; 0.50 T400K TT 183 6.16 &#b1; 0.75 4.03 &#b1; 0.60 1.55 &#b1; 0.40 1.10 [0.29-3.93] 1.48 &#b1; 0.69 1.14 &#b1; 0.55 1.49 &#b1; 0.35 1.25 &#b1; 0.48 TK/KK 61 6.24 &#b1; 0.76 4.19 &#b1; 0.66 1.47 &#b1; 0.37 1.14 [0.47-2.61] 1.38 &#b1; 0.76 1.09 &#b1; 0.59 1.45 &#b1; 0.31 1.27 &#b1; 0.59 A632V AA 139 6.22 &#b1; 0.72 4.12 &#b1; 0.60 1.51 &#b1; 0.37 1.12 [0.33-2.90] 1.49 &#b1; 0.72 1.16 &#b1; 0.58 1.51 &#b1; 0.37 1.21 &#b1; 0.49 AV/VV 105 6.14 &#b1; 0.79 3.99 &#b1; 0.63 1.57 &#b1; 0.43 1.07 [0.29-3.93] 1.42 &#b1; 0.70 1.09 &#b1; 0.52 1.44 &#b1; 0.30 1.31 &#b1; 0.52 Values shown are means &#b1; SD. Triglycerides are shown as median [range].
X
ABCG5 p.Gln604Glu 20581104:140:267
status: NEW
PMID: 21039829
[PubMed]
Yoon JH et al: "ABCG8 D19H polymorphism: a basis for the genetic prediction of cholesterol gallstone disease."
No.
Sentence
Comment
11
Other studies have identified a variety of polymorphisms in ABCG8 (A632V, T400K, D19H, and C54Y) and in ABCG5 (Q604E) that have been linked to baseline plasma cholesterol levels, cholesterol absorption, or responsiveness to dietary intervention.
X
ABCG5 p.Gln604Glu 21039829:11:111
status: VERIFIED13 Hubacek et al.10 reported that none of the polymorphisms examined, including ABCG5 Q604E, ABCG8 D19H, and ABCG8 A632V, were related to plasma lipid levels in patients after 'evolutionary`dietary changes from a traditional, high-fat Eastern European diet to a lower-fat diet based on nutritional advice.
X
ABCG5 p.Gln604Glu 21039829:13:83
status: VERIFIED15 Wang et al.11 examined five common polymorphisms in the ABCG5 (Q604E) and ABCG8 (D19H,Y54C, T400K, A632V) genes in 287 patients with gallstone disease.
X
ABCG5 p.Gln604Glu 21039829:15:63
status: VERIFIED
PMID: 21128988
[PubMed]
Wei KK et al: "Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin."
No.
Sentence
Comment
27
Several previous studies have found that 5 nonsynonymous single-nucleotide polymorphisms in the ABCG5 (Q604E) and ABCG8 (D19H, Y54C, T400K, A632V) coding sequences may affect plasma plant sterol or cholesterol levels (16-19).
X
ABCG5 p.Gln604Glu 21128988:27:103
status: VERIFIED
No.
Sentence
Comment
127
Missense polymorphisms (Gln604Glu in the ABCG5, and Asp19His, Tyr54Cys, Thr400Lys, and Ala632Val in the ABCG8) were examined, and the Thr400Lys in the ABCG8 gene was associated with changes in lipid levels in response to reduced dietary animal fat and cholesterol intake.
X
ABCG5 p.Gln604Glu 21437027:127:24
status: VERIFIED129 Missense polymorphisms (Gln604Glu in the ABCG5, and Asp19His, Tyr54Cys, Thr400Lys, and Ala632Val in the ABCG8) were examined, and the Thr400Lys in the ABCG8 gene was associated with changes in lipid levels in response to reduced dietary animal fat and cholesterol intake.
X
ABCG5 p.Gln604Glu 21437027:129:24
status: NEW
PMID: 21353662
[PubMed]
Van Erpecum KJ et al: "Pathogenesis of cholesterol and pigment gallstones: an update."
No.
Sentence
Comment
91
Recently, variants of ABCG5/8 were linked to gallstone disease; ABCG8 D19H in Caucasians and ABCG5 Q604E in Chinese populations [35,36].
X
ABCG5 p.Gln604Glu 21353662:91:99
status: NEW90 Recently, variants of ABCG5/8 were linked to gallstone disease; ABCG8 D19H in Caucasians and ABCG5 Q604E in Chinese populations [35,36].
X
ABCG5 p.Gln604Glu 21353662:90:99
status: NEW
PMID: 20494111
[PubMed]
Marschall HU et al: "The genetic background of gallstone formation: an update."
No.
Sentence
Comment
37
In Chinese gallstone populations, also other non-synonymous polymorphisms, Q604E on the ABCG5 gene [14], and T400 K on the ABCG8 gene [15] were associated with increased risk (OR, 6.4; CI, 1.3-30.7 [14] and 2.3; CI, 1.12-4.76 [15], respectively) but only in male patients older than 50 years of age.
X
ABCG5 p.Gln604Glu 20494111:37:75
status: NEW39 We also found a trend (p = 0.052) for a positive association with the Q604E variant of the ABCG5 gene in this particular Swedish population (OR, 1.5; CI, 1.00-2.16) [16].
X
ABCG5 p.Gln604Glu 20494111:39:70
status: NEW41 Lower total cholesterol and triglyceride levels were also found in another study in Caucasian gallstone siblings, in this case both for carriers of the ABCG5 Q604E or ABCG8 D19H variants [19].
X
ABCG5 p.Gln604Glu 20494111:41:158
status: NEW
PMID: 22898925
[PubMed]
von Kampen O et al: "Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus."
No.
Sentence
Comment
85
The significance of their disease associations was approximately seven orders of magnitude higher than that of the next "best" SNP (rs6720173, ABCG5-Q604E, pallelic=0.0024) which, moreover, is located well outside the disease-associated region defined above.
X
ABCG5 p.Gln604Glu 22898925:85:149
status: NEW
PMID: 22213168
[PubMed]
Krawczyk M et al: "Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease."
No.
Sentence
Comment
39
All studied individuals were genotyped for the ABCG5 p.Q604E (rs6720173, c__29001998_10) and ABCG8 p.D19H (rs11887534, c__26135643_10), Address reprint requests to: Prof. Dr. Frank Lammert, Department of Medicine II, Saarland University Medical Center, Saarland University, Kirrberger Str.
X
ABCG5 p.Gln604Glu 22213168:39:55
status: NEW
PMID: 22297561
[PubMed]
Wang G et al: "Macrothrombocytopenia/Stomatocytosis specially associated with phytosterolemia."
No.
Sentence
Comment
72
In addition, several neutral polymorphisms, such as Q604E of ABCG5, C54Y, T400K, and A632V of ABCG8 which had been previously described were also found in this study (not shown).
X
ABCG5 p.Gln604Glu 22297561:72:52
status: NEW71 In addition, several neutral polymorphisms, such as Q604E of ABCG5, C54Y, T400K, and A632V of ABCG8 which had been previously described were also found in this study (not shown).
X
ABCG5 p.Gln604Glu 22297561:71:52
status: NEW
PMID: 22655090
[PubMed]
Li Q et al: "ATP-binding cassette transporter G5 and G8 polymorphisms and several environmental factors with serum lipid levels."
No.
Sentence
Comment
42
Therefore, the aim of the present study was to explore the association of ABCG5 (rs4131229, i7892 T.C and rs6720173, Q604E G.C) and ABCG8 (rs3806471, 5U145 A.C and rs4148211, Y54C A.G) SNPs and several environmental factors with serum lipid profiles in the Mulao and Han populations.
X
ABCG5 p.Gln604Glu 22655090:42:117
status: NEW192 Weggemans et al. [29] found that subjects with the EE genotype of ABCG5 Q604E had higher serum cholesterol concentrations than carriers with the wild-type Q allele.
X
ABCG5 p.Gln604Glu 22655090:192:72
status: NEWX
ABCG5 p.Gln604Glu 22655090:192:114
status: NEW193 Herron et al. [30] found that a shift from a low to a high-dietary- cholesterol diet in individuals with the ABCG5 Q604E mutant allele was associated with a greater increase in plasma LDL-C compared to subjects who were heterozygous or who carried only the wild-type allele.
X
ABCG5 p.Gln604Glu 22655090:193:115
status: NEW203 On the other hand, nonsmokers carriers of the minor alleles at ABCG5 (i18429C.T and Gln604Glu C.G) SNPs had significantly lower TG concentrations (P = 0.012 and P = 0.035) compared with homozygous for the major allele.
X
ABCG5 p.Gln604Glu 22655090:203:84
status: NEW217 The other ABCG5/G8 SNPs (Q604E, Y54C, T400K and A632V) did not show any significant interactions with the CYP7A1 polymorphism.
X
ABCG5 p.Gln604Glu 22655090:217:25
status: NEW226 The remaining SNPs (Q604E, D19H, Y54C, and T400K) were not associated with plasma lipid levels [60].
X
ABCG5 p.Gln604Glu 22655090:226:20
status: NEW241 020 0.062 2.509 0.012 Systolic blood pressure 0.001 0.001 0.066 2.590 0.010 ApoA1/ApoB Waist circumference 20.019 0.002 20.198 27.862 0.000 Age 20.005 0.001 20.089 23.544 0.000 Han TC Waist circumference 0.019 0.005 0.131 3.767 0.000 Age 0.009 0.003 0.126 3.443 0.001 Alcohol consumption 0.302 0.057 0.179 5.286 0.000 Diastolic blood pressure 0.017 0.004 0.168 4.661 0.000 Blood glucose 0.066 0.024 0.095 2.723 0.007 TG Waist circumference 0.075 0.013 0.254 5.661 0.000 Cigarette smoking 0.805 0.165 0.185 4.889 0.000 Blood glucose 0.265 0.049 0.186 5.407 0.000 Diastolic blood pressure 0.030 0.007 0.147 4.120 0.000 Age 20.017 0.005 20.113 23.114 0.002 Alcohol consumption 0.269 0.132 0.078 2.040 0.042 Body mass index 20.065 0.030 20.096 22.157 0.031 HDL-C Waist circumference 20.011 0.002 20.155 24.279 0.000 Gender 0.130 0.046 0.120 2.825 0.005 Alcohol consumption 0.111 0.034 0.138 3.317 0.001 LDL-C Age 0.012 0.002 0.212 6.219 0.000 Body mass index 0.026 0.012 0.101 2.222 0.027 Waist circumference 0.013 0.005 0.115 2.471 0.014 Cigarette smoking 20.310 0.072 20.187 24.227 0.000 hypercholesterolaemic Japanese subjects, Miwa et al. [42] reported that carriers of the ABCG8 M429V or a specific haplotype (wild-type allele of ABCG5 Q604E, and wild-type alleles of ABCG8 C54Y, T400K, and M429V) had higher cholesterol absorption efficiency than non-carriers.
X
ABCG5 p.Gln604Glu 22655090:241:1238
status: NEW242 However, no difference was observed in serum lipid profiles in relation to common SNPs studied previously in Caucasian populations (ABCG5 Q604E and ABCG8 A632V, T400K, D19H and C54Y).
X
ABCG5 p.Gln604Glu 22655090:242:138
status: NEW254 Recently, in 845 self-identified Puerto Ricans from Boston, Junyent et al. [38] reported that ABCG5/G8 (i7892T.C, rs4131229; 5U145A.C, rs3806471; Y54C; T400K) SNPs were significantly associated with HDL-C concentrations.
X
ABCG5 p.Gln604Glu 22655090:254:43
status: NEW257 Carriers of the minor alleles at ABCG5/G8 (Q604E, D19H, i14222 A.G, rs6709904) SNPs displayed lower levels of HDL-C only if they were smokers.
X
ABCG5 p.Gln604Glu 22655090:257:43
status: NEW41 Therefore, the aim of the present study was to explore the association of ABCG5 (rs4131229, i7892 T.C and rs6720173, Q604E G.C) and ABCG8 (rs3806471, 5U145 A.C and rs4148211, Y54C A.G) SNPs and several environmental factors with serum lipid profiles in the Mulao and Han populations.
X
ABCG5 p.Gln604Glu 22655090:41:117
status: NEW190 Weggemans et al. [29] found that subjects with the EE genotype of ABCG5 Q604E had higher serum cholesterol concentrations than carriers with the wild-type Q allele.
X
ABCG5 p.Gln604Glu 22655090:190:72
status: NEW191 Herron et al. [30] found that a shift from a low to a high-dietary-cholesterol diet in individuals with the ABCG5 Q604E mutant allele was associated with a greater increase in plasma LDL-C compared to subjects who were heterozygous or who carried only the wild-type allele.
X
ABCG5 p.Gln604Glu 22655090:191:72
status: NEWX
ABCG5 p.Gln604Glu 22655090:191:114
status: NEW201 On the other hand, nonsmokers carriers of the minor alleles at ABCG5 (i18429C.T and Gln604Glu C.G) SNPs had significantly lower TG concentrations (P = 0.012 and P = 0.035) compared with homozygous for the major allele.
X
ABCG5 p.Gln604Glu 22655090:201:84
status: NEW215 The other ABCG5/G8 SNPs (Q604E, Y54C, T400K and A632V) did not show any significant interactions with the CYP7A1 polymorphism.
X
ABCG5 p.Gln604Glu 22655090:215:25
status: NEW216 No association was observed between ABCG8 T400K and total and LDL-C levels [32-34,36,38-41].
X
ABCG5 p.Gln604Glu 22655090:216:25
status: NEW224 The remaining SNPs (Q604E, D19H, Y54C, and T400K) were not associated with plasma lipid levels [60].
X
ABCG5 p.Gln604Glu 22655090:224:20
status: NEW239 020 0.062 2.509 0.012 Systolic blood pressure 0.001 0.001 0.066 2.590 0.010 ApoA1/ApoB Waist circumference 20.019 0.002 20.198 27.862 0.000 Age 20.005 0.001 20.089 23.544 0.000 Han TC Waist circumference 0.019 0.005 0.131 3.767 0.000 Age 0.009 0.003 0.126 3.443 0.001 Alcohol consumption 0.302 0.057 0.179 5.286 0.000 Diastolic blood pressure 0.017 0.004 0.168 4.661 0.000 Blood glucose 0.066 0.024 0.095 2.723 0.007 TG Waist circumference 0.075 0.013 0.254 5.661 0.000 Cigarette smoking 0.805 0.165 0.185 4.889 0.000 Blood glucose 0.265 0.049 0.186 5.407 0.000 Diastolic blood pressure 0.030 0.007 0.147 4.120 0.000 Age 20.017 0.005 20.113 23.114 0.002 Alcohol consumption 0.269 0.132 0.078 2.040 0.042 Body mass index 20.065 0.030 20.096 22.157 0.031 HDL-C Waist circumference 20.011 0.002 20.155 24.279 0.000 Gender 0.130 0.046 0.120 2.825 0.005 Alcohol consumption 0.111 0.034 0.138 3.317 0.001 LDL-C Age 0.012 0.002 0.212 6.219 0.000 Body mass index 0.026 0.012 0.101 2.222 0.027 Waist circumference 0.013 0.005 0.115 2.471 0.014 Cigarette smoking 20.310 0.072 20.187 24.227 0.000 hypercholesterolaemic Japanese subjects, Miwa et al. [42] reported that carriers of the ABCG8 M429V or a specific haplotype (wild-type allele of ABCG5 Q604E, and wild-type alleles of ABCG8 C54Y, T400K, and M429V) had higher cholesterol absorption efficiency than non-carriers.
X
ABCG5 p.Gln604Glu 22655090:239:1238
status: NEW240 However, no difference was observed in serum lipid profiles in relation to common SNPs studied previously in Caucasian populations (ABCG5 Q604E and ABCG8 A632V, T400K, D19H and C54Y).
X
ABCG5 p.Gln604Glu 22655090:240:138
status: NEW255 Carriers of the minor alleles at ABCG5/G8 (Q604E, D19H, i14222 A.G, rs6709904) SNPs displayed lower levels of HDL-C only if they were smokers.
X
ABCG5 p.Gln604Glu 22655090:255:43
status: NEW202 On the other hand, nonsmokers carriers of the minor alleles at ABCG5 (i18429C.T and Gln604Glu C.G) SNPs had significantly lower TG concentrations (P = 0.012 and P = 0.035) compared with homozygous for the major allele.
X
ABCG5 p.Gln604Glu 22655090:202:84
status: NEW225 The remaining SNPs (Q604E, D19H, Y54C, and T400K) were not associated with plasma lipid levels [60].
X
ABCG5 p.Gln604Glu 22655090:225:20
status: NEW
PMID: 20172523
[PubMed]
Garcia-Rios A et al: "Genetic variations at ABCG5/G8 genes modulate plasma lipids concentrations in patients with familial hypercholesterolemia."
No.
Sentence
Comment
73
(A) ABCG5 i11836 (HDL-C; P = 0.023) (B) ABCG5 Q604E (TG; P = 0.017).
X
ABCG5 p.Gln604Glu 20172523:73:46
status: NEW119 G5 i7892 Nonsmokers Smokers P A/A (n = 139) A/G + G/G (n = 198) A/A (n = 53) A/G + G/G (n = 75) TC 266.3 ± 5.9 266.4 ± 4.8 266.2 ± 9.5 289.5 ± 8.0 0.112 TG 4.55 ± 0.03 4.47 ± 0.02 4.56 ± 0.05 4.68 ± 0.04 0.013 LDL-C 197.4 ± 5.7 198.5 ± 4.7 199.1 ± 9.3 223.9 ± 7.8 0.095 HDL-C 46.6 ± 1.0 48.6 ± 0.8 44.6 ± 1.6 41.2 ± 1.3 0.030 VLDL-C 20.1 ± 0.7 18.9 ± 0.5 20.8 ± 1.1 23.6 ± 0.9 0.022 G5 i18429 C/C (n = 259) C/T + T/T (n = 78) C/C (n = 85) C/T + T/T (n = 43) TC 266.9 ± 4.2 264.1 ± 7.8 270.2 ± 7.5 299.5 ± 10.6 0.042 TG 4.53 ± 0.02 4.41 ± 0.04 4.61 ± 0.04 4.67 ± 0.06 0.047 LDL-C 198.0 ± 4.1 198.1 ± 7.6 204.6 ± 7.3 232.0 ± 10.3 0.077 HDL-C 47.9 ± 0.7 47.3 ± 1.3 43.5 ± 1.2 40.8 ± 1.8 0.472 VLDL-C 19.9 ± 0.5 17.6 ± 0.9 22.4 ± 0.9 22.8 ± 1.3 0.173 G5 i11836 G/G (n = 208) A/G + A/A (n = 129) G/G (n = 84) A/G + A/A (n = 44) TC 264.2 ± 4.8 269.8 ± 6.0 275.1 ± 7.6 289.3 ± 10.4 0.574 TG 4.53 ± 0.02 4.47 ± 0.03 4.59 ± 0.04 4.70 ± 0.05 0.039 LDL-C 196.4 ± 4.7 200.7 ± 5.9 209.9 ± 7.4 220.9 ± 10.2 0.646 HDL-C 46.3 ± 0.8 50.1 ± 1.0 42.9 ± 1.3 42.3 ± 1.7 0.092 VLDL-C 20.0 ± 0.5 18.4 ± 0.7 21.4 ± 0.9 24.3 ± 1.2 0.014 G5 Q604E C/C (n = 248) C/G + G/G (n = 89) C/C (n = 84) C/G + G/G (n = 44) TC 268.4 ± 4.3 260.4 ± 7.3 278.2 ± 7.6 283.4 ± 10.5 0.400 TG 4.55 ± 0.02 4.39 ± 0.04 4.62 ± 0.04 4.65 ± 0.05 0.038 LDL-C 199.0 ± 4.2 195.1 ± 7.2 211.3 ± 7.4 218.2 ± 10.2 0.477 HDL-C 48.0 ± 0.7 47.2 ± 1.2 43.3 ± 1.3 41.3 ± 1.8 0.637 VLDL-C 20.1 ± 0.5 17.3 ± 0.8 22.8 ± 0.9 22.0 ± 1.2 0.265 All values are mean ± standard error. P for interaction.
X
ABCG5 p.Gln604Glu 20172523:119:1415
status: NEW141 (A) Interaction ABCG5 i7892-smoking for HDL-C (B) Interaction ABCG5 i11836-smoking for TG (C) Interaction ABCG5 i18429-smoking for TG (D) Interaction ABCG5 Gln604Glu-smoking for TG.
X
ABCG5 p.Gln604Glu 20172523:141:156
status: NEW150 On the other hand, Miwa et al. [11] reported no significant associations between three ABCG5/G8 (Q604E, C54Y and T400K) SNPs and serum lipid concentrations in 100 Japanese primary hypercholesterolaemic patients.
X
ABCG5 p.Gln604Glu 20172523:150:72
status: NEWX
ABCG5 p.Gln604Glu 20172523:150:97
status: NEW151 Consistent with both studies [11,12] we did not find associations between D19H, T400K and C54Y SNPs and plasma lipid concentrations.
X
ABCG5 p.Gln604Glu 20172523:151:97
status: NEW152 However, in contrast to Miwa et al. our data showed association between Q604E SNP and VLDL-C and TG concentrations.
X
ABCG5 p.Gln604Glu 20172523:152:72
status: NEWX
ABCG5 p.Gln604Glu 20172523:152:82
status: NEW154 Additionally, Santosa et al. [10] examined the association of four SNPs at ABCG5 (Q604E, i7892, i18429 and M216) and four ABCG8 (C54Y, D19H, i14222 and T400K) with plasma lipids concentrations in 35 young women with mildly hypercholesterolemia.
X
ABCG5 p.Gln604Glu 20172523:154:82
status: NEW155 They found that C54Y and Q604E SNPs were associated with the response of cholesterol metabolism to weight loss.
X
ABCG5 p.Gln604Glu 20172523:155:25
status: NEWX
ABCG5 p.Gln604Glu 20172523:155:82
status: NEW120 G5 i7892 Nonsmokers Smokers P A/A (n = 139) A/G + G/G (n = 198) A/A (n = 53) A/G + G/G (n = 75) TC 266.3 &#b1; 5.9 266.4 &#b1; 4.8 266.2 &#b1; 9.5 289.5 &#b1; 8.0 0.112 TG 4.55 &#b1; 0.03 4.47 &#b1; 0.02 4.56 &#b1; 0.05 4.68 &#b1; 0.04 0.013 LDL-C 197.4 &#b1; 5.7 198.5 &#b1; 4.7 199.1 &#b1; 9.3 223.9 &#b1; 7.8 0.095 HDL-C 46.6 &#b1; 1.0 48.6 &#b1; 0.8 44.6 &#b1; 1.6 41.2 &#b1; 1.3 0.030 VLDL-C 20.1 &#b1; 0.7 18.9 &#b1; 0.5 20.8 &#b1; 1.1 23.6 &#b1; 0.9 0.022 G5 i18429 C/C (n = 259) C/T + T/T (n = 78) C/C (n = 85) C/T + T/T (n = 43) TC 266.9 &#b1; 4.2 264.1 &#b1; 7.8 270.2 &#b1; 7.5 299.5 &#b1; 10.6 0.042 TG 4.53 &#b1; 0.02 4.41 &#b1; 0.04 4.61 &#b1; 0.04 4.67 &#b1; 0.06 0.047 LDL-C 198.0 &#b1; 4.1 198.1 &#b1; 7.6 204.6 &#b1; 7.3 232.0 &#b1; 10.3 0.077 HDL-C 47.9 &#b1; 0.7 47.3 &#b1; 1.3 43.5 &#b1; 1.2 40.8 &#b1; 1.8 0.472 VLDL-C 19.9 &#b1; 0.5 17.6 &#b1; 0.9 22.4 &#b1; 0.9 22.8 &#b1; 1.3 0.173 G5 i11836 G/G (n = 208) A/G + A/A (n = 129) G/G (n = 84) A/G + A/A (n = 44) TC 264.2 &#b1; 4.8 269.8 &#b1; 6.0 275.1 &#b1; 7.6 289.3 &#b1; 10.4 0.574 TG 4.53 &#b1; 0.02 4.47 &#b1; 0.03 4.59 &#b1; 0.04 4.70 &#b1; 0.05 0.039 LDL-C 196.4 &#b1; 4.7 200.7 &#b1; 5.9 209.9 &#b1; 7.4 220.9 &#b1; 10.2 0.646 HDL-C 46.3 &#b1; 0.8 50.1 &#b1; 1.0 42.9 &#b1; 1.3 42.3 &#b1; 1.7 0.092 VLDL-C 20.0 &#b1; 0.5 18.4 &#b1; 0.7 21.4 &#b1; 0.9 24.3 &#b1; 1.2 0.014 G5 Q604E C/C (n = 248) C/G + G/G (n = 89) C/C (n = 84) C/G + G/G (n = 44) TC 268.4 &#b1; 4.3 260.4 &#b1; 7.3 278.2 &#b1; 7.6 283.4 &#b1; 10.5 0.400 TG 4.55 &#b1; 0.02 4.39 &#b1; 0.04 4.62 &#b1; 0.04 4.65 &#b1; 0.05 0.038 LDL-C 199.0 &#b1; 4.2 195.1 &#b1; 7.2 211.3 &#b1; 7.4 218.2 &#b1; 10.2 0.477 HDL-C 48.0 &#b1; 0.7 47.2 &#b1; 1.2 43.3 &#b1; 1.3 41.3 &#b1; 1.8 0.637 VLDL-C 20.1 &#b1; 0.5 17.3 &#b1; 0.8 22.8 &#b1; 0.9 22.0 &#b1; 1.2 0.265 All values are mean &#b1; standard error. P for interaction.
X
ABCG5 p.Gln604Glu 20172523:120:1355
status: NEW142 (A) Interaction ABCG5 i7892-smoking for HDL-C (B) Interaction ABCG5 i11836-smoking for TG (C) Interaction ABCG5 i18429-smoking for TG (D) Interaction ABCG5 Gln604Glu-smoking for TG.
X
ABCG5 p.Gln604Glu 20172523:142:156
status: NEW153 However, in contrast to Miwa et al. our data showed association between Q604E SNP and VLDL-C and TG concentrations.
X
ABCG5 p.Gln604Glu 20172523:153:25
status: NEWX
ABCG5 p.Gln604Glu 20172523:153:72
status: NEW156 They found that C54Y and Q604E SNPs were associated with the response of cholesterol metabolism to weight loss.
X
ABCG5 p.Gln604Glu 20172523:156:25
status: NEW71 (A) ABCG5 i11836 (HDL-C; P = 0.023) (B) ABCG5 Q604E (TG; P = 0.017).
X
ABCG5 p.Gln604Glu 20172523:71:46
status: NEW117 G5 i7892 Nonsmokers Smokers P A/A (n = 139) A/G + G/G (n = 198) A/A (n = 53) A/G + G/G (n = 75) TC 266.3 &#b1; 5.9 266.4 &#b1; 4.8 266.2 &#b1; 9.5 289.5 &#b1; 8.0 0.112 TG 4.55 &#b1; 0.03 4.47 &#b1; 0.02 4.56 &#b1; 0.05 4.68 &#b1; 0.04 0.013 LDL-C 197.4 &#b1; 5.7 198.5 &#b1; 4.7 199.1 &#b1; 9.3 223.9 &#b1; 7.8 0.095 HDL-C 46.6 &#b1; 1.0 48.6 &#b1; 0.8 44.6 &#b1; 1.6 41.2 &#b1; 1.3 0.030 VLDL-C 20.1 &#b1; 0.7 18.9 &#b1; 0.5 20.8 &#b1; 1.1 23.6 &#b1; 0.9 0.022 G5 i18429 C/C (n = 259) C/T + T/T (n = 78) C/C (n = 85) C/T + T/T (n = 43) TC 266.9 &#b1; 4.2 264.1 &#b1; 7.8 270.2 &#b1; 7.5 299.5 &#b1; 10.6 0.042 TG 4.53 &#b1; 0.02 4.41 &#b1; 0.04 4.61 &#b1; 0.04 4.67 &#b1; 0.06 0.047 LDL-C 198.0 &#b1; 4.1 198.1 &#b1; 7.6 204.6 &#b1; 7.3 232.0 &#b1; 10.3 0.077 HDL-C 47.9 &#b1; 0.7 47.3 &#b1; 1.3 43.5 &#b1; 1.2 40.8 &#b1; 1.8 0.472 VLDL-C 19.9 &#b1; 0.5 17.6 &#b1; 0.9 22.4 &#b1; 0.9 22.8 &#b1; 1.3 0.173 G5 i11836 G/G (n = 208) A/G + A/A (n = 129) G/G (n = 84) A/G + A/A (n = 44) TC 264.2 &#b1; 4.8 269.8 &#b1; 6.0 275.1 &#b1; 7.6 289.3 &#b1; 10.4 0.574 TG 4.53 &#b1; 0.02 4.47 &#b1; 0.03 4.59 &#b1; 0.04 4.70 &#b1; 0.05 0.039 LDL-C 196.4 &#b1; 4.7 200.7 &#b1; 5.9 209.9 &#b1; 7.4 220.9 &#b1; 10.2 0.646 HDL-C 46.3 &#b1; 0.8 50.1 &#b1; 1.0 42.9 &#b1; 1.3 42.3 &#b1; 1.7 0.092 VLDL-C 20.0 &#b1; 0.5 18.4 &#b1; 0.7 21.4 &#b1; 0.9 24.3 &#b1; 1.2 0.014 G5 Q604E C/C (n = 248) C/G + G/G (n = 89) C/C (n = 84) C/G + G/G (n = 44) TC 268.4 &#b1; 4.3 260.4 &#b1; 7.3 278.2 &#b1; 7.6 283.4 &#b1; 10.5 0.400 TG 4.55 &#b1; 0.02 4.39 &#b1; 0.04 4.62 &#b1; 0.04 4.65 &#b1; 0.05 0.038 LDL-C 199.0 &#b1; 4.2 195.1 &#b1; 7.2 211.3 &#b1; 7.4 218.2 &#b1; 10.2 0.477 HDL-C 48.0 &#b1; 0.7 47.2 &#b1; 1.2 43.3 &#b1; 1.3 41.3 &#b1; 1.8 0.637 VLDL-C 20.1 &#b1; 0.5 17.3 &#b1; 0.8 22.8 &#b1; 0.9 22.0 &#b1; 1.2 0.265 All values are mean &#b1; standard error. P for interaction.
X
ABCG5 p.Gln604Glu 20172523:117:1355
status: NEW139 (A) Interaction ABCG5 i7892-smoking for HDL-C (B) Interaction ABCG5 i11836-smoking for TG (C) Interaction ABCG5 i18429-smoking for TG (D) Interaction ABCG5 Gln604Glu-smoking for TG.
X
ABCG5 p.Gln604Glu 20172523:139:156
status: NEW148 On the other hand, Miwa et al. [11] reported no significant associations between three ABCG5/G8 (Q604E, C54Y and T400K) SNPs and serum lipid concentrations in 100 Japanese primary hypercholesterolaemic patients.
X
ABCG5 p.Gln604Glu 20172523:148:97
status: NEW
PMID: 19932478
[PubMed]
Lu Y et al: "The potential influence of genetic variants in genes along bile acid and bile metabolic pathway on blood cholesterol levels in the population."
No.
Sentence
Comment
1748
Several polymorphisms in ABCG5 (Q604E, rs6720173) and ABCG8 (T400K, rs4148217; D19H, rs11887534; A632V, rs6544718; and Y54C, rs4148211) have been found to be associated with several facets of cholesterol metabolism, including cholesterol level, cholesterol kinetics, and individual responsiveness of blood cholesterol to dietary and pharmaceutical intervention [41].
X
ABCG5 p.Gln604Glu 19932478:1748:32
status: NEW1749 Regarding Q604E of ABCG5, Weggemans et al. [42] demonstrated that EE homozygotes had higher plasma total cholesterol levels than carriers of the wild-type allele.
X
ABCG5 p.Gln604Glu 19932478:1749:10
status: NEW1759 No modulating effect was observed from Q604E on cholesterol lowering response to atorvastatin [25,26].
X
ABCG5 p.Gln604Glu 19932478:1759:39
status: NEW1760 Overall, the various studies reviewed on effects of Q604E of ABCG5 gene on blood cholesterol levels and cholesterol metabolic kinetics suggest that the rare E allele is consistently associated with lower cholesterol absorption and higher cholesterol synthesis.
X
ABCG5 p.Gln604Glu 19932478:1760:52
status: NEW1795 In 100 hypercholesterolaemic Japanese subjects, Miwa et al. [56] reported that carriers of the M429V variant of ABCG8 or a specific haplotype (wild-type allele of Q604E ABCG5, and wild-type allele of C54Y, wild-type allele of T400K, mutant allele of M429V ABCG8) had higher cholesterol absorption efficiency than non-carriers.
X
ABCG5 p.Gln604Glu 19932478:1795:163
status: NEW1796 However, no difference was observed in serum lipid profiles in relation to common polymorphisms studied previously in Caucasian populations [ABCG5 (Q604E) and ABCG8 (A632V, T400K, D19H and C54Y)].
X
ABCG5 p.Gln604Glu 19932478:1796:148
status: NEW1805 Carriers of the minor alleles at ABCG5/G8 (Q604E; D19H; i14222A > G, rs6709904) SNPs displayed lower levels of HDL cholesterol only if they were smokers.
X
ABCG5 p.Gln604Glu 19932478:1805:43
status: NEW1859 Hubacek et al. [29] 114 Czech males More reductions in TC and LDL-C in C allele carriers (p < 0.01 and p = 0.07, respectively) CYP7A1 rs1023649, rs1023651 Klos et al. [23] 2054 whites and 1939 blacks Two SNPs associated with TC and LDL-C in black with increased levels in carriers of the rare alleles, no association observed in white ABCG5 Q604E (rs6720173, C > G) Weggemans et al. [42] 486 Dutch subjects Higher TC in EE than wild-type allele carriers Viturro et al. [43] 1227 healthy Spanish school children Heterozygotes (CG) higher in TC, LDL-C and apoB levels than CC, but only observed in the 70 boys of lowest tertile of saturated fat intake Berge et al. [44] 142 healthy American Caucasians No difference in TC Gylling et al. [45] 262 mildly to moderately hypercholesterolemic Finnish subjects No association between E allele carriers and wild-type homozygotes in TC, LDL-C and HDL-C Hubacek et al. [46] 285 Czech participants No difference in TC, LDL-C and HDL-C Junyent et al. [47] 845 self-identified Puerto Ricans No difference in TC, LDL-C and HDL-C Santosa et al. [48] 42 overweight/obese Canadian women No difference in TC and LDL-C Acalovschi et al. [49] 68 Romanian siblings with gallstone disease Lower TC and higher HDL-C in E allele carriers than QQ Plat et al. [50] 112 healthy Dutch volunteers Lower LDL-C in E allele carriers than QQ, no difference in HDL-C Gylling et al. [45] 262 mildly to moderately hypercholesterolemic Finnish subjects Lower cholesterol absorption (lower level of serum cholesterol adjusted campesterol and sitosterol) and higher cholesterol synthesis (high levels of serum cholesterol adjusted cholestenol) in E allele carriers than QQ Santosa et al. [48] 35 hypercholesterolemic Canadian women.
X
ABCG5 p.Gln604Glu 19932478:1859:341
status: NEW1860 Larger reduction in cholesterol absorption and greater increase in synthesis in EE than Q carriers during weight loss Herron et al. [51] 91 Caucasian subjects (40 men and 51 premenopausal women) E allele carriers responded less compared to QQ in TC and LDL-C after 1 more egg consumption/day over 30 days, no difference in HDL-C Kajinami et al. [25] 337 hypercholesterolemic subjects, mainly Caucasians No modulating effect from Q604E on cholesterol lowering response to atorvastatin Y.Luetal./Atherosclerosis210(2010)14-2721 Table 1(Continued).
X
ABCG5 p.Gln604Glu 19932478:1860:429
status: NEW
PMID: 18641716
[PubMed]
Rudkowska I et al: "Association between non-responsiveness to plant sterol intervention and polymorphisms in cholesterol metabolism genes: a case-control study."
No.
Sentence
Comment
119
In addition, a previous study by Weggemans et al. (2002), determined that subjects with the ABCG5 Q604E (rs6720173) mutant allele genotype had higher baseline TC levels than subjects with the wild-type allele, even if the response to dietary interventions was not related to this specific genotype.
X
ABCG5 p.Gln604Glu 18641716:119:98
status: NEW121 In agreement with our study, the previous investigations (Kajinami et al. 2004b; Weggemans et al. 2002; Gylling et al. 2004) failed to identify any associations between ABCG5 Q604E and plasma lipid responses to PS intervention.
X
ABCG5 p.Gln604Glu 18641716:121:175
status: NEW
PMID: 17612515
[PubMed]
Wang Y et al: "ATP binding cassette G8 T400K polymorphism may affect the risk of gallstone disease among Chinese males."
No.
Sentence
Comment
2
To investigate a possible association between transporter gene polymorphism and gallstone formation, we examined five common polymorphisms in the ABCG5 (Q604E) and ABCG8 (D19H, Y54C, T400K, A632V) genes in patients with gallstone disease (GS).
X
ABCG5 p.Gln604Glu 17612515:2:153
status: NEW24 Of these variants, it is suggested that 5 non-synonymous single nucleotide polymorphisms (SNPs) in the ABCG5 (Q604E) and ABCG8 (D19H, Y54C, T400K, A632V) coding sequences may effect plasma plant sterol or cholesterol levels [11-14].
X
ABCG5 p.Gln604Glu 17612515:24:109
status: NEW41 Four SNP sites in ABCG5 Q604E, ABCG8 Y54C, ABCG8 T400K, and ABCG8 A632V were assayed by PCR amplification and RFLP analysis, as previously described [10,11].
X
ABCG5 p.Gln604Glu 17612515:41:24
status: NEW72 Table 2 Linkage disequilibrium in 5 common polymorphisms of ABCG5 and ABCG8 genes D' Locus Q604E D19H Y54C T400K A632V r2 Q604E - 0.368 0.007 0.477 0.087 D19H 0.009 - 0.843 0.718 1.000 Y54C 0.000 0.045 - 0.824 0.211 T400K 0.003 0.000 0.579 - 1.000 A632V 0.000 0.000 0.000 0.001 - D' and r2 were calculated from all 506 subjects in the study.
X
ABCG5 p.Gln604Glu 17612515:72:91
status: NEWX
ABCG5 p.Gln604Glu 17612515:72:122
status: NEW82 No differences were observed when the frequencies of ABCG5 Q604E, ABCG8 D19H, and Y54C and A632V were compared between GS and Table 3 Frequency distribution of the different genotypes and alleles of 5 common ABCG5 and ABCG8 polymorphisms in GS and GSF Polymorphism All (%) Men (%) Women (%) GS GSF GS GSF GS GSF (n=287) (n=219) (n=121) (n=105) (n=166) (n=114) ABCG5:Q604E QQ 78.7 80.4 78.5 78.1 78.9 82.5 QE 20.9 18.7 21.5 20.0 20.5 17.5 EE 0.3 0.9 0 1.9 0.6 0 E allele 10.8 10.3 10.7 11.9 10.8 8.8 OR [95% CI]a 0.95 [0.63~1.42] 1.12 [0.63~2.01] 0.79 [0.45~1.41] ABCG8:D19H DD 98.3 98.6 99.2 99.0 97.6 98.2 DH 1.7 1.4 0.8 1.0 2.4 1.8 HH 0 0 0 0 0 0 H allele 0.9 0.7 0.4 0.5 1.2 0.9 OR [95% CI] 1.27 [0.30~5.36] 0.87 [0.05~13.95] 1.38 [0.25~7.59] ABCG8:Y54C YY 77.4 79.9 76.0 83.8 78.3 76.3 YC 22.3 18.3 24.0 14.3 21.1 21.9 CC 0.3 1.8 0 1.9 0.6 1.8 C allele 11.5 11.0 12.0 9.0 11.1 12.7 OR [95% CI] 1.06 [0.71~1.57] 1.369 [0.74~2.52] 0.861 [0.51~1.45] ABCG8:T400K TT 79.1 83.1 75.2 87.6 81.9 78.9 TK 20.6 16.4 24.8b 12.4 17.5 20.2 KK 0.3 0.5 0 0 0.6 0.9 K allele 10.6 8.7 12.4c 6.2 9.3 11.0 OR [95% CI] 1.25 [0.82~1.92] 2.14 [1.09~4.23] 0.83 [0.48~1.46] ABCG8:A632V AA 99.0 99.1 99.2 100.0 98.8 98.2 AV 1.0 0.9 0.8 0 1.2 1.8 VV 0 0 0 0 0 0 V allele 0.5 0.5 0.4 0 2(0.6) 0.9 OR [95% CI] 0.87 [0.14~5.27] 0.382 [0.02~9.44]d 1.46 [0.20~10.44] a Odds ratio (OR) statistics and 95% confidence intervals (95% CI) were calculated from allele distributions.
X
ABCG5 p.Gln604Glu 17612515:82:59
status: NEW99 Due to limited number of subjects, heterozygous and homozygous carriers of the genetic variants were combined as follows: ABCG5 Q604E (QE+EE), ABCG8 Y54C (YC+CC), and ABCG8 (TK+KK).
X
ABCG5 p.Gln604Glu 17612515:99:128
status: NEW102 However, no significant differences were found in the plasma and biliary lipid levels or biliary CSI of subjects with different genotypes of ABCG5 Q604E and ABCG8 Y54C.
X
ABCG5 p.Gln604Glu 17612515:102:147
status: NEW73 Table 2 Linkage disequilibrium in 5 common polymorphisms of ABCG5 and ABCG8 genes D' Locus Q604E D19H Y54C T400K A632V r2 Q604E - 0.368 0.007 0.477 0.087 D19H 0.009 - 0.843 0.718 1.000 Y54C 0.000 0.045 - 0.824 0.211 T400K 0.003 0.000 0.579 - 1.000 A632V 0.000 0.000 0.000 0.001 - D' and r2 were calculated from all 506 subjects in the study.
X
ABCG5 p.Gln604Glu 17612515:73:91
status: NEWX
ABCG5 p.Gln604Glu 17612515:73:122
status: NEW83 No differences were observed when the frequencies of ABCG5 Q604E, ABCG8 D19H, and Y54C and A632V were compared between GS and Table 3 Frequency distribution of the different genotypes and alleles of 5 common ABCG5 and ABCG8 polymorphisms in GS and GSF Polymorphism All (%) Men (%) Women (%) GS GSF GS GSF GS GSF (n=287) (n=219) (n=121) (n=105) (n=166) (n=114) ABCG5:Q604E QQ 78.7 80.4 78.5 78.1 78.9 82.5 QE 20.9 18.7 21.5 20.0 20.5 17.5 EE 0.3 0.9 0 1.9 0.6 0 E allele 10.8 10.3 10.7 11.9 10.8 8.8 OR [95% CI]a 0.95 [0.63~1.42] 1.12 [0.63~2.01] 0.79 [0.45~1.41] ABCG8:D19H DD 98.3 98.6 99.2 99.0 97.6 98.2 DH 1.7 1.4 0.8 1.0 2.4 1.8 HH 0 0 0 0 0 0 H allele 0.9 0.7 0.4 0.5 1.2 0.9 OR [95% CI] 1.27 [0.30~5.36] 0.87 [0.05~13.95] 1.38 [0.25~7.59] ABCG8:Y54C YY 77.4 79.9 76.0 83.8 78.3 76.3 YC 22.3 18.3 24.0 14.3 21.1 21.9 CC 0.3 1.8 0 1.9 0.6 1.8 C allele 11.5 11.0 12.0 9.0 11.1 12.7 OR [95% CI] 1.06 [0.71~1.57] 1.369 [0.74~2.52] 0.861 [0.51~1.45] ABCG8:T400K TT 79.1 83.1 75.2 87.6 81.9 78.9 TK 20.6 16.4 24.8b 12.4 17.5 20.2 KK 0.3 0.5 0 0 0.6 0.9 K allele 10.6 8.7 12.4c 6.2 9.3 11.0 OR [95% CI] 1.25 [0.82~1.92] 2.14 [1.09~4.23] 0.83 [0.48~1.46] ABCG8:A632V AA 99.0 99.1 99.2 100.0 98.8 98.2 AV 1.0 0.9 0.8 0 1.2 1.8 VV 0 0 0 0 0 0 V allele 0.5 0.5 0.4 0 2(0.6) 0.9 OR [95% CI] 0.87 [0.14~5.27] 0.382 [0.02~9.44]d 1.46 [0.20~10.44] a Odds ratio (OR) statistics and 95% confidence intervals (95% CI) were calculated from allele distributions.
X
ABCG5 p.Gln604Glu 17612515:83:59
status: NEW100 Due to limited number of subjects, heterozygous and homozygous carriers of the genetic variants were combined as follows: ABCG5 Q604E (QE+EE), ABCG8 Y54C (YC+CC), and ABCG8 (TK+KK).
X
ABCG5 p.Gln604Glu 17612515:100:128
status: NEW103 However, no significant differences were found in the plasma and biliary lipid levels or biliary CSI of subjects with different genotypes of ABCG5 Q604E and ABCG8 Y54C.
X
ABCG5 p.Gln604Glu 17612515:103:147
status: NEW
PMID: 17543849
[PubMed]
Gylling H et al: "Cholesterol synthesis prevails over absorption in metabolic syndrome."
No.
Sentence
Comment
111
Polymorphisms of the different genes tested were evenly distributed between MBO and controls (heterozygotesϩhomozygotes/wild type: ABCG8: D19H, MBO 16/56, controls 13/61; T400K, MBO 29/ 43, controls 26/48; A632V, MBO 27/45, controls 27/ 47; ABCG5: Q604E, MBO 16/56, controls 16/58).
X
ABCG5 p.Gln604Glu 17543849:111:254
status: NEW110 Polymorphisms of the different genes tested were evenly distributed between MBO and controls (heterozygotesaf9;homozygotes/wild type: ABCG8: D19H, MBO 16/56, controls 13/61; T400K, MBO 29/ 43, controls 26/48; A632V, MBO 27/45, controls 27/ 47; ABCG5: Q604E, MBO 16/56, controls 16/58).
X
ABCG5 p.Gln604Glu 17543849:110:254
status: NEW
PMID: 17098593
[PubMed]
Acalovschi M et al: "Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones."
No.
Sentence
Comment
7
Triglyceride levels were higher in carriers of the common alleles for ABCG5 Q604E and ABCG8 D19H sequence variants, and HDL-cholesterol was lower in carriers of the common alleles for ABCG5 Q604E than in carriers of the rare alleles.
X
ABCG5 p.Gln604Glu 17098593:7:76
status: NEWX
ABCG5 p.Gln604Glu 17098593:7:190
status: NEW54 Genotype analysis The patients were genotyped for the ABCG5 single nucleotide polymorphism (SNP) Q604E and the ABCG8 SNPs D19H, Y54C, T400K, and A632V [5,11,12] by TaqMan allelic discrimination.
X
ABCG5 p.Gln604Glu 17098593:54:97
status: NEW78 Triglyceride levels in the carriers of the common alleles were higher than in the carriers of the rare alleles for the ABCG5 Q604E ( p=0.002), ABCG8 D19H ( p=0.058), and ABCG8 Y54C ( p=0.050) sequence variants (Table 4).
X
ABCG5 p.Gln604Glu 17098593:78:125
status: NEW79 The cholesterol levels, although within normal ranges, were higher in carriers of the common versus rare alleles for the ABCG5 Q604E polymorphism ( p=0.011) and for the ABCG8 D19H polymorphism ( p=0.052).
X
ABCG5 p.Gln604Glu 17098593:79:121
status: NEWX
ABCG5 p.Gln604Glu 17098593:79:127
status: NEW80 Furthermore, the HDL-cholesterol level was significantly ( p=0.007) lower in carriers of the common allele for the ABCG5 Q604E polymorphism.
X
ABCG5 p.Gln604Glu 17098593:80:121
status: NEW109 Variation in plasma concentrations of non-cholesterol sterols has been demonstrated to be highly heritable, and D19H and T400K polymorphisms in ABCG8 have been found to contribute to genetic variations in the plasma concentrations of plant sterols [10].
X
ABCG5 p.Gln604Glu 17098593:109:78
status: NEW110 Other polymorphisms in ABCG8 (A632V [10], T400K, and Y54C [27]) and in ABCG5 (Q604E [28]) have been suggested to be associated with plasma cholesterol levels.
X
ABCG5 p.Gln604Glu 17098593:110:78
status: NEWX
ABCG5 p.Gln604Glu 17098593:110:145
status: NEW111 In our siblings with gallstones we found significantly higher plasma triglyceride levels in carriers of the common alleles for the polymorphisms Q604E in ABCG5 and D19H and Y54C in ABCG8 than in carriers of the rare alleles.
X
ABCG5 p.Gln604Glu 17098593:111:75
status: NEWX
ABCG5 p.Gln604Glu 17098593:111:145
status: NEW112 HDL-cholesterol levels were lower in carriers of the common alleles of the Q604E polymorphism in ABCG5.
X
ABCG5 p.Gln604Glu 17098593:112:72
status: NEW113 Cholesterol levels were higher in carriers of the common alleles of the Q604E polymorphism in ABCG5 and the D19H variant in ABCG8.
X
ABCG5 p.Gln604Glu 17098593:113:12
status: NEWX
ABCG5 p.Gln604Glu 17098593:113:72
status: NEW114 Because the Q604E polymorphism in the ABCG5 gene was associated with the most significant plasma lipid changes in the affected siblings, our results suggest that this polymorphism might be responsible for an altered function of the ABCG5 transporter in gallstone patients.
X
ABCG5 p.Gln604Glu 17098593:114:12
status: NEW119 Plasma lipids in affected siblings Table 4 Plasma triglycerides, cholesterol, and HDL-cholesterol in the 68 siblings with gallstones in relation to ABCG5/G8 genotypes (bold indicates pb0.05) Triglycerides (mg/dl) Cholesterol (mg/dl) HDL cholesterol (mg/dl) ABCG8 A632V CT/TT=28 155.5±57.3 205.7±32.6 48.1±13.2 CC=44 154.1±67.3 204.6±39.2 45.6±18.2 T400K CA/AA=30 168.5±76.9 209.9±37.5 46.0±17.3 CC=42 144.7±50.1 201.5±35.8 48.2±14.4 Y54C AG/GG=44 144.5±58.4 202.7±39.6 44.9±17.0 AA=28 170.6±68.3 210.3±32.8 48.0±15.6 D19H GC/CC=12 130.9±52.6 192.5±27.3 49.0±19.5 GG=60 159.4±64.5 208.3±38.4 46.0±16.0 ABCG5 Q604E CG/GG=24 127.4±51.9 191.7±35.1 55.9±12.9 CC=48 168.2±64.5 212.7±36.3 42.7±15.7 did not correlate with those in controls.
X
ABCG5 p.Gln604Glu 17098593:119:727
status: NEW121 In the affected siblings, the Q604E polymorphism in ABCG5 was associated with the most significant plasma lipid changes.
X
ABCG5 p.Gln604Glu 17098593:121:30
status: NEW53 Genotype analysis The patients were genotyped for the ABCG5 single nucleotide polymorphism (SNP) Q604E and the ABCG8 SNPs D19H, Y54C, T400K, and A632V [5,11,12] by TaqMan allelic discrimination.
X
ABCG5 p.Gln604Glu 17098593:53:97
status: NEW77 Triglyceride levels in the carriers of the common alleles were higher than in the carriers of the rare alleles for the ABCG5 Q604E ( p=0.002), ABCG8 D19H ( p=0.058), and ABCG8 Y54C ( p=0.050) sequence variants (Table 4).
X
ABCG5 p.Gln604Glu 17098593:77:125
status: NEW118 Plasma lipids in affected siblings Table 4 Plasma triglycerides, cholesterol, and HDL-cholesterol in the 68 siblings with gallstones in relation to ABCG5/G8 genotypes (bold indicates pb0.05) Triglycerides (mg/dl) Cholesterol (mg/dl) HDL cholesterol (mg/dl) ABCG8 A632V CT/TT=28 155.5&#b1;57.3 205.7&#b1;32.6 48.1&#b1;13.2 CC=44 154.1&#b1;67.3 204.6&#b1;39.2 45.6&#b1;18.2 T400K CA/AA=30 168.5&#b1;76.9 209.9&#b1;37.5 46.0&#b1;17.3 CC=42 144.7&#b1;50.1 201.5&#b1;35.8 48.2&#b1;14.4 Y54C AG/GG=44 144.5&#b1;58.4 202.7&#b1;39.6 44.9&#b1;17.0 AA=28 170.6&#b1;68.3 210.3&#b1;32.8 48.0&#b1;15.6 D19H GC/CC=12 130.9&#b1;52.6 192.5&#b1;27.3 49.0&#b1;19.5 GG=60 159.4&#b1;64.5 208.3&#b1;38.4 46.0&#b1;16.0 ABCG5 Q604E CG/GG=24 127.4&#b1;51.9 191.7&#b1;35.1 55.9&#b1;12.9 CC=48 168.2&#b1;64.5 212.7&#b1;36.3 42.7&#b1;15.7 did not correlate with those in controls.
X
ABCG5 p.Gln604Glu 17098593:118:703
status: NEW120 In the affected siblings, the Q604E polymorphism in ABCG5 was associated with the most significant plasma lipid changes.
X
ABCG5 p.Gln604Glu 17098593:120:30
status: NEW
PMID: 15530894
[PubMed]
Kajinami K et al: "Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management."
No.
Sentence
Comment
1308
(year/type) Locus Polymorphisma (amino acid changes) No. of patients Country (trial) Drug Baseline LDLC (mmol/l) Reduction of LDLC (%) P-value for difference Ojala et al. [44] (1991/P) APOE E3/3 34 Finland Lova 20 mg 5.3 28 0.043†† E3/4 13 5.3 20 Ordovas et al. [53] (1995/C) APOE E3/2 + E2/2 12 USA Prava 40 mg 3.98 36 <0.05‡‡ E3/3 66 4.29 27 (ANOVA) E3/4 + E4/4 19 4.42 26 APOA4 Wild 125 USA Prava 40 mg 4.29 28 n.s. Variant 17 4.27 30 Nestel et al. [54] (1997/C) APOE 3/2 + 2/2 49 Australia Simva 20 mg 5.60 as a whole 33 as a whole Responder was more prevalent in E2 3/3 69 3/4 + 4/4 59 Sanllehy et al. [55] (1998/C) APOE E3/2 15 Spain Lova 40 mg 5.72 31 n.s.‡‡ E3/3 62 5.53 34 (ANOVA) E3/4 29 5.72 33 Sing et al. [56] (1999/P) LPL (N291S) 184 as a whole USA Fluva 40 mg 3.74 as a whole n.s. (S447X) Salazar et al. [57] (2000/P) LDLR AvaII 55 as a whole Brazil Fluva 5.83 as a whole 23-27 <0.05§ HincII 40-80 mg <0.05§ PvuII <0.05§ Guzman et al. [58] (2000/P) APOB ins/del 54 as a whole Brazil Fluva 5.42 as a whole 28-34 0.044§ XbaI 40-80 mg n.s.§ EcoRI n.s.§ Ballantyne et al. [59] (2000/C) APOE 3/2 10 USA Fluva 40 mg 3.59 24 0.02† 3/3 102 (LCAS) 3.85 29 (ANOVA) 3/4 + 4/4 49 3.70 23 Mulder et al. [60] (2001/P) CYP2D6 88 as a whole Netherlands Simva n.a. ** 10-40 mg Pedro-Botet et al. [61] (2001/C) APOE 3/2 + 2/2 20 USA Atorva 10 mg 5.04 39 0.01 in men 3/3 187 4.86 38 n.s. in women 3/4 + 4/4 121 4.81 36 (ANOVA) Fan et al. [62] (2001/P) SCAP MslI 22 as a whole Finland Prava 40 mg 3.8 as a whole n.s. Malin et al. [63] (2001/P) PON (M55L) 25 as a whole Finland Prava 40 mg 3.61 as a whole n.s. (R192Q) 0.095 in HDLC# Pena et al. [64] (2002/C) APOE 3/2 13 Spain Prava 20 mg 4.75 17 n.s.‡ 3/3 293 5.24 22 3/4 + 4/4 92 5.12 18 Lahoz et al. [65] (2003/P) APOA1 Promoter 397 as a whole Spain Prava 20 mg n.s. in LDLC 0.04 in HDLC‡‡ Ruano et al. [66] (2003/P) ABCA1 Haplotype 425 as a whole USA Various n.a. <0.0001$ HMGCR Haplotype n.s.$ van Venrooij et al. [67] (2003/P) CETP TaqI B 217 as a whole Netherlands Atorva 10-80 mg 3.7 as a whole <0.05 in HDLC A-629C (DALI) <0.05 in HDLC Kajinami et al. [68] (2004/P) ABCG5/G8 (Q604E) 338 as a whole USA Atorva 10 mg 4.86 as a whole n.s. (D19H) 36 vs. 40 0.036§ (Y54C) n.s. (T400K) n.s. Table 3 (Continued ) Author [Ref.
X
ABCG5 p.Gln604Glu 15530894:1308:2374
status: NEW1307 (year/type) Locus Polymorphisma (amino acid changes) No. of patients Country (trial) Drug Baseline LDLC (mmol/l) Reduction of LDLC (%) P-value for difference Ojala et al. [44] (1991/P) APOE E3/3 34 Finland Lova 20 mg 5.3 28 0.043ߤߤ E3/4 13 5.3 20 Ordovas et al. [53] (1995/C) APOE E3/2 + E2/2 12 USA Prava 40 mg 3.98 36 <0.05ߥߥ E3/3 66 4.29 27 (ANOVA) E3/4 + E4/4 19 4.42 26 APOA4 Wild 125 USA Prava 40 mg 4.29 28 n.s. Variant 17 4.27 30 Nestel et al. [54] (1997/C) APOE ॻ3/2 + ॻ2/2 49 Australia Simva 20 mg 5.60 as a whole 33 as a whole Responder was more prevalent in E2 ॻ3/3 69 ॻ3/4 + ॻ4/4 59 Sanllehy et al. [55] (1998/C) APOE E3/2 15 Spain Lova 40 mg 5.72 31 n.s.ߥߥ E3/3 62 5.53 34 (ANOVA) E3/4 29 5.72 33 Sing et al. [56] (1999/P) LPL (N291S) 184 as a whole USA Fluva 40 mg 3.74 as a whole n.s. (S447X) Salazar et al. [57] (2000/P) LDLR AvaII 55 as a whole Brazil Fluva 5.83 as a whole 23-27 <0.05&#a7; HincII 40-80 mg <0.05&#a7; PvuII <0.05&#a7; Guzman et al. [58] (2000/P) APOB ins/del 54 as a whole Brazil Fluva 5.42 as a whole 28-34 0.044&#a7; XbaI 40-80 mg n.s.&#a7; EcoRI n.s.&#a7; Ballantyne et al. [59] (2000/C) APOE ॻ3/2 10 USA Fluva 40 mg 3.59 24 0.02ߤ ॻ3/3 102 (LCAS) 3.85 29 (ANOVA) ॻ3/4 + ॻ4/4 49 3.70 23 Mulder et al. [60] (2001/P) CYP2D6 88 as a whole Netherlands Simva n.a. ** 10-40 mg Pedro-Botet et al. [61] (2001/C) APOE ॻ3/2 + ॻ2/2 20 USA Atorva 10 mg 5.04 39 0.01 in men ॻ3/3 187 4.86 38 n.s. in women ॻ3/4 + ॻ4/4 121 4.81 36 (ANOVA) Fan et al. [62] (2001/P) SCAP MslI 22 as a whole Finland Prava 40 mg 3.8 as a whole n.s. Malin et al. [63] (2001/P) PON (M55L) 25 as a whole Finland Prava 40 mg 3.61 as a whole n.s. (R192Q) 0.095 in HDLC# Pena et al. [64] (2002/C) APOE ॻ3/2 13 Spain Prava 20 mg 4.75 17 n.s.ߥ ॻ3/3 293 5.24 22 ॻ3/4 + ॻ4/4 92 5.12 18 Lahoz et al. [65] (2003/P) APOA1 Promoter 397 as a whole Spain Prava 20 mg n.s. in LDLC 0.04 in HDLCߥߥ Ruano et al. [66] (2003/P) ABCA1 Haplotype 425 as a whole USA Various n.a. <0.0001$ HMGCR Haplotype n.s.$ van Venrooij et al. [67] (2003/P) CETP TaqI B 217 as a whole Netherlands Atorva 10-80 mg 3.7 as a whole <0.05 in HDLC A-629C (DALI) <0.05 in HDLC Kajinami et al. [68] (2004/P) ABCG5/G8 (Q604E) 338 as a whole USA Atorva 10 mg 4.86 as a whole n.s. (D19H) 36 vs. 40 0.036&#a7; (Y54C) n.s. (T400K) n.s. Table 3 (Continued ) Author [Ref.
X
ABCG5 p.Gln604Glu 15530894:1307:2341
status: NEW
PMID: 15262185
[PubMed]
Kajinami K et al: "Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin."
No.
Sentence
Comment
1
To investigate the interactions between common polymorphisms in ABCG5/G8 and CYP7A1 and statin response, we examined the relationships between five non-synonymous polymorphisms in ABCG5/G8 (Q604E, D19H, Y54C, T400K, and A632V) and a promoter variant in CYP7A1 (A-204C) in 337 hypercholesterolemic patients treated with atorvastatin 10 mg.
X
ABCG5 p.Gln604Glu 15262185:1:190
status: NEW43 The set of polymorphisms in ABCG5/G8 (Q604E, D19H, Y54C, T400K, and A632V) and CYP7A1 (A-204C) was examined in 337 subjects from the atorvastatin (10 mg per day) arm. The means (±S.D.) of age and BMI were 58 ± 11 years old and 27.0 ± 3.0 kg/m2, respectively [15].
X
ABCG5 p.Gln604Glu 15262185:43:38
status: NEW76 K.Kajinamietal./Atherosclerosis175(2004)287-293291 Table 3 Associations between ABCG5 Q604E, ABCG8 T400K, ABCG8 A632V/CYP7A1 A-204C and the LDL-lowering response to atorvastatin* ABCG5/G8 All subjects CYP7A1 P-values among CYP7A1 genotype† Unadjusted Adjusted AA AC CC Additive Dominant Recessive ABCG5 Q604E QQ 36.9 ± 10.1 37.0, 35.7-38.2 (212) 39.4, 37.0-41.8 (57) 36.6, 34.8-38.4 (104) 35.0, 32.4-37.5 (51) 0.055 0.031 0.080 QE 37.1 ± 9.5 36.9, 35.1-38.6 (111) 37.6, 34.7-40.5 (39) 37.3, 34.8-39.9 (54) 33.9, 29.6-38.2 (18) 0.321 0.646 0.131 EE 36.9 ± 9.3 37.8, 32.9-42.7 (14) 44.3, 35.1-53.4 (4) 36.9, 30.0-43.7 (7) 31.0, 20.5-41.5 (3) 0.159 0.081 0.164 ABCG8 T400K TT 37.3 ± 10.3 37.4, 36.2-38.8 (197) 37.5, 34.4-40.6 (62) 36.4, 34.4-38.4 (92) 34.1, 30.4-37.7 (43) 0.022 0.030 0.019 TK 36.5 ± 8.6 36.2, 34.6-37.9 (128) 38.7, 36.2-41.3 (33) 36.4, 34.1-38.8 (67) 35.4, 32.5-38.4 (28) 0.611 0.726 0.320 KK 35.8 ± 13.5 36.0, 30.7-41.3 (12) 42.4, 37.9-46.9 (5) 39.1, 35.7-42.5 (6) 31.9, 26.1-37.6 (1) 0.157 0.046 0.988 ABCG8 A632V AA 36.5 ± 10.0 36.4, 35.2-37.6 (224) 39.8, 37.4-42.1 (65) 37.4, 35.6-39.3 (116) 34.3, 31.4-37.1 (43) 0.005 0.004 0.020 AV 38.0 ± 9.6 38.3, 36.4-40.2 (97) 36.7, 33.5-39.8 (28) 36.6, 34.4-38.8 (41) 34.9, 31.6-38.3 (28) 0.288 0.794 0.126 VV 36.9 ± 7.3 36.2, 31.7-40.8 (16) 42.4, 34.3-50.5 (7) 30.4, 23.0-37.8 (8) 37.0, 18.9-55.1 (1) 0.697 0.992 0.397 In testing the effects of ABCG5 (Q604E) or ABCG8 (T400K and A632V) genotype on LDL-lowering response, none of P-values reached statistical significance.
X
ABCG5 p.Gln604Glu 15262185:76:86
status: NEWX
ABCG5 p.Gln604Glu 15262185:76:310
status: NEWX
ABCG5 p.Gln604Glu 15262185:76:1464
status: NEW77 P-values in testing genotype interaction between ABCG5 Q604E and CYP7A1 using two-way ANOVA were 0.584 when additive model of both genotypes were used; 0.568 when a dominant model of ABCG5 Q604E and recessive model of CYP7A1 were used, and 0.359 when a recessive model for each genotype was used.
X
ABCG5 p.Gln604Glu 15262185:77:55
status: NEWX
ABCG5 p.Gln604Glu 15262185:77:189
status: NEW78 Corresponding values between ABCG8 T400K and CYP7A1 were 0.439, 0.709, and 0.641, and those between ABCG8 A632V and CYP7A1 were 0.267, 0.593, and 0.279, respectively.
X
ABCG5 p.Gln604Glu 15262185:78:35
status: NEWX
ABCG5 p.Gln604Glu 15262185:78:258
status: NEWX
ABCG5 p.Gln604Glu 15262185:78:1403
status: NEW44 The set of polymorphisms in ABCG5/G8 (Q604E, D19H, Y54C, T400K, and A632V) and CYP7A1 (A-204C) was examined in 337 subjects from the atorvastatin (10 mg per day) arm. The means (&#b1;S.D.) of age and BMI were 58 &#b1; 11 years old and 27.0 &#b1; 3.0 kg/m2, respectively [15].
X
ABCG5 p.Gln604Glu 15262185:44:38
status: NEW79 P-values in testing genotype interaction between ABCG5 Q604E and CYP7A1 using two-way ANOVA were 0.584 when additive model of both genotypes were used; 0.568 when a dominant model of ABCG5 Q604E and recessive model of CYP7A1 were used, and 0.359 when a recessive model for each genotype was used.
X
ABCG5 p.Gln604Glu 15262185:79:55
status: NEWX
ABCG5 p.Gln604Glu 15262185:79:189
status: NEW
PMID: 11452359
[PubMed]
Lu K et al: "Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively."
No.
Sentence
Comment
169
OF IDENTIFIED POLYMORPHISMS HARDY-WEINBERG EQUILIBRIUM?ϩ/ϩ ϩ/- -/- ABCG5: 167CrT (Pro9Pro) Gain of BstNI … … … … 1950CrG (Gln604Glu) Loss of SmlI 46 25 1 Yes ABCG8: Exon 1 141CrT (Pro17Pro) … 49 1 0 Yes Exon 1 145GrC (Asp19His) Loss of BaeI 74 3 1 No Exon 2 251GrA (Cys54Tyr) Gain of SexAI 21 23 23 No Exon 6 802GrA (Glu238Lys) … 10 1 0 Yes Exon 6 866CrT (Ala259Val) Loss of HaeIII 0 5 0 … Exon 8 1289CrA (Thr400Lys) Gain of MseI 116 53 4 Yes Exon 11 1785CrT (Ala565Ala) Loss of MnlI 20 7 1 Yes Exon 11 1813GrC (Gly575Arg) Gain of HhaI 188 6 4 No Exon 13 1984CrT (Ala632Val) Loss of StyI 107 50 13 No 5 UTR -15ArC Gain of BstEII 47 4 0 Yes 5 UTR -19TrG Loss of Tsp451 38 42 29 No 5 UTR -41CrT Loss of DdeI 7 2 4 No Intron 1 -7CrT Loss of BsmAI 21 23 4 Yes Intron 1 -21CrA Loss of MnlI 20 23 4 Yes Intron 9 -19CrT … 1 3 4 … Intron 10 IVS10 ϩ34delCC … 3 1 4 … Intron 10 -50CrT … 4 4 2 … cohort of patients with sitosterolemia.
X
ABCG5 p.Gln604Glu 11452359:169:168
status: NEW170 af9;/af9; af9;/afa; afa;/afa; ABCG5: 167CrT (Pro9Pro) Gain of BstNI ߪ ߪ ߪ ߪ 1950CrG (Gln604Glu) Loss of SmlI 46 25 1 Yes ABCG8: Exon 1 141CrT (Pro17Pro) ߪ 49 1 0 Yes Exon 1 145GrC (Asp19His) Loss of BaeI 74 3 1 No Exon 2 251GrA (Cys54Tyr) Gain of SexAI 21 23 23 No Exon 6 802GrA (Glu238Lys) ߪ 10 1 0 Yes Exon 6 866CrT (Ala259Val) Loss of HaeIII 0 5 0 ߪ Exon 8 1289CrA (Thr400Lys) Gain of MseI 116 53 4 Yes Exon 11 1785CrT (Ala565Ala) Loss of MnlI 20 7 1 Yes Exon 11 1813GrC (Gly575Arg) Gain of HhaI 188 6 4 No Exon 13 1984CrT (Ala632Val) Loss of StyI 107 50 13 No 5 UTR afa;15ArC Gain of BstEII 47 4 0 Yes 5 UTR afa;19TrG Loss of Tsp451 38 42 29 No 5 UTR afa;41CrT Loss of DdeI 7 2 4 No Intron 1 afa;7CrT Loss of BsmAI 21 23 4 Yes Intron 1 afa;21CrA Loss of MnlI 20 23 4 Yes Intron 9 afa;19CrT ߪ 1 3 4 ߪ Intron 10 IVS10 af9;34delCC ߪ 3 1 4 ߪ Intron 10 afa;50CrT ߪ 4 4 2 ߪ cohort of patients with sitosterolemia.
X
ABCG5 p.Gln604Glu 11452359:170:127
status: NEW171 af9;/af9; af9;/afa; afa;/afa; ABCG5: 167CrT (Pro9Pro) Gain of BstNI ߪ ߪ ߪ ߪ 1950CrG (Gln604Glu) Loss of SmlI 46 25 1 Yes ABCG8: Exon 1 141CrT (Pro17Pro) ߪ 49 1 0 Yes Exon 1 145GrC (Asp19His) Loss of BaeI 74 3 1 No Exon 2 251GrA (Cys54Tyr) Gain of SexAI 21 23 23 No Exon 6 802GrA (Glu238Lys) ߪ 10 1 0 Yes Exon 6 866CrT (Ala259Val) Loss of HaeIII 0 5 0 ߪ Exon 8 1289CrA (Thr400Lys) Gain of MseI 116 53 4 Yes Exon 11 1785CrT (Ala565Ala) Loss of MnlI 20 7 1 Yes Exon 11 1813GrC (Gly575Arg) Gain of HhaI 188 6 4 No Exon 13 1984CrT (Ala632Val) Loss of StyI 107 50 13 No 5 UTR afa;15ArC Gain of BstEII 47 4 0 Yes 5 UTR afa;19TrG Loss of Tsp451 38 42 29 No 5 UTR afa;41CrT Loss of DdeI 7 2 4 No Intron 1 afa;7CrT Loss of BsmAI 21 23 4 Yes Intron 1 afa;21CrA Loss of MnlI 20 23 4 Yes Intron 9 afa;19CrT ߪ 1 3 4 ߪ Intron 10 IVS10 af9;34delCC ߪ 3 1 4 ߪ Intron 10 afa;50CrT ߪ 4 4 2 ߪ cohort of patients with sitosterolemia.
X
ABCG5 p.Gln604Glu 11452359:171:127
status: NEW
PMID: 23179156
[PubMed]
Yoon JH et al: "ATP-binding cassette sterol transporters are differentially expressed in normal and diseased human gallbladder."
No.
Sentence
Comment
112
Other studies have identified a variety of polymorphisms in ABCG8 (A632 V, T400 K, D19H, and C54Y) and in ABCG5 (Q604E) that have been linked to baseline plasma cholesterol levels, cholesterol absorption, or responsiveness to dietary intervention [23-25].
X
ABCG5 p.Gln604Glu 23179156:112:113
status: NEW
PMID: 23340007
[PubMed]
Krawczyk M et al: "Genetics of biliary lithiasis from an ethnic perspective."
No.
Sentence
Comment
39
For this study, common ABCG5 (p.Q604E) and ABCG8 (p.D19H, p.Y54C, p.T400K, p.A632V) variants were selected and the nonparametric linkage (NPL) as well as case-control analyses were performed.
X
ABCG5 p.Gln604Glu 23340007:39:32
status: NEW
PMID: 24657701
[PubMed]
Stender S et al: "The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease."
No.
Sentence
Comment
22
We genotyped all common nonsynonymous variants (minor allelefrequency >5%) inABCG5/ 8 (ABCG8D19H, Y54C, T400K, A632V; ABCG5 Q604E) and a functional intronic variant (ABCG8 IVS3&#fe;981) in 2 prospective studies of the Danish general population, CGPS (Copenhagen General Population Study) and CCHS (Copenhagen City Heart Study), and in a case-control study, CIHDS (Copenhagen Ischemic Heart Disease Study), totaling 60,239 participants, including 5,647 with MI and 3,174 with symptomatic gallstone disease.
X
ABCG5 p.Gln604Glu 24657701:22:124
status: NEW60 For all genotypes except ABCG5 Q604E, there were stepwise decreases in total and LDL cholesterol levels as a function of genotypes from 0.8% (0.04 mmol/l) to 4.1% (0.24 mmol/l) for total cholesterol and 1.1% (0.04 mmol/l) to 5.8% (0.19 mmol/l) for LDL cholesterol, in homozygotes versus noncarriers (p for trend: 0.08 to 1 10-28 ).
X
ABCG5 p.Gln604Glu 24657701:60:31
status: NEW137 Although 3 smaller studies (287 gallstone cases) have reported associations for ABCG5 Q604E and ABCG8 T400K with risk of gallstone disease, the large genome-wide association study (n &#bc; 2,280 cases) that initially identified ABCG8 D19H did not report other risk variants in ABCG5/8 (27-30).
X
ABCG5 p.Gln604Glu 24657701:137:87
status: NEW138 However, re-evaluating the thorough fine-mapping of variants in the ABCG5/8-region performed in this genome-wide association study revealed that ABCG8 IVS&#fe;981 and T400K, as well as ABCG5 Q604E, were indeed associated with gallstone disease, but that the associations did not reach the stringent requirements for statistical significance and/or replication (30).
X
ABCG5 p.Gln604Glu 24657701:138:191
status: NEW139 We found that ABCG8 IVS&#fe;981 and T400K, as well as ABCG5 Q604E, were individually associated with risk of symptomatic gallstone disease independent of D19H genotype.
X
ABCG5 p.Gln604Glu 24657701:139:60
status: NEW145 ABCG5 Q604E was associated with an increased risk of symptomatic gallstone disease in heterozygotes, but in contrast to the ABCG8 alleles that increased the risk of gallstones in the present study, Q604E did not associate with low LDL cholesterol.
X
ABCG5 p.Gln604Glu 24657701:145:6
status: NEWX
ABCG5 p.Gln604Glu 24657701:145:198
status: NEW
PMID: 25920552
[PubMed]
Rodriguez S et al: "Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array."
No.
Sentence
Comment
140
Two further independent SNPs were identified in ABCG5, rs10439467:C4T in intron 10 and rs6720173:G4C NM_022436.2 (ABCG5)c.1810C4G (p.Gln604Glu).
X
ABCG5 p.Gln604Glu 25920552:140:133
status: NEW
PMID: 26088706
[PubMed]
Gok O et al: "ABCG5 and ABCG8 gene polymorphisms in type 2 diabetes mellitus in the Turkish population."
No.
Sentence
Comment
41
There is no investigation related to ABCG5 Gln604Glu and ABCG8 Tyr54Cys single nucleotide polymorphisms (SNPs) and lipid levels in patients with diabetes. According to this knowledge, we aimed to investigate the association between ABCG5 and ABCG8 gene polymorphisms and lipid levels in Turkish patients with type 2 diabetes as compared to controls.
X
ABCG5 p.Gln604Glu 26088706:41:43
status: NEW55 Determination of ABCG5 Gln604Glu and ABCG8 Tyr54Cys polymorphisms ABCG5 and ABCG8 gene polymorphisms were analyzed using the PCR-restriction fragment length polymorphism (RFLP) method, as described previously (21).
X
ABCG5 p.Gln604Glu 26088706:55:23
status: NEW56 A segment of the ABCG5 gene encompassing the Gln604Glu polymorphic site was amplified with the help of PCR by using the forward (5`-AAC CAC ACC TGA CAC TGT CAA TCT TTT CCT-3`) and reverse primers (5`-GGG CAG GTT TTC TCA ATG AAT TGA ATT CCT C-3`), and a segment of the ABCG8 gene encompassing the Tyr54Cys polymorphic site was amplified using the forward (5`-AGG GCC TCC AGG ATA GAT TGT TCT CCT C-3`) and reverse primers (5`CCT TGA ACC CAG GCG TGC GCC TAC CTG-3`) (21).
X
ABCG5 p.Gln604Glu 26088706:56:45
status: NEW73 * p<0.05. Table 2 Distribution of ABCG5 Gln604Glu and ABCG8 Tyr54Cys genotypes and alleles in study groups Patients (n&#bc;80) Controls (n&#bc;135) p % n % n ABCG5 Gln604Glu genotype CC 36.2* 29 60.3 44 0.003 GG 22.5* 18 9.6 7 0.031 CG 41.2 33 30.1 22 NS Allele C 56.8* 91 75.4 110 0.031 G 43.2* 69 24.6 36 0.003 ABCG8 Tyr54Cys genotype AA 55.0* 44 21.9 16 0.001 GG 12.5 10 12.3 9 NS AG 32.5* 26 65.8 48 0.001 Allele A 71.2 114 54.80 80 NS G 28.8* 46 45.20 66 0.001 n, Number of individuals; NS, not significant.
X
ABCG5 p.Gln604Glu 26088706:73:40
status: NEWX
ABCG5 p.Gln604Glu 26088706:73:164
status: NEW75 * p<0.05. Table 3 Distribution of ABCG5 Gln604Glu and ABCG8 Tyr54Cys genotypes and alleles by gender in study groups Patients (n&#bc;80) Controls (n&#bc;73) Female (n&#bc;59) Male (n&#bc;21) Female (n&#bc;26) Male (n&#bc;47) % n % n % n % n ABCG5 Gln604Glu genotype CC 33.9 20 42.9 9 61.5 16 59.6 28 GG 25.4 15 14.3 3 19.2 5 4.2 2 CG 40.7 24 42.9 9 19.2 5 36.2 17 Allele C 54.2 64 64.28 27 71.1 37 77.7 73 G 45.8 54 35.72 15 28.85 15 22.3 21 ABCG8 Tyr54Cys genotype AA 62.7* 37 33.3 7 19.2 5 23.4 4 GG 13.6 8 9.5 2 7.7 2 14.9 7 AG 23.7 14 57.2* 12 73.1 19 61.7 29 Allele A 74.6 88 61.9 26 55.7 29 54.3 51 G 25.4 30 38.1* 16 44.3 23 45.7 43 n, Number of individuals.
X
ABCG5 p.Gln604Glu 26088706:75:40
status: NEWX
ABCG5 p.Gln604Glu 26088706:75:247
status: NEW79 Frequencies of ABCG5 and ABCG8 gene polymorphisms The frequencies of genotypes and alleles in ABCG5 Gln604Glu and ABCG8 Tyr54Cys genes in both control and patient groups are shown in Table 2.
X
ABCG5 p.Gln604Glu 26088706:79:100
status: NEW84 The distributions of genotypes and alleles in ABCG5 Gln604Glu and ABCG8 Tyr54Cys genes bygenderare showninTable 3.
X
ABCG5 p.Gln604Glu 26088706:84:52
status: NEW89 Some frequencies of genotypes were not in the Hardy-Weinberg equilibrium (frequency of the ABCG8 Tyr54Cys genotype in control subjects, frequency of the ABCG8 Tyr54Cys genotype in female patients, frequency of the ABCG5 Gln604Glu genotype and Tyr54Cys genotypes in female control subjects, and frequency of the ABCG5 Tyr54Cys genotype in male control subjects).
X
ABCG5 p.Gln604Glu 26088706:89:220
status: NEW94 Discussion Type 2 diabetes mellitus is associated with gene-environment interactions due to epigenetic factors, such as defects in lipid metabolism, hyperlipidemia, hypertension, obesity, smoking and Table 4 Comparison of ABCG5 Gln604Glu and ABCG8 Tyr54Cys genotypes with lipid/anthropometric parameters in study groups ABCG5 Gln604Glu genotype ABCG8 Tyr54Cys genotype Patients (n&#bc;80) Controls (n&#bc;73) Patients (n&#bc;80) Controls (n&#bc;73) CC (n&#bc;29) GG (n&#bc;18) CG (n&#bc;33) P CC (n&#bc;29) GG (n&#bc;18) CG (n&#bc;33) P AA (n&#bc;44) GG (n&#bc;10) AG (n&#bc;21) P AA (n&#bc;44) GG (n&#bc;10) AG (n&#bc;21) p Triglyceride (mg/dL) 176.8382.37 176.6166.59 162.2175.04 NS 139.5949.75 123.5742.26 136.7356.21 NS 177.2383.33 137.4050.36 172.6267.88 NS 147.5068.90 130.4431.14 135.0246.99 NS Total cholesterol (mg/dL) 231.5755.85 231.3248.58 214.1459.23 NS 195.5831.07 202.7178.85 204.7135.56 NS 221.7056.57 216.0839.72 231.9560.41 NS 200.6956.77 207.9846.73 196.7829.13 NS HDL cholesterol (mg/dL) 40.6912.36 36.229.441 36.188.36 NS 36.597.01 39.575.15 34.689.15 NS 37.778.66 41.5014.50 36.5011.14 NS 38.758.59 33.568.81 36.006.96 NS LDL cholesterol (mg/dL) 155.5253.72 159.7848.56 145.5253.34 NS 131.0730.32 138.4371.95 142.6837.32 NS 148.4852.78 147.1043.52 160.9254.81 NS 132.4452.19 148.3350.33 133.7728.81 NS VLDL cholesterol (mg/dL) 35.3716.47 35.3213.31 32.4415.00 NS 27.929.95 24.718.45 27.3511.24 NS 35.4516.66 27.4810.07 34.5213.57 NS 29.5013.78 26.096.22 27.009.39 NS Total cholesterol/ HDL cholesterol (mg/dL) 6.252.77 6.932.66 6.222.33 NS 5.581.80 5.101.68 6.362.33 NS 6.312.70 5.872.64 6.742.32 NS 5.381.66 6.873.53 5.691.65 NS BMI (kg/m 2 ) 26.084.65 26.823.55 26.423.83 NS 26.532.81 * 23.363.30 26.583.91 0.018 26.784.13 24.745.15 26.353.41 NS 25.693.18 25.803.27 26.503.40 NS HDL, High density lipoprotein; LDL, low density lipoprotein; n, number of individuals; NS, not significant; SD, standard deviation; VLDL, very low-density lipoprotein; BMI, body mass index. Statistical evaluation was made by using the Student t test and the 1-way ANOVA test. The results are shown as mean SD.
X
ABCG5 p.Gln604Glu 26088706:94:228
status: NEWX
ABCG5 p.Gln604Glu 26088706:94:326
status: NEW109 We observed that the frequencies of the ABCG5 Gln604Glu GG genotype (p&#bc;0.031) and G allele (p&#bc;0.003) were significantly higher in patients than in the control group.
X
ABCG5 p.Gln604Glu 26088706:109:46
status: NEW117 In addition, they observed no association between lipid profiles and genotype distribution and allele frequencies for ABCG5 Gln604Glu polymorphism in both genders of the study population (131 male and 154 female).
X
ABCG5 p.Gln604Glu 26088706:117:124
status: NEW124 Junyent et al (39) genotyped ABCG5 Gln604Glu and ABCG8 Tyr54Cys genetic variants in 845 subjects and observed that minor alleles in these SNPs had a lowering effect on HDL cholesterol concentrations.
X
ABCG5 p.Gln604Glu 26088706:124:35
status: NEW130 Table 5 Comparison of ABCG5 Gln604Glu and ABCG8 Tyr54Cys genotypes with lipid/anthropometric parameters in all study populations ABCG5 Gln604Glu genotype ABCG8 Tyr54Cys genotype CC (n&#bc;73) CG (n&#bc;25) CG (n&#bc;55) p AA (n&#bc;60) GG (n&#bc;19) AG (n&#bc;74) p Triglyceride (mg/dL) 154.3866.74 161.7664.64 152.0268.73 NS 169.3080.27* 134.1141.37 148.2357.67 0.045 Total cholesterol (mg/dL) 209.8845.87 223.3158.29 210.3750.92 NS 216.0956.92 212.2442.15 209.1345.63 NS HDL cholesterol (mg/dL) 38.229.64 37.168.49 35.588.63 NS 38.038.58 37.7412.50 36.188.59 NS LDL cholesterol (mg/dL) 140.7842.62 153.8053.32 144.3847.22 NS 144.2052.66 147.6845.52 143.3141.64 NS VLDL cholesterol (mg/dL) 30.8813.34 32.3512.92 30.4013.74 NS 33.8616.05* 26.828.27 29.6511.53 0.045 Total cholesterol /HDL cholesterol (mg/dL) 5.852.24 6.422.53 6.282.31 NS 6.062.48 6.343.05 6.061.96 NS BMI (kg/m2 ) 26.353.63 25.853.76 26.483.83 NS 26.493.90 25.244.28 26.453.38 NS HDL, High density lipoprotein; LDL, low density lipoprotein; n, number of individuals; NS, not significant; SD, standard deviation; VLDL, very low-density lipoprotein; BMI, body mass index. Statistical evaluation was made by using the Student t test and the 1-way ANOVA test. The results are shown as mean SD.
X
ABCG5 p.Gln604Glu 26088706:130:28
status: NEWX
ABCG5 p.Gln604Glu 26088706:130:135
status: NEW132 Conclusions This study reports the first data about ABCG5 Gln604Glu and ABCG8 Tyr54Cys gene polymorphisms and lipid parameters in diabetes.
X
ABCG5 p.Gln604Glu 26088706:132:58
status: NEW136 Therefore, future studies with larger sample sizes in differing races will help us to understand the relationship between ABCG5 Gln604Glu and ABCG8 Tyr54Cys polymorphisms and lipid profiles in diabetes mellitus.
X
ABCG5 p.Gln604Glu 26088706:136:128
status: NEW
PMID: 26358204
[PubMed]
Castro-Torres IG et al: "Future therapeutic targets for the treatment and prevention of cholesterol gallstones."
No.
Sentence
Comment
1440
An experiment assessed the association of genetic alterations with biliary lithiasis and with elevated levels of blood lipids; it determined that some alleles of these transporters present in subjects with gallstones (Q604E for ABCG5 and D19H for ABCG8) are associated with increased levels of plasma lipids (cholesterol and triglycerides), as well as with a decrease in HDL cholesterol (Acalovschi et al., 2006).
X
ABCG5 p.Gln604Glu 26358204:1440:218
status: NEW